1
|
Sallée L, Souchet L, Boutolleau D, Nguyen S. Amenamevir for Treating Acyclovir-Resistant or Refractory Herpes Simplex Virus Infection in Allogeneic Hematopoietic Stem Cell Transplantation Recipients. Two Case Reports. Int J Antimicrob Agents 2024:107169. [PMID: 38608846 DOI: 10.1016/j.ijantimicag.2024.107169] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/16/2023] [Revised: 02/23/2024] [Accepted: 03/28/2024] [Indexed: 04/14/2024]
Affiliation(s)
- Léo Sallée
- AP-HP, Hôpital Pitié-Salpêtrière, Service d'hématologie clinique, Sorbonne Université, Paris, France.
| | - Laetitia Souchet
- AP-HP, Hôpital Pitié-Salpêtrière, Service d'hématologie clinique, Sorbonne Université, Paris, France
| | - David Boutolleau
- Centre National de Référence Herpèsvirus (Laboratoire Associé), Hôpital Pitié-Salpêtrière, Service de Virologie, and Sorbonne Université, INSERM, UMR-S 1136, Institut Pierre Louis d'Épidémiologie et de Santé Publique (iPLESP), Paris, France
| | - Stéphanie Nguyen
- AP-HP, Hôpital Pitié-Salpêtrière, Service d'hématologie clinique, Sorbonne Université, Paris, France
| |
Collapse
|
2
|
Guiraud V, Thévenet H, Boutolleau D. Detection of varicella zoster virus DNA in blood from immunocompromised patients during the week preceding the onset of herpes zoster rash. J Clin Virol 2023; 169:105609. [PMID: 37839137 DOI: 10.1016/j.jcv.2023.105609] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/25/2023] [Revised: 09/20/2023] [Accepted: 10/06/2023] [Indexed: 10/17/2023]
Abstract
OBJECTIVE To assess whether varicella zoster virus (VZV) DNA can be detected in blood before herpes zoster (HZ) rash onset. METHOD Monocentric retrospective study from January 2019 to March 2023 including patients with HZ and stored blood samples performed during the week preceding the onset of HZ rash. Blood samples were retrospectively analyzed for VZV DNA by quantitative PCR. RESULTS Among the 138 patients with HZ during the study period, stored blood samples performed during the week preceding the onset of HZ rash were available for 13 of them. Twelve (92 %) patients were immunosuppressed, mostly due to solid organ transplantation (38 %), solid malignancy (31 %) or autoimmune disease (23 %). During the week preceding HZ onset, VZV DNA was detected in blood from 10 (77 %) patients, with a median value of 3.6 log (copies/mL) (IQR 3.3-3.9). At the time of HZ onset, all VZV PCR performed in available blood samples were positive. CONCLUSION Our findings demonstrates that VZV DNA can be commonly detected in blood from immunocompromised patients during the prodromal phase of HZ. Early screening of VZV DNA in blood from high-risk immunocompromised patients might improve HZ therapeutic management.
Collapse
Affiliation(s)
- Vincent Guiraud
- Centre National de Référence Herpèsvirus (Laboratoire Associé), AP-HP. Sorbonne Université, Hôpital Pitié-Salpêtrière, Service de Virologie, Paris, France; Sorbonne Université, INSERM, UMR-S 1136, Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), Paris, France.
| | - Henri Thévenet
- Centre National de Référence Herpèsvirus (Laboratoire Associé), AP-HP. Sorbonne Université, Hôpital Pitié-Salpêtrière, Service de Virologie, Paris, France
| | - David Boutolleau
- Centre National de Référence Herpèsvirus (Laboratoire Associé), AP-HP. Sorbonne Université, Hôpital Pitié-Salpêtrière, Service de Virologie, Paris, France; Sorbonne Université, INSERM, UMR-S 1136, Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), Paris, France
| |
Collapse
|
3
|
Velly L, Cancella de Abreu M, Boutolleau D, Cherubini I, Houas E, Aurousseau A, Hausfater P. Point-of-care multiplex molecular diagnosis coupled with procalcitonin-guided algorithm for antibiotic stewardship in lower respiratory tract infection: a randomized controlled trial. Clin Microbiol Infect 2023:S1198-743X(23)00359-2. [PMID: 37549731 DOI: 10.1016/j.cmi.2023.07.031] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/25/2023] [Revised: 07/25/2023] [Accepted: 07/29/2023] [Indexed: 08/09/2023]
Abstract
OBJECTIVE We aimed to show that coupling molecular syndromic respiratory panel (RP) testing with procalcitonin (PCT) measurement in the emergency department improves antibiotic (ATB) stewardship in lower respiratory tract infection. METHODS Open-label, prospective, randomized interventional trial, conducted from 2019 to 2022 in an adult emergency department. Patients with a suspicion of lower respiratory tract infection were randomized into an intervention arm (PCT measurement and point-of-care BIOFIRE RP2.1 plus testing, accompanied by a recommended ATB algorithm) or a standard of care (SOC) arm (PCT allowed as current practice). The primary endpoint was the duration of antibiotic exposure. RESULTS Four hundred fifty-one patients were randomized, median age 65 years (Q1-Q3: 49-77), the hospitalization rate was 59.9% (270/451), the median length of stay 5 days (Q1-Q3: 3 - 12), and the 28-day mortality rate 5.3% (23/451). The median duration of ATB exposure was 6 days (Q1-Q3: 0-9) and 5 days (Q1-Q3: 0-9) in the SOC and interventional arm respectively (p = 0.71). ATB was started in 29.6 % (67/226) and 33.8% (76/225) respectively (p = 0.54). The BIOFIRE RP2.1 plus identified at least one viral species in 112/225 patients (49.8%) of intervention arm. Two hundred twelve out of two hundred twenty-six (93.8%) SOC patients had PCT measurement. The adherence rate to algorithm in the intervention arm was 93.3 % (210/225). CONCLUSION Displaying PCT and real-time RP results to emergency physicians failed to significantly reduce ATB exposure in lower respiratory tract infection suspicions. However, the median ATB duration and rate of initiation were already low in the SOC arm using PCT measurement routinely.
Collapse
Affiliation(s)
- Laetitia Velly
- Emergency Department, APHP-Sorbonne Université, Hôpital Pitié-Salpêtrière, Paris, France; GRC-14 BIOSFAST, CIMI, UMR 1135, Sorbonne Université, Paris, France
| | - Marta Cancella de Abreu
- Emergency Department, APHP-Sorbonne Université, Hôpital Pitié-Salpêtrière, Paris, France; GRC-14 BIOSFAST, CIMI, UMR 1135, Sorbonne Université, Paris, France
| | - David Boutolleau
- Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), GH AP-HP. Sorbonne Université, Hôpital Pitié-Salpêtrière, Service de Virologie, Paris, France
| | - Ilaria Cherubini
- Emergency Department, APHP-Sorbonne Université, Hôpital Pitié-Salpêtrière, Paris, France
| | - Enfel Houas
- Emergency Department, APHP-Sorbonne Université, Hôpital Pitié-Salpêtrière, Paris, France
| | | | - Pierre Hausfater
- Emergency Department, APHP-Sorbonne Université, Hôpital Pitié-Salpêtrière, Paris, France; GRC-14 BIOSFAST, CIMI, UMR 1135, Sorbonne Université, Paris, France.
| |
Collapse
|
4
|
Mageau A, Ambert-Balay K, Boutolleau D, Schuffenecker I, Burrel S, Kaplon J, Nguyen Quoc S, Uzunov M, Souchet L, de Rougemont A, Roos-Weil D, Baron M. Norovirus and sapovirus infections after allogeneic hematopoietic stem cell transplantation: is it worth it to look for them? Leuk Lymphoma 2023; 64:1295-1303. [PMID: 37165601 DOI: 10.1080/10428194.2023.2211186] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/06/2022] [Revised: 12/26/2022] [Accepted: 04/04/2023] [Indexed: 05/12/2023]
Abstract
Norovirus (NoV) and Sapovirus (SaV) are potential causative agents of diarrhea after allogeneic HSCT but little is known in this population. We performed a retrospective analysis by RT-PCR of calicivirus (NoV and SaV), Human adenovirus (HAdV), rotavirus (RV), Aichi virus (AiV), enterovirus (EV), human parechovirus (HPeV) and Human bocavirus (HBoV) in the diarrheal stools of patients after allogeneic HSCT. 49/162 patients had positive viral assays: HAdV (17%), EV (7%), NoV (4.3%), RV and HBoV (3.1% each), SaV (1.9%), AiV (1.2%), HPeV (0.6%). Seven patients were positive for NoV and 3 for SaV. Among viruses-positive samples, the frequency of caliciviruses cases was 7% in the 6 months post-HSCT compared to 40% after (p < 0.0001). The median duration of symptom was 0.7 months but 2 cases, occurring more than one year after HSCT, were chronic, undiagnosed and strongly contributed to morbidity. Systematic testing of caliciviruses appears especially useful in late chronic diarrhea.
Collapse
Affiliation(s)
- Arthur Mageau
- Sorbonne Université, Service d'hématologie, Groupe hospitalier Pitié-Salpêtrière Charles Foix, APHP, Paris
| | - Katia Ambert-Balay
- Centre National de Référence virus des gastro-entérites, Laboratoire de virologie-sérologie, Plateforme de Biologie Hospitalo-Universitaire, CHU Dijon Bourgogne, Dijon, France
| | - David Boutolleau
- Sorbonne Université, Service de virologie, Groupe hospitalier Pitié-Salpêtrière Charles Foix, APHP, Paris
| | - Isabelle Schuffenecker
- Centre National de Référence des Entérovirus et Paréchovirus, Laboratoire de Virologie, Centre de Biologie et de Pathologie Nord, Hôpital de la Croix-Rousse, Hospices Civils de Lyon, France
| | - Sonia Burrel
- Sorbonne Université, Service de virologie, Groupe hospitalier Pitié-Salpêtrière Charles Foix, APHP, Paris
| | - Jérome Kaplon
- Centre National de Référence virus des gastro-entérites, Laboratoire de virologie-sérologie, Plateforme de Biologie Hospitalo-Universitaire, CHU Dijon Bourgogne, Dijon, France
| | - Stéphanie Nguyen Quoc
- Sorbonne Université, Service d'hématologie, Groupe hospitalier Pitié-Salpêtrière Charles Foix, APHP, Paris
| | - Madalina Uzunov
- Sorbonne Université, Service d'hématologie, Groupe hospitalier Pitié-Salpêtrière Charles Foix, APHP, Paris
| | - Laetitia Souchet
- Sorbonne Université, Service d'hématologie, Groupe hospitalier Pitié-Salpêtrière Charles Foix, APHP, Paris
| | - Alexis de Rougemont
- Centre National de Référence virus des gastro-entérites, Laboratoire de virologie-sérologie, Plateforme de Biologie Hospitalo-Universitaire, CHU Dijon Bourgogne, Dijon, France
- UMR PAM A 02.102 Procédés Alimentaires et Microbiologiques, Université de Bourgogne Franche-Comté/AgroSup Dijon, Dijon, France
| | - Damien Roos-Weil
- Sorbonne Université, Service d'hématologie, Groupe hospitalier Pitié-Salpêtrière Charles Foix, APHP, Paris
| | - Marine Baron
- Sorbonne Université, Service d'hématologie, Groupe hospitalier Pitié-Salpêtrière Charles Foix, APHP, Paris
| |
Collapse
|
5
|
Tamzali Y, Pourcher V, Azoyan L, Ouali N, Barrou B, Conti F, Coutance G, Gay F, Tourret J, Boutolleau D. Factors Associated With Genotypic Resistance and Outcome Among Solid Organ Transplant Recipients With Refractory Cytomegalovirus Infection. Transpl Int 2023; 36:11295. [PMID: 37398559 PMCID: PMC10307959 DOI: 10.3389/ti.2023.11295] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/21/2023] [Accepted: 05/31/2023] [Indexed: 07/04/2023]
Abstract
Genotypically resistant cytomegalovirus (CMV) infection is associated with increased morbi-mortality. We herein aimed at understanding the factors that predict CMV genotypic resistance in refractory infections and disease in the SOTR (Solid Organ Transplant Recipients) population, and the factors associated with outcomes. We included all SOTRs who were tested for CMV genotypic resistance for CMV refractory infection/disease over ten years in two centers. Eighty-one refractory patients were included, 26 with genotypically resistant infections (32%). Twenty-four of these genotypic profiles conferred resistance to ganciclovir (GCV) and 2 to GCV and cidofovir. Twenty-three patients presented a high level of GCV resistance. We found no resistance mutation to letermovir. Age (OR = 0.94 per year, IC95 [0.089-0.99]), a history of valganciclovir (VGCV) underdosing or of low plasma concentration (OR= 5.6, IC95 [1.69-20.7]), being on VGCV at infection onset (OR = 3.11, IC95 [1.18-5.32]) and the recipients' CMV negative serostatus (OR = 3.40, IC95 [0.97-12.8]) were independently associated with CMV genotypic resistance. One year mortality was higher in the resistant CMV group (19.2 % versus 3.6 %, p = 0.02). Antiviral drugs severe adverse effects were also independently associated with CMV genotypic resistance. CMV genotypic resistance to antivirals was independently associated with a younger age, exposure to low levels of GCV, the recipients' negative serostatus, and presenting the infection on VGCV prophylaxis. This data is of importance, given that we also found a poorer outcome in the patients of the resistant group.
Collapse
Affiliation(s)
- Yanis Tamzali
- Sorbonne Université, Paris, France
- Department of Infectious and Tropical Diseases, Assistance Publique—Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Paris, France
- Assistance Publique—Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Medicosurgical Unit of Kidney Transplantation, Paris, France
- INSERM UMR 1146, Paris, France
| | - V. Pourcher
- Sorbonne Université, Paris, France
- Department of Infectious and Tropical Diseases, Assistance Publique—Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Paris, France
- Institut Pierre Louis d’Epidémiologie et de Santé Publique, INSERM UMR, Paris, France
| | - L. Azoyan
- Sorbonne Université, Paris, France
- Department of Infectious and Tropical Diseases, Assistance Publique—Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Paris, France
| | - N. Ouali
- Department of Nephrology Unité SINRA, Assistance Publique—Hôpitaux de Paris, Hôpital Tenon, Paris, France
| | - B. Barrou
- Sorbonne Université, Paris, France
- Department of Infectious and Tropical Diseases, Assistance Publique—Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Paris, France
- Assistance Publique—Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Medicosurgical Unit of Kidney Transplantation, Paris, France
- INSERM UMR 1038, Paris, France
| | - F. Conti
- Sorbonne Université, Paris, France
- Department of Hepatogastroenterlogy, Assistance Publique—Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Liver Transplantation Unit, Paris, France
| | - G. Coutance
- Sorbonne Université, Paris, France
- Department of Cardiosurgery, Assistance Publique—Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Fédération de Cardiologie, Paris, France
| | - F. Gay
- Sorbonne Université, Paris, France
- Department of Parasitology and Mycology, Assistance Publique—Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Paris, France
| | - J. Tourret
- Sorbonne Université, Paris, France
- Department of Infectious and Tropical Diseases, Assistance Publique—Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Paris, France
- Assistance Publique—Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Medicosurgical Unit of Kidney Transplantation, Paris, France
- INSERM UMR 1146, Paris, France
| | - D. Boutolleau
- Sorbonne Université, Paris, France
- Institut Pierre Louis d’Epidémiologie et de Santé Publique, INSERM UMR, Paris, France
- Department of Virology, Assistance Publique—Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Centre National de Référence Herpèsvirus (Laboratoire Associé), Paris, France
| |
Collapse
|
6
|
Truffot A, Noble J, Dartevel A, Chevalier E, Dard C, Giovannini D, Andreani J, Burrel S, Boutolleau D, Epaulard O, Pavese P, Morand P, Lupo J, Germi R. Fatal HSV-2 primary infection most likely acquired by kidney transplantation: A case report. Int J Antimicrob Agents 2023; 61:106769. [PMID: 36870404 DOI: 10.1016/j.ijantimicag.2023.106769] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/27/2022] [Revised: 12/27/2022] [Accepted: 02/25/2023] [Indexed: 03/06/2023]
Abstract
Herpes simplex virus 2 (HSV-2) rarely causes severe disease, even in solid organ transplant recipients. This paper describes a fatal case of HSV-2 infection, probably transmitted from a donor to a kidney transplant recipient. The donor was seropositive for HSV-2 but not for HSV-1, whereas the recipient was seronegative for both viruses before transplantation, suggesting that the graft was the source of infection. The recipient received valganciclovir prophylaxis due to cytomegalovirus seropositivity. Three months after transplantation, the recipient presented with rapidly disseminated cutaneous HSV-2 infection with meningoencephalitis. The HSV-2 strain was resistant to acyclovir, probably acquired under valganciclovir prophylaxis. Despite early initiation of acyclovir therapy, the patient died. This fatal case of HSV-2 infection, probably transmitted by the kidney graft with acyclovir-resistant HSV-2 from the onset, is uncommon.
Collapse
Affiliation(s)
- Aurélie Truffot
- Laboratoire de Virologie, CHU Grenoble Alpes, Grenoble, France; Institut de Biologie Structurale, UMR 5075 CEA-CNRS-Université Grenoble-Alpes, Grenoble, France.
| | - Johan Noble
- Service de Néphrologie, Hémodialyse, Aphérèses et Transplantation, CHU Grenoble Alpes, Grenoble, France
| | - Anaïs Dartevel
- Médecine intensive et réanimation, CHU Grenoble-Alpes, Grenoble, France
| | - Eloi Chevalier
- Service de Néphrologie, Hémodialyse, Aphérèses et Transplantation, CHU Grenoble Alpes, Grenoble, France
| | - Celine Dard
- Human Leukocyte Antigen Laboratory, Etablissement Français du Sang, La Tronche, France
| | - Diane Giovannini
- Service d'anatomopathologie, CHU Grenoble Alpes, Grenoble, France
| | - Julien Andreani
- Laboratoire de Virologie, CHU Grenoble Alpes, Grenoble, France
| | - Sonia Burrel
- AP-HP, Sorbonne Université, Hôpital Pitié-Salpêtrière, Service de Virologie, Centre National de Référence Herpèsvirus (laboratoire associé), Paris, France; Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, Paris, France
| | - David Boutolleau
- AP-HP, Sorbonne Université, Hôpital Pitié-Salpêtrière, Service de Virologie, Centre National de Référence Herpèsvirus (laboratoire associé), Paris, France; Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, Paris, France
| | - Olivier Epaulard
- Service des Maladies Infectieuses, CHU Grenoble Alpes, Grenoble, France
| | - Patricia Pavese
- Service des Maladies Infectieuses, CHU Grenoble Alpes, Grenoble, France
| | - Patrice Morand
- Laboratoire de Virologie, CHU Grenoble Alpes, Grenoble, France; Institut de Biologie Structurale, UMR 5075 CEA-CNRS-Université Grenoble-Alpes, Grenoble, France
| | - Julien Lupo
- Laboratoire de Virologie, CHU Grenoble Alpes, Grenoble, France; Institut de Biologie Structurale, UMR 5075 CEA-CNRS-Université Grenoble-Alpes, Grenoble, France
| | - Raphaële Germi
- Laboratoire de Virologie, CHU Grenoble Alpes, Grenoble, France; Institut de Biologie Structurale, UMR 5075 CEA-CNRS-Université Grenoble-Alpes, Grenoble, France
| |
Collapse
|
7
|
Guiraud V, Burrel S, Luyt CE, Boutolleau D. Prevalence and clinical relevance of VZV lung detection in intensive care unit: A retrospective cohort study. J Clin Virol 2023; 164:105470. [PMID: 37120914 DOI: 10.1016/j.jcv.2023.105470] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/01/2023] [Revised: 03/30/2023] [Accepted: 04/24/2023] [Indexed: 05/02/2023]
Abstract
OBJECTIVE To assess the clinical relevance of varicella zoster virus (VZV) lung detection among patients hospitalized in intensive care unit (ICU). METHODS We present a monocentric retrospective cohort study from 2012 to 2020. VZV genome was detected in bronchoalveolar lavage (BAL) fluid by real-time PCR. RESULTS Twelve of 1389 (0.8%) patients exhibited VZV lung detection, corresponding to an incidence of 13.4 (95% confidence interval [CI] 5.8-21.0) per 100 person-years. Immunosuppression and prolonged ICU stay constituted the main risks factors. VZV detection was not associated with pulmonary deterioration but associated with a risk of shingles occurrence during the following days. CONCLUSION VZV lung detection is a rare event among ICU patients, occurring mostly in immunocompromised patients with prolonged ICU stay. Due to its scarcity and the lack of association with pulmonary failure, a targeted approach to the VZV lung detection diagnosis may allow a significant cost saving without affecting the quality of patients care.
Collapse
Affiliation(s)
- Vincent Guiraud
- Centre National de Référence Herpèsvirus (Laboratoire Associé), AP-HP. Sorbonne Université, Hôpital Pitié-Salpêtrière, Service de Virologie, Paris, France; Sorbonne Université, INSERM, UMR-S 1136, Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), Paris, France.
| | - Sonia Burrel
- Centre National de Référence Herpèsvirus (Laboratoire Associé), AP-HP. Sorbonne Université, Hôpital Pitié-Salpêtrière, Service de Virologie, Paris, France; Sorbonne Université, INSERM, UMR-S 1136, Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), Paris, France
| | - Charles-Edouard Luyt
- AP-HP. Sorbonne Université, Service de Médecine Intensive Réanimation, Institut de Cardiologie, Hôpital Pitié-Salpêtrière, Paris, France; Sorbonne Université, INSERM, UMR-S 1166, Institute of Cardiometabolism and Nutrition (ICAN), Paris, France
| | - David Boutolleau
- Centre National de Référence Herpèsvirus (Laboratoire Associé), AP-HP. Sorbonne Université, Hôpital Pitié-Salpêtrière, Service de Virologie, Paris, France; Sorbonne Université, INSERM, UMR-S 1136, Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), Paris, France
| |
Collapse
|
8
|
Labetoulle M, Boutolleau D, Burrel S, Haigh O, Rousseau A. Herpes simplex virus, varicella-zoster virus and cytomegalovirus keratitis: Facts for the clinician. Ocul Surf 2023; 28:336-350. [PMID: 34314898 DOI: 10.1016/j.jtos.2021.07.002] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/14/2021] [Revised: 07/05/2021] [Accepted: 07/18/2021] [Indexed: 01/16/2023]
Abstract
Keratitis due to Herpes simplex virus (HSK), Varicella-Zoster virus (VZK) and Cytomegalovirus remains a frequent source of concern for many ophthalmologists. They are a frequent cause of emergency consultations at eye care centers and carry the risk of permanent loss of visual acuity or visual quality and/or chronic neurotrophic keratitis, resulting in a significant decrease in the quality of life. HSK and VZK can affect the corneal epithelium, stroma, or endothelium or a combination of layers. In contrast, most cases of CMV keratitis present as isolated endothelitis (CMVE), a clinical entity that has been described within the last 2 decades. These three types of viral keratitis are characterized by a high frequency of recurrences and each new episode increases the risk of sequelae. Hence, ophthalmologists must adapt the treatment to the clinical presentation of each recurrent episode in order to mitigate the immediate consequences of viral replication and the immune response on corneal transparency. In patients with frequent recurrences, preventive long-term antiviral treatment is strongly recommended. However, in some rare cases, continuous exposure to antivirals may promote the emergence of resistant viral strains, which can be difficult to manage. In the future, the introduction of new antiviral drugs, with differing modes of action compared to current medical therapy, could be an alternative until a truly effective preventive solution, such as a vaccine, is available.
Collapse
Affiliation(s)
- Marc Labetoulle
- Ophthalmologie Department, Hôpital Bicêtre, APHP, Université Paris Sud, 94275, Le Kremlin-Bicêtre, France; Center for Immunology of Viral Infections and Autoimmune Diseases (IMVA), IDMIT Infrastructure, CEA, Université Paris Sud, Inserm U1184 18 Route Du Panorama, 92265, Fontenay-aux-Roses Cedex, France.
| | - David Boutolleau
- Virology Department, Hôpital Pitié-Salpétrière, APHP, National Reference Center for Herperviruses (Associated Laboratory), Paris, France; Sorbonne University, INSERM UMR-S 1136, Pierre Louis Institute of Epidemiology and Public Health (IPLESP), Paris, France
| | - Sonia Burrel
- Virology Department, Hôpital Pitié-Salpétrière, APHP, National Reference Center for Herperviruses (Associated Laboratory), Paris, France; Sorbonne University, INSERM UMR-S 1136, Pierre Louis Institute of Epidemiology and Public Health (IPLESP), Paris, France
| | - Oscar Haigh
- Center for Immunology of Viral Infections and Autoimmune Diseases (IMVA), IDMIT Infrastructure, CEA, Université Paris Sud, Inserm U1184 18 Route Du Panorama, 92265, Fontenay-aux-Roses Cedex, France
| | - Antoine Rousseau
- Ophthalmologie Department, Hôpital Bicêtre, APHP, Université Paris Sud, 94275, Le Kremlin-Bicêtre, France; Center for Immunology of Viral Infections and Autoimmune Diseases (IMVA), IDMIT Infrastructure, CEA, Université Paris Sud, Inserm U1184 18 Route Du Panorama, 92265, Fontenay-aux-Roses Cedex, France
| |
Collapse
|
9
|
Luyt CE, Burrel S, Guiraud V, Combes A, Boutolleau D. 2199. Herpesviridae lung reactivation and infection in patients with severe Covid-19 or influenza virus pneumonia: a comparative study. Open Forum Infect Dis 2022. [PMCID: PMC9752926 DOI: 10.1093/ofid/ofac492.1818] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/23/2022] Open
Abstract
Background Lung reactivations of Herpesviridae, herpes simplex virus (HSV) and cytomegalovirus (CMV) have been reported in Covid-19 patients. Whether or not those viral reactivations are more frequent than in other patients is not known. Methods Retrospective monocentric cohort study of 145 patients with severe Covid-19 pneumonia requiring invasive mechanical ventilation and who were tested for HSV and CMV in bronchoalveolar lavage performed during fiberoptic bronchoscopy for ventilator-associated pneumonia suspicion. Rates of HSV and CMV lung reactivations, and HSV bronchopneumonitis were assessed and compared with an historical cohort of 89 patients with severe influenza pneumonia requiring invasive mechanical ventilation. Results Among the 145 Covid-19 patients included, 50% and 42 % had HSV and CMV lung reactivations, respectively; whereas among the 89 influenza patients, 63% and 28% had CMV lung reactivations, respectively. Cumulative incidence of HSV lung reactivation (taking into account extubation and death as competing events) was higher in influenza than in Covid-19 patients (p = 0.03, see figure 1), whereas the rate of HSV bronchopneumonitis was similar in both groups (31% and 25%, respectively). Cumulative incidence of CMV lung reactivation (taking into account extubation and death as competing events) was similar in Covid-19 and influenza patients (p=0.07). Outcomes of patients with HSV or CMV lung reactivations were similar to that of patients without, whatever the underlying conditions, i.e., in Covid-19 patients, in influenza patients, or when all patients were grouped. Estimated cumulative incidence of herpes simplex virus (HSV) lung reactivation, extubation or death in Covid-19 and influenza patients, taking into account only the first event that occurred.
![]() p values for differences between Covid-19 and influenza patients were 0.03 for HSV reactivation, 0.53 for death and 0.87 for extubation. Conclusion HSV and CMV lung reactivations are frequent in Covid-19 patients, but not more frequent than in patients with influenza-associated severe pneumonia, despite a higher severity of illness at intensive care unit (ICU) admission of the latter and a longer duration of mechanical ventilation of the former. Although no impact on outcome of HSV and CMV lung reactivations was detected, the effect of antiviral treatment against these Herpesviridae remains to be determined in these patients. Disclosures CHARLES-EDOUARD LUYT, MD PhD, AdvanzPharma: Honoraria|Aerogen: Honoraria|Merck: Honoraria.
Collapse
Affiliation(s)
| | - Sonia Burrel
- Assistance publique hopitaux de Paris, Paris, Ile-de-France, France
| | - Vincent Guiraud
- Assistance publique hopitaux de Paris, Paris, Ile-de-France, France
| | - Alain Combes
- Assistance publique hopitaux de Paris, Paris, Ile-de-France, France
| | | |
Collapse
|
10
|
Khellaf L, Bouscarat F, Burrel S, Fidouh N, Hachon L, Bucau M, Lariven S, Boutolleau D, Joly V, Ghosn J, Le Pluart D, Thy M. Novel mutations in antiviral multiresistant HSV-2 genital lesion: A case report. J Med Virol 2022; 94:6122-6126. [PMID: 35973907 DOI: 10.1002/jmv.28070] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/28/2022] [Revised: 08/02/2022] [Accepted: 08/15/2022] [Indexed: 01/07/2023]
Abstract
HSV-2 antiviral resistance mainly occurs in immunocompromised patients and especially in HIV-positive individuals receiving long-term antiviral treatment. Those situations can be challenging as few alternatives are available for HSV infection management. To describe clinical and virological significance of two novel potential HSV-2 resistance mutations after treating an obese patient with a pseudotumoral genital HSV-related lesion. Consecutive different antiviral treatments were used: valacyclovir (VACV) then foscarnet (FOS) then topical cidofovir (CDV) and finally imiquimod. Under VACV, genotypic resistance testing revealed a novel mutation within viral thymidine kinase (TK, gene UL23) not previously reported but probably accounting for antiviral resistance: W89G, similar to W88R mutation reported in HSV-1 TK, known to be associated with ACV resistance for HSV-1. Under FOS, while initial mutations were still present, a second genotypic resistance testing performed on persisting lesions showed a novel mutation within viral DNA polymerase (DNA pol, gene UL30): C625R. All three antivirals used in this case are small molecules and pharmacokinetics of VACV, FOS, and CDV have not been evaluated in animals and there are very few studies in human. As small molecules are poorly bound to proteins and distribution volume is increased in obese patients, there is risk of underdosage. This mechanism is suspected to be involved in emergence of resistance mutation and further data is needed to adapt, closely to patient profile, antiviral dosage. This report describes a chronic HSV-2 genital lesion, with resistance to current antivirals and novel mutations within viral TK and DNA pol which may confer antiviral resistance.
Collapse
Affiliation(s)
- Lucas Khellaf
- Department of Infectious Diseases, Hôpital Bichat, Université de Paris, Paris, France
| | - Fabrice Bouscarat
- Department of Dermatology, Hôpital Bichat, Université de Paris, Paris, France
| | - Sonia Burrel
- Department of Virology, Centre National de Référence Herpès virus, Hôpital Pitié-Salpétrière, Sorbonne Université, INSERM U1136, Institut Pierre Louis d'épidémiologie et de santé publique (IPLESP), Paris, France
| | - Nadhira Fidouh
- Department of Virology, Hôpital Bichat, Université de Paris, Paris, France
| | - Lorry Hachon
- Department of Pharmacy, Hôpital Bichat, Université de Paris, Paris, France
| | - Margot Bucau
- Department of Pathology, Hôpital Bichat, Université de Paris, Paris, France
| | - Sylvie Lariven
- Department of Infectious Diseases, Hôpital Bichat, Université de Paris, Paris, France
| | - David Boutolleau
- Department of Virology, Centre National de Référence Herpès virus, Hôpital Pitié-Salpétrière, Sorbonne Université, INSERM U1136, Institut Pierre Louis d'épidémiologie et de santé publique (IPLESP), Paris, France
| | - Véronique Joly
- Department of Infectious Diseases, Hôpital Bichat, Université de Paris, Paris, France
| | - Jade Ghosn
- Department of Infectious Diseases, Hôpital Bichat, Université de Paris, Paris, France
| | - Diane Le Pluart
- Department of Infectious Diseases, Hôpital Bichat, Université de Paris, Paris, France
| | - Michaël Thy
- Department of Infectious Diseases, Hôpital Bichat, Université de Paris, Paris, France
| |
Collapse
|
11
|
Luyt CE, Burrel S, Mokrani D, Pineton de Chambrun M, Luyt D, Chommeloux J, Guiraud V, Bréchot N, Schmidt M, Hekimian G, Combes A, Boutolleau D. Herpesviridae lung reactivation and infection in patients with severe COVID-19 or influenza virus pneumonia: a comparative study. Ann Intensive Care 2022; 12:87. [PMID: 36153427 PMCID: PMC9509504 DOI: 10.1186/s13613-022-01062-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/12/2022] [Accepted: 09/12/2022] [Indexed: 11/12/2022] Open
Abstract
Background Lung reactivations of Herpesviridae, herpes simplex virus (HSV) and cytomegalovirus (CMV) have been reported in COVID-19 patients. Whether or not those viral reactivations are more frequent than in other patients is not known. Methods Retrospective monocentric cohort study of 145 patients with severe COVID-19 pneumonia requiring invasive mechanical ventilation and who were tested for HSV and CMV in bronchoalveolar lavage performed during fiberoptic bronchoscopy for ventilator-associated pneumonia suspicion. Rates of HSV and CMV lung reactivations, and HSV bronchopneumonitis were assessed and compared with an historical cohort of 89 patients with severe influenza pneumonia requiring invasive mechanical ventilation. Results Among the 145 COVID-19 patients included, 50% and 42% had HSV and CMV lung reactivations, respectively, whereas among the 89 influenza patients, 63% and 28% had HSV and CMV lung reactivations, respectively. Cumulative incidence of HSV lung reactivation (taking into account extubation and death as competing events) was higher in influenza than in COVID-19 patients (p = 0.03), whereas the rate of HSV bronchopneumonitis was similar in both groups (31% and 25%, respectively). Cumulative incidence of CMV lung reactivation (taking into account extubation and death as competing events) was similar in COVID-19 and influenza patients (p = 0.07). Outcomes of patients with HSV or CMV lung reactivations were similar to that of patients without, whatever the underlying conditions, i.e., in COVID-19 patients, in influenza patients, or when all patients were grouped. Conclusions HSV and CMV lung reactivations are frequent in COVID-19 patients, but not more frequent than in patients with influenza-associated severe pneumonia, despite a higher severity of illness at intensive care unit admission of the latter and a longer duration of mechanical ventilation of the former. Although no impact on outcome of HSV and CMV lung reactivations was detected, the effect of antiviral treatment against these Herpesviridae remains to be determined in these patients. Supplementary Information The online version contains supplementary material available at 10.1186/s13613-022-01062-0.
Collapse
|
12
|
Serris A, Pouvaret A, Loiseau C, Abid H, Burrel S, Fourgeaud J, Rouzaud C, Lanternier F, Boutolleau D, Frange P. Pritelivir for recurrent aciclovir-resistant herpes simplex virus 2 infections in immunocompromised patients. J Antimicrob Chemother 2022; 77:2303-2305. [PMID: 35639560 DOI: 10.1093/jac/dkac165] [Citation(s) in RCA: 7] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/23/2022] Open
Affiliation(s)
- Alexandra Serris
- Service de Maladies infectieuses et tropicales, Hôpital Necker - Enfants malades, Groupe hospitalo-universitaire Assistance Publique - Hôpitaux de Paris (APHP) Centre - Université Paris Cité, Paris, France
| | - Anne Pouvaret
- Service de Maladies infectieuses et tropicales, Hôpital Necker - Enfants malades, Groupe hospitalo-universitaire Assistance Publique - Hôpitaux de Paris (APHP) Centre - Université Paris Cité, Paris, France
| | - Clémence Loiseau
- Service d'hématologie, Hôpital Necker - Enfants malades, Groupe hospitalo-universitaire APHP Centre - Université Paris Cité, Paris, France
| | - Hanene Abid
- Laboratoire de microbiologie clinique, Hôpital Necker - Enfants malades, Groupe hospitalo-universitaire APHP Centre - Université Paris Cité, Paris, France
| | - Sonia Burrel
- Laboratoire de virologie, Centre National de Référence Herpèsvirus (laboratoire associé), Hôpital Pitié-Salpêtrière, Groupe hospitalo-universitaire APHP, Sorbonne Université, Paris, France.,Institut Pierre Louis d'Epidémiologie et de Santé Publique (IPLESP), INSERM, Sorbonne Université, Paris, France
| | - Jacques Fourgeaud
- Laboratoire de microbiologie clinique, Hôpital Necker - Enfants malades, Groupe hospitalo-universitaire APHP Centre - Université Paris Cité, Paris, France.,Centre National de Référence Herpèsvirus (laboratoire associé), Hôpital Necker - Enfants malades, Groupe hospitalo-universitaire APHP Centre - Université Paris Cité, Paris, France.,EHU 7328 PACT, Institut Imagine, Université Paris Cité, Paris, France
| | - Claire Rouzaud
- Service de Maladies infectieuses et tropicales, Hôpital Necker - Enfants malades, Groupe hospitalo-universitaire Assistance Publique - Hôpitaux de Paris (APHP) Centre - Université Paris Cité, Paris, France
| | - Fanny Lanternier
- Service de Maladies infectieuses et tropicales, Hôpital Necker - Enfants malades, Groupe hospitalo-universitaire Assistance Publique - Hôpitaux de Paris (APHP) Centre - Université Paris Cité, Paris, France
| | - David Boutolleau
- Laboratoire de virologie, Centre National de Référence Herpèsvirus (laboratoire associé), Hôpital Pitié-Salpêtrière, Groupe hospitalo-universitaire APHP, Sorbonne Université, Paris, France.,Institut Pierre Louis d'Epidémiologie et de Santé Publique (IPLESP), INSERM, Sorbonne Université, Paris, France
| | - Pierre Frange
- Laboratoire de microbiologie clinique, Hôpital Necker - Enfants malades, Groupe hospitalo-universitaire APHP Centre - Université Paris Cité, Paris, France.,EHU 7328 PACT, Institut Imagine, Université Paris Cité, Paris, France
| |
Collapse
|
13
|
Hausfater P, Boutolleau D, Lacombe K, Beurton A, Dumont M, Constantin JM, Ghosn J, Combes A, Cury N, Guedj R, Djibré M, Bompard R, Mazerand S, Pourcher V, Gimeno L, Marois C, Teyssou E, Marcelin AG, Hajage D, Tubach F. Cumulative incidence of SARS-CoV-2 infection and associated risk factors among frontline health care workers in Paris: the SEROCOV cohort study. Sci Rep 2022; 12:7211. [PMID: 35508515 PMCID: PMC9068621 DOI: 10.1038/s41598-022-10945-y] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/08/2021] [Accepted: 03/30/2022] [Indexed: 12/30/2022] Open
Abstract
With the COVID-19 pandemic, documenting whether health care workers (HCWs) are at increased risk of SARS-CoV-2 contamination and identifying risk factors is of major concern. In this multicenter prospective cohort study, HCWs from frontline departments were included in March and April 2020 and followed for 3 months. SARS-CoV-2 serology was performed at month 0 (M0), M1, and M3 and RT-PCR in case of symptoms. The primary outcome was laboratory-confirmed SARS-CoV-2 infection at M3. Risk factors of laboratory-confirmed SARS-CoV-2 infection at M3 were identified by multivariate logistic regression. Among 1062 HCWs (median [interquartile range] age, 33 [28–42] years; 758 [71.4%] women; 321 [30.2%] physicians), the cumulative incidence of SARS-CoV-2 infection at M3 was 14.6% (95% confidence interval [CI] [12.5; 16.9]). Risk factors were the working department specialty, with increased risk for intensive care units (odds ratio 1.80, 95% CI [0.38; 8.58]), emergency departments (3.91 [0.83; 18.43]) and infectious diseases departments (4.22 [0.92; 18.28]); current smoking was associated with reduced risk (0.36 [0.21; 0.63]). Age, sex, professional category, number of years of experience in the job or department, and public transportation use were not significantly associated with laboratory-confirmed SARS-CoV-2 infection at M3. The rate of SARS-CoV-2 infection in frontline HCWs was 14.6% at the end of the first COVID-19 wave in Paris and occurred mainly early. The study argues for an origin of professional in addition to private life contamination and therefore including HCWs in the first-line vaccination target population. It also highlights that smokers were at lower risk. Trial registration The study has been registered on ClinicalTrials.gov: NCT04304690 first registered on 11/03/2020.
Collapse
Affiliation(s)
- Pierre Hausfater
- Emergency Department, Hôpital Pitié-Salpêtrière, APHP, Sorbonne Université, 83 Boulevard de l'Hôpital, 75651, Paris Cedex 13, France. .,GRC-14 BIOSFAST, UMR INSERM 1166, IHU ICAN, Sorbonne Université, Paris, France.
| | - David Boutolleau
- INSERM, Institut Pierre Louis d'Epidémiologie Et de Santé Publique (iPLESP), GH AP-HP, Hôpital Pitié-Salpêtrière, Service de Virologie, Sorbonne Université, Paris, France
| | - Karine Lacombe
- Infectious Disease Department, Sorbonne Université Hôpital Saint-Antoine, Paris, France
| | - Alexandra Beurton
- Service de Pneumologie-Médecine Intensive Réanimation, Hôpital Pitié-Salpêtrière, APHP, Sorbonne Université Inserm UMRS Neurophysiologie Respiratoire Expérimentale et Clinique, Sorbonne Université, Paris, France
| | - Margaux Dumont
- Emergency Department, Hôpital Pitié-Salpêtrière, APHP, Sorbonne Université, 83 Boulevard de l'Hôpital, 75651, Paris Cedex 13, France
| | - Jean-Michel Constantin
- Department of Anaesthesiology and Critical Care, GRC 29, AP-HP, DMU DREAM, Hôpital Pitié-Salpêtrière, GH APHP, Sorbonne Université, Paris, France
| | - Jade Ghosn
- AP-HP, Nord, Service des Maladies Infectieuses et Tropicales, Hôpital Bichat-Claude Bernard, and Université de Paris, INSERM, UMR 1137 IAME, Paris, France
| | - Alain Combes
- INSERM, UMRS_1166-ICAN, Institute of Cardiometabolism and Nutrition, and Service de Médecine Intensive-Réanimation, Institut de Cardiologie, GH APHP Sorbonne Université Hôpital Pitié-Salpêtrière, Sorbonne Université, Paris, France
| | - Nicolas Cury
- Emergency Department, APHP, Sorbonne Université Hôpital Saint-Antoine, Paris, France
| | - Romain Guedj
- Pediatric Emergency Deparment, APHP Hôpital Armand Trousseau-Sorbonne Université, Faculté de Médecine, Paris, France.,Centre of Research in Epidemiology and Statistics-CRESS, INSERM, Université de Paris, 75004, Paris, France
| | - Michel Djibré
- Service de Médecine Intensive Réanimation, APHP, Sorbonne Université Hôpital Tenon, Paris, France
| | - Rudy Bompard
- Emergency Department, Hôpital Tenon, APHP, Sorbonne Université, Paris, France
| | - Sandie Mazerand
- Service de Médecine Intensive-Réanimation, APHP, Sorbonne Université Hôpital Saint-Antoine, Paris, France
| | - Valérie Pourcher
- AP-HP, Hôpitaux Universitaires Pitié-Salpêtrière Charles Foix, Service de Maladies Infectieuses et Tropicales, INSERM 1136, Institut Pierre Louis d'Epidémiologie et de Santé Publique, Sorbonne Université, 75013, Paris, France
| | - Linda Gimeno
- APHP, Unité de Recherche Clinique Pitié Salpêtrière Charles Foix, Sorbonne Université, 75013, Paris, France
| | - Clémence Marois
- Unité de Médecine Intensive Réanimation Neurologique, Département de Neurologie, DMU Neurosciences, APHP, Sorbonne Université Hôpital Pitié-Salpêtrière, Paris, France
| | - Elisa Teyssou
- INSERM, Institut Pierre Louis d'Epidémiologie Et de Santé Publique (iPLESP), GH AP-HP, Hôpital Pitié-Salpêtrière, Service de Virologie, Sorbonne Université, Paris, France
| | - Anne-Geneviève Marcelin
- INSERM, Institut Pierre Louis d'Epidémiologie Et de Santé Publique (iPLESP), GH AP-HP, Hôpital Pitié-Salpêtrière, Service de Virologie, Sorbonne Université, Paris, France
| | - David Hajage
- APHP, Unité de Recherche Clinique Pitié Salpêtrière Charles Foix, Sorbonne Université, 75013, Paris, France.,Département de Santé Publique, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, AP-HP, Hôpital Pitié Salpêtrière, Sorbonne Université, CIC-1422, 75013, Paris, France
| | - Florence Tubach
- APHP, Unité de Recherche Clinique Pitié Salpêtrière Charles Foix, Sorbonne Université, 75013, Paris, France.,Département de Santé Publique, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, AP-HP, Hôpital Pitié Salpêtrière, Sorbonne Université, CIC-1422, 75013, Paris, France
| |
Collapse
|
14
|
Teyssou E, Zafilaza K, Sayon S, Marot S, Dropy M, Soulie C, Abdi B, Tubach F, Hausfater P, Marcelin AG, Boutolleau D. Long-term evolution of humoral immune response after SARS-CoV-2 infection. Clin Microbiol Infect 2022; 28:1027.e1-1027.e4. [PMID: 35307573 PMCID: PMC8928754 DOI: 10.1016/j.cmi.2022.03.012] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/12/2022] [Revised: 03/07/2022] [Accepted: 03/09/2022] [Indexed: 11/15/2022]
Abstract
Objective We aimed to characterize the evolution of humoral immune response up to 1 year after SARS-CoV-2 infection in healthcare workers (HCWs) during the first wave of COVID-19 in Paris. Methods Serum samples from 92 HCWs were tested at month 0 (M0), M6, and M12 after SARS-CoV-2 infection for IgG targeting the nucleocapsid (N), IgG targeting the receptor-binding domain (RBD) of spike (S) protein, IgA targeting S, and anti-RBD neutralizing antibodies. After M6, 46 HCWs received a single dose of COVID-19 vaccine. Results We observed a significant decrease in all SARS-CoV-2 immunologic markers at M6 post-infection: median decreases were 0.26 log binding antibody units/mL (M0: 1.9 (interquartile range (IQR) 1.47–2.27); M6: 1.64 (IQR 1.22–1.92)) for anti-RBD IgG; 4.10 (index) (M0: 4.94 (IQR 2.72–6.82); M6: 0.84 (IQR 0.25–1.55)) for anti-N IgG; 0.64 (index) (M0: 2.50 (IQR 1.18–4.62); M6: 1.86 (IQR 0.85–3.54)) for anti-S IgA; and 24.4% (M0: 66.4 (IQR 39.7–82.5); M6: 42.0 (IQR 16.8–68.8)) inhibition activity for the RBD neutralizing antibodies. Between M6 and M12, anti-RBD IgG level, anti-S IgA index, and anti-RBD neutralizing activity significantly increased among COVID-19 vaccinated HCWs, whereas they remained stable among unvaccinated HCWs. Anti-N IgG index significantly decreased between M6 and M12 among both vaccinated (median: 0.73 (IQR 0.23–1.11) at M6 and 0.52 (IQR 0.20–0.73) at M12) and unvaccinated HCWs (median: 0.79 (IQR 0.21–4.67) at M6 and 0.34 (IQR 0.24–2.78) at M12). Discussion A steady decline in the anti-N IgG response was observed during the first year after SARS-CoV-2 infection among HCWs, whereas the anti-RBD IgG and the anti-S IgA responses remained stable and could be enhanced by COVID-19 vaccination.
Collapse
Affiliation(s)
- Elisa Teyssou
- Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, AP-HP, Paris, France; Sorbonne Université, Hôpital Pitié-Salpêtrière, Service de virologie, Paris, France.
| | - Karen Zafilaza
- Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, AP-HP, Paris, France; Sorbonne Université, Hôpital Pitié-Salpêtrière, Service de virologie, Paris, France
| | - Sophie Sayon
- Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, AP-HP, Paris, France; Sorbonne Université, Hôpital Pitié-Salpêtrière, Service de virologie, Paris, France
| | - Stéphane Marot
- Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, AP-HP, Paris, France; Sorbonne Université, Hôpital Pitié-Salpêtrière, Service de virologie, Paris, France
| | - Margot Dropy
- Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, AP-HP, Paris, France; Sorbonne Université, Hôpital Pitié-Salpêtrière, Département de Santé Publique, Unité de Recherche Clinique PSL-CFX, Paris, France
| | - Cathia Soulie
- Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, AP-HP, Paris, France; Sorbonne Université, Hôpital Pitié-Salpêtrière, Service de virologie, Paris, France
| | - Basma Abdi
- Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, AP-HP, Paris, France; Sorbonne Université, Hôpital Pitié-Salpêtrière, Service de virologie, Paris, France
| | - Florence Tubach
- Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, AP-HP, Paris, France; Sorbonne Université, Hôpital Pitié-Salpêtrière, Service de virologie, Paris, France
| | - Pierre Hausfater
- Sorbonne Université, GRC-14 BIOSFAST, UMR INSERM 1166, IHU ICAN, APHP, Paris, France; Sorbonne Université, Hôpital Pitié-Salpêtrière, Service d'Accueil des Urgences, Paris, France
| | - Anne-Geneviève Marcelin
- Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, AP-HP, Paris, France; Sorbonne Université, Hôpital Pitié-Salpêtrière, Service de virologie, Paris, France
| | - David Boutolleau
- Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, AP-HP, Paris, France; Sorbonne Université, Hôpital Pitié-Salpêtrière, Service de virologie, Paris, France
| |
Collapse
|
15
|
Miyara M, Saichi M, Sterlin D, Anna F, Marot S, Mathian A, Atif M, Quentric P, Mohr A, Claër L, Parizot C, Dorgham K, Yssel H, Fadlallah J, Chazal T, Haroche J, Luyt CE, Mayaux J, Beurton A, Benameur N, Boutolleau D, Burrel S, de Alba S, Mudumba S, Hockett R, Gunn C, Charneau P, Calvez V, Marcelin AG, Combes A, Demoule A, Amoura Z, Gorochov G. Pre-COVID-19 Immunity to Common Cold Human Coronaviruses Induces a Recall-Type IgG Response to SARS-CoV-2 Antigens Without Cross-Neutralisation. Front Immunol 2022; 13:790334. [PMID: 35222375 PMCID: PMC8873934 DOI: 10.3389/fimmu.2022.790334] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/06/2021] [Accepted: 01/11/2022] [Indexed: 12/26/2022] Open
Abstract
The capacity of pre-existing immunity to human common coronaviruses (HCoV) to cross-protect against de novo COVID-19is yet unknown. In this work, we studied the sera of 175 COVID-19 patients, 76 healthy donors and 3 intravenous immunoglobulins (IVIG) batches. We found that most COVID-19 patients developed anti-SARS-CoV-2 IgG antibodies before IgM. Moreover, the capacity of their IgGs to react to beta-HCoV, was present in the early sera of most patients before the appearance of anti-SARS-CoV-2 IgG. This implied that a recall-type antibody response was generated. In comparison, the patients that mounted an anti-SARS-COV2 IgM response, prior to IgG responses had lower titres of anti-beta-HCoV IgG antibodies. This indicated that pre-existing immunity to beta-HCoV was conducive to the generation of memory type responses to SARS-COV-2. Finally, we also found that pre-COVID-19-era sera and IVIG cross-reacted with SARS-CoV-2 antigens without neutralising SARS-CoV-2 infectivity in vitro. Put together, these results indicate that whilst pre-existing immunity to HCoV is responsible for recall-type IgG responses to SARS-CoV-2, it does not lead to cross-protection against COVID-19.
Collapse
Affiliation(s)
- Makoto Miyara
- Sorbonne Université, Inserm, Centre d’Immunologie et des Maladies Infectieuses (CIMI-Paris), Assistance Publique Hôpitaux de Paris (AP-HP), Hôpital Pitié-Salpêtrière, Paris, France
| | - Melissa Saichi
- Sorbonne Université, Inserm, Centre d’Immunologie et des Maladies Infectieuses (CIMI-Paris), Assistance Publique Hôpitaux de Paris (AP-HP), Hôpital Pitié-Salpêtrière, Paris, France
| | - Delphine Sterlin
- Sorbonne Université, Inserm, Centre d’Immunologie et des Maladies Infectieuses (CIMI-Paris), Assistance Publique Hôpitaux de Paris (AP-HP), Hôpital Pitié-Salpêtrière, Paris, France
- Unit of Antibodies in Therapy and Pathology, Institut Pasteur, Paris, France
| | - François Anna
- Unité de Virologie Moléculaire et Vaccinologie, Institut Pasteur, Paris, France
- Theravectys, Paris, France
| | - Stéphane Marot
- Sorbonne Université, Inserm, Institut Pierre Louis d’Epidémiologie et de Santé Publique (iPLESP), AP-HP, Hôpital Pitié Salpêtrière, Service de Virologie, Paris, France
| | - Alexis Mathian
- Sorbonne Université, Inserm, Centre d’Immunologie et des Maladies Infectieuses (CIMI-Paris), Assistance Publique Hôpitaux de Paris (AP-HP), Hôpital Pitié-Salpêtrière, Paris, France
- Service de Médecine Interne 2, Institut E3M, Assistance Publique Hôpitaux de Paris (AP-HP), Hôpital Pitié-Salpêtrière, Paris, France
| | - Mo Atif
- Sorbonne Université, Inserm, Centre d’Immunologie et des Maladies Infectieuses (CIMI-Paris), Assistance Publique Hôpitaux de Paris (AP-HP), Hôpital Pitié-Salpêtrière, Paris, France
| | - Paul Quentric
- Sorbonne Université, Inserm, Centre d’Immunologie et des Maladies Infectieuses (CIMI-Paris), Assistance Publique Hôpitaux de Paris (AP-HP), Hôpital Pitié-Salpêtrière, Paris, France
| | - Audrey Mohr
- Sorbonne Université, Inserm, Centre d’Immunologie et des Maladies Infectieuses (CIMI-Paris), Assistance Publique Hôpitaux de Paris (AP-HP), Hôpital Pitié-Salpêtrière, Paris, France
| | - Laetitia Claër
- Sorbonne Université, Inserm, Centre d’Immunologie et des Maladies Infectieuses (CIMI-Paris), Assistance Publique Hôpitaux de Paris (AP-HP), Hôpital Pitié-Salpêtrière, Paris, France
| | - Christophe Parizot
- Sorbonne Université, Inserm, Centre d’Immunologie et des Maladies Infectieuses (CIMI-Paris), Assistance Publique Hôpitaux de Paris (AP-HP), Hôpital Pitié-Salpêtrière, Paris, France
| | - Karim Dorgham
- Sorbonne Université, Inserm, Centre d’Immunologie et des Maladies Infectieuses (CIMI-Paris), Assistance Publique Hôpitaux de Paris (AP-HP), Hôpital Pitié-Salpêtrière, Paris, France
| | - Hans Yssel
- Sorbonne Université, Inserm, Centre d’Immunologie et des Maladies Infectieuses (CIMI-Paris), Assistance Publique Hôpitaux de Paris (AP-HP), Hôpital Pitié-Salpêtrière, Paris, France
| | - Jehane Fadlallah
- Sorbonne Université, Inserm, Centre d’Immunologie et des Maladies Infectieuses (CIMI-Paris), Assistance Publique Hôpitaux de Paris (AP-HP), Hôpital Pitié-Salpêtrière, Paris, France
- Service de Médecine Interne 2, Institut E3M, Assistance Publique Hôpitaux de Paris (AP-HP), Hôpital Pitié-Salpêtrière, Paris, France
| | - Thibaut Chazal
- Sorbonne Université, Inserm, Centre d’Immunologie et des Maladies Infectieuses (CIMI-Paris), Assistance Publique Hôpitaux de Paris (AP-HP), Hôpital Pitié-Salpêtrière, Paris, France
- Service de Médecine Interne 2, Institut E3M, Assistance Publique Hôpitaux de Paris (AP-HP), Hôpital Pitié-Salpêtrière, Paris, France
| | - Julien Haroche
- Sorbonne Université, Inserm, Centre d’Immunologie et des Maladies Infectieuses (CIMI-Paris), Assistance Publique Hôpitaux de Paris (AP-HP), Hôpital Pitié-Salpêtrière, Paris, France
- Service de Médecine Interne 2, Institut E3M, Assistance Publique Hôpitaux de Paris (AP-HP), Hôpital Pitié-Salpêtrière, Paris, France
| | - Charles-Edouard Luyt
- Service de Médecine Intensive Réanimation, Institut de Cardiologie, APHP, Sorbonne-Université, Hôpital Pitié-Salpêtrière, Paris, France
- Sorbonne Université, INSERM, UMRS 1166-ICAN Institute of Cardiometabolism and Nutrition, Paris, France
| | - Julien Mayaux
- Service de Médecine Intensive-Réanimation, APHP, Hôpital Pitié-Salpêtrière, Paris, France
| | - Alexandra Beurton
- Service de Médecine Intensive-Réanimation, APHP, Hôpital Pitié-Salpêtrière, Paris, France
- Sorbonne Université, Inserm UMRS Neurophysiologie Respiratoire Expérimentale et Clinique, Paris, France
| | - Neila Benameur
- Service de la pharmacie, Assistance Publique Hôpitaux de Paris (AP-HP), Hôpital Pitié-Salpêtrière, Paris, France
| | - David Boutolleau
- Sorbonne Université, Inserm, Institut Pierre Louis d’Epidémiologie et de Santé Publique (iPLESP), AP-HP, Hôpital Pitié Salpêtrière, Service de Virologie, Paris, France
| | - Sonia Burrel
- Sorbonne Université, Inserm, Institut Pierre Louis d’Epidémiologie et de Santé Publique (iPLESP), AP-HP, Hôpital Pitié Salpêtrière, Service de Virologie, Paris, France
| | | | | | | | - Cary Gunn
- Genalyte Inc., San Diego, CA, United States
| | - Pierre Charneau
- Unité de Virologie Moléculaire et Vaccinologie, Institut Pasteur, Paris, France
- Theravectys, Paris, France
| | - Vincent Calvez
- Sorbonne Université, Inserm, Institut Pierre Louis d’Epidémiologie et de Santé Publique (iPLESP), AP-HP, Hôpital Pitié Salpêtrière, Service de Virologie, Paris, France
| | - Anne-Geneviève Marcelin
- Sorbonne Université, Inserm, Institut Pierre Louis d’Epidémiologie et de Santé Publique (iPLESP), AP-HP, Hôpital Pitié Salpêtrière, Service de Virologie, Paris, France
| | - Alain Combes
- Service de Médecine Intensive Réanimation, Institut de Cardiologie, APHP, Sorbonne-Université, Hôpital Pitié-Salpêtrière, Paris, France
- Sorbonne Université, INSERM, UMRS 1166-ICAN Institute of Cardiometabolism and Nutrition, Paris, France
| | - Alexandre Demoule
- Service de Médecine Intensive-Réanimation, APHP, Hôpital Pitié-Salpêtrière, Paris, France
| | - Zahir Amoura
- Sorbonne Université, Inserm, Centre d’Immunologie et des Maladies Infectieuses (CIMI-Paris), Assistance Publique Hôpitaux de Paris (AP-HP), Hôpital Pitié-Salpêtrière, Paris, France
- Service de Médecine Interne 2, Institut E3M, Assistance Publique Hôpitaux de Paris (AP-HP), Hôpital Pitié-Salpêtrière, Paris, France
| | - Guy Gorochov
- Sorbonne Université, Inserm, Centre d’Immunologie et des Maladies Infectieuses (CIMI-Paris), Assistance Publique Hôpitaux de Paris (AP-HP), Hôpital Pitié-Salpêtrière, Paris, France
- *Correspondence: Guy Gorochov,
| |
Collapse
|
16
|
Troger A, Burrel S, Pineton de Chambrun M, Schmidt M, Bréchot N, Bomme O, Hékimian G, Combes A, Boutolleau D, Luyt CE. Preemptive acyclovir to prevent herpes simplex virus bronchopneumonitis in mechanically ventilated patients with herpes simplex virus oropharyngeal reactivation: An ancillary study of the preemptive treatment for herpesviridae trial. Antivir Ther 2022. [DOI: 10.1177/13596535211072673] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Background To evaluate the impact of preemptive acyclovir treatment on herpes simplex virus (HSV) bronchopneumonitis in mechanically ventilated patients with HSV oropharyngeal reactivation. Methods Ancillary study of the Preemptive Treatment for Herpesviridae (PTH) clinical trial. Patients included in that trial from one centre (Pitié-Salpêtrière Hospital) and in whom at least one bronchoalveolar lavage (BAL) was performed for ventilator-associated pneumonia suspicion were included in the present study. Rate of HSV bronchopneumonitis, defined as clinical symptoms suggesting of pneumonia and presence of HSV in BAL fluid ≥105 copies of HSV/106 cells, were compared in patients who received either acyclovir or placebo. Results Eighty-three patients were included; 40 having received preemptive acyclovir and 43 having received a placebo, without differences between groups at admission or at randomization. The number of patients who developed HSV bronchopneumonitis was lower among acyclovir-treated patients than among placebo-treated patients (40% vs. 72%, respectively, p = .003). Results were similar when restricted to patients without HSV detected in the lower respiratory tract at randomization (31% vs. 61%, respectively, p = .03). Conclusions Preemptive acyclovir treatment in mechanically ventilated patients with HSV oropharyngeal reactivation reduces HSV bronchopneumonitis rate.
Collapse
Affiliation(s)
- Antoine Troger
- Service de Médecine Intensive Réanimation, Groupe Hospitalier Pitié-Salpêtrière, Assistance Publique–Hôpitaux de Paris, Sorbonne Université, Paris, France
| | - Sonia Burrel
- Département de Virologie, Centre National de Référence (CNR) Herpèsvirus, Groupe Hospitalier Pitié-Salpêtrière, Assistance Publique–Hôpitaux de Paris and INSERM U1136, Institut Pierre Louis d'Epidémiologie et de Santé Publique (IPLESP), Sorbonne Université, Paris, France
| | - Marc Pineton de Chambrun
- Service de Médecine Intensive Réanimation, Groupe Hospitalier Pitié-Salpêtrière, Assistance Publique–Hôpitaux de Paris, Sorbonne Université, Paris, France
| | - Matthieu Schmidt
- Service de Médecine Intensive Réanimation, Groupe Hospitalier Pitié-Salpêtrière, Assistance Publique–Hôpitaux de Paris, Sorbonne Université, Paris, France
- INSERM UMRS_1166-iCAN, Institute of Cardiometabolism and Nutrition, Paris, France
| | - Nicolas Bréchot
- Service de Médecine Intensive Réanimation, Groupe Hospitalier Pitié-Salpêtrière, Assistance Publique–Hôpitaux de Paris, Sorbonne Université, Paris, France
- INSERM UMRS_1166-iCAN, Institute of Cardiometabolism and Nutrition, Paris, France
| | - Olivier Bomme
- Département de Virologie, Centre National de Référence (CNR) Herpèsvirus, Groupe Hospitalier Pitié-Salpêtrière, Assistance Publique–Hôpitaux de Paris and INSERM U1136, Institut Pierre Louis d'Epidémiologie et de Santé Publique (IPLESP), Sorbonne Université, Paris, France
| | - Guillaume Hékimian
- Service de Médecine Intensive Réanimation, Groupe Hospitalier Pitié-Salpêtrière, Assistance Publique–Hôpitaux de Paris, Sorbonne Université, Paris, France
| | - Alain Combes
- Service de Médecine Intensive Réanimation, Groupe Hospitalier Pitié-Salpêtrière, Assistance Publique–Hôpitaux de Paris, Sorbonne Université, Paris, France
- INSERM UMRS_1166-iCAN, Institute of Cardiometabolism and Nutrition, Paris, France
| | - David Boutolleau
- Département de Virologie, Centre National de Référence (CNR) Herpèsvirus, Groupe Hospitalier Pitié-Salpêtrière, Assistance Publique–Hôpitaux de Paris and INSERM U1136, Institut Pierre Louis d'Epidémiologie et de Santé Publique (IPLESP), Sorbonne Université, Paris, France
| | - Charles-Edouard Luyt
- Service de Médecine Intensive Réanimation, Groupe Hospitalier Pitié-Salpêtrière, Assistance Publique–Hôpitaux de Paris, Sorbonne Université, Paris, France
- INSERM UMRS_1166-iCAN, Institute of Cardiometabolism and Nutrition, Paris, France
| |
Collapse
|
17
|
Paccoud O, Alain S, Gozlan J, Jarboui S, Boutolleau D, Hantz S, Battipaglia G, Pavaglianiti A, Duléry R, Malard F, Médiavilla C, Sestili S, Gaugler B, Meynard JL, Pacanowski J, Mohty M, Brissot E. Immune restoration therapy for multidrug-resistant CMV disease in an allogenic stem cell transplant recipient. Curr Res Transl Med 2022; 70:103329. [PMID: 35021130 DOI: 10.1016/j.retram.2021.103329] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/22/2021] [Accepted: 12/20/2021] [Indexed: 11/16/2022]
Affiliation(s)
- Olivier Paccoud
- Sorbonne University, Department of Clinical Hematology, Saint-Antoine Hospital, Assistance Publique des Hôpitaux de Paris (AP-HP), Paris, France
| | - Sophie Alain
- National Reference Center for Herpesviruses central laboratory, Limoges University Hospital, Inserm U1092, University of Limoges, Limoges, France
| | - Joel Gozlan
- Sorbonne University, Virology Department, Saint-Antoine Hospital, AP-HP, "Cancer Biology and Therapeutics" INSERM UMR_S 938, Centre de Recherche Saint-Antoine, Paris, France
| | - Sabrine Jarboui
- National Reference Center for Herpesviruses central laboratory, Limoges University Hospital, Inserm U1092, University of Limoges, Limoges, France
| | - David Boutolleau
- National Reference Center for Herpesviruses Associate Laboratory, Virology Department, Pitié-Salpêtrière University Hospital, AP-HP, and Sorbonne University, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), Paris France
| | - Sébastien Hantz
- National Reference Center for Herpesviruses central laboratory, Limoges University Hospital, Inserm U1092, University of Limoges, Limoges, France
| | - Giorgia Battipaglia
- Sorbonne University, Department of Clinical Hematology, Saint-Antoine Hospital, Assistance Publique des Hôpitaux de Paris (AP-HP), Paris, France
| | - Annalisa Pavaglianiti
- Sorbonne University, Department of Clinical Hematology, Saint-Antoine Hospital, Assistance Publique des Hôpitaux de Paris (AP-HP), Paris, France
| | - Rémy Duléry
- Sorbonne University, Department of Clinical Hematology, Saint-Antoine Hospital, Assistance Publique des Hôpitaux de Paris (AP-HP), Paris, France
| | - Florent Malard
- Sorbonne University, Department of Clinical Hematology, Saint-Antoine Hospital, Assistance Publique des Hôpitaux de Paris (AP-HP), Paris, France; ″Graft-Versus-Host Reactions after Allogeneic Stem Cell Transplantation" INSERM UMR_S 938, Centre de Recherche Saint-Antoine, Paris, France
| | - Clémence Médiavilla
- Sorbonne University, Department of Clinical Hematology, Saint-Antoine Hospital, Assistance Publique des Hôpitaux de Paris (AP-HP), Paris, France
| | - Simona Sestili
- Sorbonne University, Department of Clinical Hematology, Saint-Antoine Hospital, Assistance Publique des Hôpitaux de Paris (AP-HP), Paris, France
| | - Béatrice Gaugler
- ″Graft-Versus-Host Reactions after Allogeneic Stem Cell Transplantation" INSERM UMR_S 938, Centre de Recherche Saint-Antoine, Paris, France
| | - Jean-Luc Meynard
- Department of Infectious Diseases, AP-HP, Saint-Antoine Hospital, Paris, France
| | - Jérôme Pacanowski
- Department of Infectious Diseases, AP-HP, Saint-Antoine Hospital, Paris, France
| | - Mohamad Mohty
- Sorbonne University, Department of Clinical Hematology, Saint-Antoine Hospital, Assistance Publique des Hôpitaux de Paris (AP-HP), Paris, France; ″Graft-Versus-Host Reactions after Allogeneic Stem Cell Transplantation" INSERM UMR_S 938, Centre de Recherche Saint-Antoine, Paris, France
| | - Eolia Brissot
- Sorbonne University, Department of Clinical Hematology, Saint-Antoine Hospital, Assistance Publique des Hôpitaux de Paris (AP-HP), Paris, France; ″Graft-Versus-Host Reactions after Allogeneic Stem Cell Transplantation" INSERM UMR_S 938, Centre de Recherche Saint-Antoine, Paris, France.
| |
Collapse
|
18
|
Luyt CE, Hajage D, Burrel S, Hraiech S, Diallo MH, Papazian L, Boutolleau D. Efficacy of Acyclovir to Suppress Herpes Simplex Virus Oropharyngeal Reactivation in Patients Who Are Mechanically Ventilated: An Ancillary Study of the Preemptive Treatment for Herpesviridae (PTH) Trial. JAMA Netw Open 2021; 4:e2139825. [PMID: 34928361 PMCID: PMC8689380 DOI: 10.1001/jamanetworkopen.2021.39825] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
Abstract
This analysis of a randomized clinical trial examines the efficacy of acyclovir for preventing oropharyngeal HSV reactivation among patients who were mechanically ventilated.
Collapse
Affiliation(s)
- Charles-Edouard Luyt
- Service de Médecine Intensive Réanimation, Sorbonne Université, Hôpitaux Universitaires Pitié Salpêtrière-Charles Foix, Assistance Publique-Hôpitaux de Paris, Paris, France
- Institut national de la Santé et de la Recherche Médicale Unité Mixte de Recherche S 1166-Institute of Cardiometabolism and Nutrition, Paris, France
| | - David Hajage
- Sorbonne Université, Institut national de la Santé et de la Recherche Médicale, Institut Pierre Louis d’Epidémiologie et de Santé Publique, Assistance Publique-Hôpitaux de Paris, Hôpitaux Universitaires Pitié Salpêtrière-Charles Foix, Département de Santé Publique, Centre de Pharmacoépidémiologie, Centre d'Investigation Clinique-1421, Paris, France
| | - Sonia Burrel
- Centre National de Référence Herpèsvirus, Département de Virologie, Sorbonne Université, Hôpitaux Universitaires Pitié Salpêtrière-Charles Foix, Assistance Publique-Hôpitaux de Paris
- Institut National de la Santé et de la Recherche Médicale U1136, Institut Pierre Louis d'Epidémiologie et de Santé Publique, Paris, France
| | - Sami Hraiech
- Médecine Intensive Réanimation, Aix-Marseille Université, Hôpital Nord, Assistance Publique-Hôpitaux de Marseille, Marseille, France
| | - Mamadou Hassimiou Diallo
- Sorbonne Université, Institut national de la Santé et de la Recherche Médicale, Institut Pierre Louis d’Epidémiologie et de Santé Publique, Assistance Publique-Hôpitaux de Paris, Hôpitaux Universitaires Pitié Salpêtrière-Charles Foix, Département de Santé Publique, Centre de Pharmacoépidémiologie, Centre d'Investigation Clinique-1421, Paris, France
| | - Laurent Papazian
- Médecine Intensive Réanimation, Aix-Marseille Université, Hôpital Nord, Assistance Publique-Hôpitaux de Marseille, Marseille, France
| | - David Boutolleau
- Centre National de Référence Herpèsvirus, Département de Virologie, Sorbonne Université, Hôpitaux Universitaires Pitié Salpêtrière-Charles Foix, Assistance Publique-Hôpitaux de Paris
- Institut National de la Santé et de la Recherche Médicale U1136, Institut Pierre Louis d'Epidémiologie et de Santé Publique, Paris, France
| |
Collapse
|
19
|
Jary A, Teguete I, Sidibé Y, Kodio A, Dolo O, Burrel S, Boutolleau D, Beauvais-Remigereau L, Sayon S, Kampo M, Traoré FT, Sylla M, Achenbach C, Murphy R, Berçot B, Bébéar C, Calvez V, Marcelin AG, Maiga AI. Prevalence of cervical HPV infection, sexually transmitted infections and associated antimicrobial resistance in women attending cervical cancer screening in Mali. Int J Infect Dis 2021; 108:610-616. [PMID: 34146691 DOI: 10.1016/j.ijid.2021.06.024] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/16/2020] [Revised: 05/23/2021] [Accepted: 06/12/2021] [Indexed: 11/30/2022] Open
Abstract
OBJECTIVES To assess the prevalence of sexually transmitted infections (STIs), antimicrobial resistance and cervical lesions among women from Sikasso, Mali. METHODS Women infected with human immunodeficiency virus (HIV) (n=44) and HIV-negative women (n=96) attending cervical cancer screening were included. Screening for human papillomavirus (HPV), Chlamydia trachomatis (CT), Mycoplasma genitalium (MG), Neisseria gonorrhoeae (NG) and Trichomonas vaginalis (TV) was performed using polymerase chain reaction assays, and herpes simplex virus (HSV-1/2) serological status was assessed using enzyme-linked immunosorbent assays. Antibiotic resistance tests were performed for MG- and NG-positive cases. RESULTS A high prevalence of high-risk HPV (hrHPV) infection (63%) was found. This was associated with cervical lesions in 7.5% of cases. An unusual distribution was found, with HPV31, HPV56 and HPV52 being the most prevalent. The hrHPV distribution differed by HIV status, with HIV-positive cases having HPV35/31/51-52-56 and HIV-negative cases having HPV31/56/52. The seroprevalence of HSV-2 was 49%, and the prevalence of other STIs was as follows: CT, 4%; MG, 9%; NG, 1%; and TV, 7%. Five of nine MG-positive specimens and the NG strains obtained were resistant to fluoroquinolone. CONCLUSIONS These results showed high prevalence of hrHPV and fluoroquinolone resistance in several NG and MG strains. Further studies are required to confirm these data in Mali, and to improve prevention, screening and management of cervical cancer and other STIs in women.
Collapse
Affiliation(s)
- Aude Jary
- Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, AP-HP, Hôpital Pitié Salpêtrière, Service de Virologie, Paris, France.
| | - Ibrahima Teguete
- CHU Gabriel Toure, Département de Gynéco-obstétrique, Bamako, Mali
| | | | - Amadou Kodio
- CHU Gabriel Toure, Département de Biologie Médicale, Bamako, Mali
| | - Oumar Dolo
- Université des Sciences Techniques et des Technologies de Bamako, USTTB, Centre de Recherche et de Formation sur le VIH et la Tuberculose SEREFO, Bamako, Mali
| | - Sonia Burrel
- Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, AP-HP, Hôpital Pitié Salpêtrière, Service de Virologie, Paris, France
| | - David Boutolleau
- Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, AP-HP, Hôpital Pitié Salpêtrière, Service de Virologie, Paris, France
| | | | - Sophie Sayon
- Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, AP-HP, Hôpital Pitié Salpêtrière, Service de Virologie, Paris, France
| | | | - Fatoumata Tata Traoré
- Université des Sciences Techniques et des Technologies de Bamako, USTTB, Centre de Recherche et de Formation sur le VIH et la Tuberculose SEREFO, Bamako, Mali
| | - Mariam Sylla
- CHU Gabriel Toure, Département de Pédiatrie, Bamako, Mali
| | - Chad Achenbach
- Northwestern University, Institute for Global Health, Chicago, IL, USA
| | - Robert Murphy
- Northwestern University, Institute for Global Health, Chicago, IL, USA
| | - Béatrice Berçot
- University of Paris, IAME and St Louis Hospital, Department of Bacteriology, Associated Laboratory of the National Reference Centre for Bacterial STIs, Paris, France
| | - Cécile Bébéar
- CHU de Bordeaux and University of Bordeaux, Department of Bacteriology, National Reference Centre for Bacterial STIs, Bordeaux, France
| | - Vincent Calvez
- Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, AP-HP, Hôpital Pitié Salpêtrière, Service de Virologie, Paris, France
| | - Anne-Geneviève Marcelin
- Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, AP-HP, Hôpital Pitié Salpêtrière, Service de Virologie, Paris, France
| | - Almoustapha I Maiga
- CHU Gabriel Toure, Département de Biologie Médicale, Bamako, Mali; Université des Sciences Techniques et des Technologies de Bamako, USTTB, Centre de Recherche et de Formation sur le VIH et la Tuberculose SEREFO, Bamako, Mali
| |
Collapse
|
20
|
Rodriguez C, Gricourt G, Ndebi M, Demontant V, Poiteau L, Burrel S, Boutolleau D, Woerther PL, Calvez V, Stroer S, Pawlotsky JM. Fatal Encephalitis Caused by Cristoli Virus, an Emerging Orthobunyavirus, France. Emerg Infect Dis 2021; 26:1287-1290. [PMID: 32441621 PMCID: PMC7258463 DOI: 10.3201/eid2606.191431] [Citation(s) in RCA: 16] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022] Open
Abstract
We report the discovery of a new orthobunyavirus, Cristoli virus, by means of shotgun metagenomics. The virus was identified in an immunodepressed patient with fatal encephalitis. Full-length genome sequencing revealed high-level expression of a virulence factor, possibly explaining the severity of the infection. The patient’s recent history suggests circulation in France.
Collapse
|
21
|
Rodriguez C, Gouilh MA, Weiss N, Stroer S, Mokhtari K, Seilhean D, Mathon B, Demontant V, N'Debi M, Gricourt G, Woerther PL, Pawlotsky JM, Stefic K, Marlet J, Dequin PF, Guillon A, Pourcher V, Boutolleau D, Vabret A, Burrel S. Fatal Measles Inclusion-Body Encephalitis in Adult with Untreated AIDS, France. Emerg Infect Dis 2021; 26:2231-2234. [PMID: 32818389 PMCID: PMC7454109 DOI: 10.3201/eid2609.200366] [Citation(s) in RCA: 12] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/24/2023] Open
Abstract
We report a fatal case of measles inclusion-body encephalitis occurring in a woman from Romania with AIDS. After an extensive but unsuccessful diagnostic evaluation, a pan-pathogen shotgun metagenomic approach revealed a measles virus infection. We identified no mutations previously associated with neurovirulence.
Collapse
|
22
|
Catroux M, Garcia M, Lévêque N, Page P, Moal GL, Boutolleau D, Roblot F, Burrel S. Post-herpetic encephalitis cerebral abscess: Viral reactivation or latency site within central nervous system? Curr Res Transl Med 2021; 69:103297. [PMID: 34139602 DOI: 10.1016/j.retram.2021.103297] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/18/2020] [Revised: 04/22/2021] [Accepted: 05/17/2021] [Indexed: 11/27/2022]
Abstract
Herpetic encephalitis results from central nervous system invasion by herpes simplex virus. We report the case of a man who developed a cerebral abscess fifteen months after initial Herpetic encephalitis. Retrospectively, antiviral should not have been associated with antibiotics during abscess episode, as transcriptomic analysis reported no viral reactivation.
Collapse
Affiliation(s)
- Mélanie Catroux
- Tropical Infectious Diseases Department, Poitiers University Hospital, Poitiers, France.
| | - Magali Garcia
- Virology and Mycobacteriology Department, Poitiers University Hospital, Poitiers, France; EA 4331, LITEC, University of Poitiers, Poitiers, France.
| | - Nicolas Lévêque
- Virology and Mycobacteriology Department, Poitiers University Hospital, Poitiers, France; EA 4331, LITEC, University of Poitiers, Poitiers, France.
| | - Philippe Page
- Department of Neurosurgery, Poitiers University Hospital, Poitiers, France.
| | - Gwenael Le Moal
- Tropical Infectious Diseases Department, Poitiers University Hospital, Poitiers, France.
| | - David Boutolleau
- Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), and AP-HP, University Hospital Pitié-Salpêtrière - Charles-Foix, National Reference Center for Herpesviruses, Virology Department, Paris, France.
| | - France Roblot
- Tropical Infectious Diseases Department, Poitiers University Hospital, Poitiers, France.
| | - Sonia Burrel
- Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), and AP-HP, University Hospital Pitié-Salpêtrière - Charles-Foix, National Reference Center for Herpesviruses, Virology Department, Paris, France.
| |
Collapse
|
23
|
Marot S, Malet I, Leducq V, Abdi B, Teyssou E, Soulie C, Wirden M, Rodriguez C, Fourati S, Pawlotsky JM, Boutolleau D, Burrel S, Calvez V, Marcelin AG, Jary A. Neutralization heterogeneity of United Kingdom and South-African SARS-CoV-2 variants in BNT162b2-vaccinated or convalescent COVID-19 healthcare workers. Clin Infect Dis 2021; 74:707-710. [PMID: 34050731 PMCID: PMC8244299 DOI: 10.1093/cid/ciab492] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/03/2021] [Indexed: 12/21/2022] Open
Abstract
There are concerns about neutralizing antibodies (NAbs) potency against SARS-CoV-2 variants. Despite decreased NAb titers elicited by BNT162b2-vaccine against VOC202012/01 and 501Y.V2 strains, 28/29 healthcare workers (HCW) had a NAb titer ≥1:10. In contrast, six months after COVID-19 mild-forms, only 9/15 (60%) of HCW displayed detectable NAbs against 501Y.V2 strain.
Collapse
Affiliation(s)
- Stéphane Marot
- Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), Assistance Publique-Hôpitaux de Paris (AP-HP), Pitié Salpêtrière Hospital, Department of Virology, Paris, France
| | - Isabelle Malet
- Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), Assistance Publique-Hôpitaux de Paris (AP-HP), Pitié Salpêtrière Hospital, Department of Virology, Paris, France
| | - Valentin Leducq
- Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), Assistance Publique-Hôpitaux de Paris (AP-HP), Pitié Salpêtrière Hospital, Department of Virology, Paris, France
| | - Basma Abdi
- Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), Assistance Publique-Hôpitaux de Paris (AP-HP), Pitié Salpêtrière Hospital, Department of Virology, Paris, France
| | - Elisa Teyssou
- Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), Assistance Publique-Hôpitaux de Paris (AP-HP), Pitié Salpêtrière Hospital, Department of Virology, Paris, France
| | - Cathia Soulie
- Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), Assistance Publique-Hôpitaux de Paris (AP-HP), Pitié Salpêtrière Hospital, Department of Virology, Paris, France
| | - Marc Wirden
- Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), Assistance Publique-Hôpitaux de Paris (AP-HP), Pitié Salpêtrière Hospital, Department of Virology, Paris, France
| | - Christophe Rodriguez
- Department of Virology, Hôpitaux Universitaires Henri Mondor, AP-HP, Créteil, France.,Team "Viruses, Hepatology, Cancer", Institut Mondor de Recherche Biomédicale, INSERM U955, Université Paris-Est, Créteil, France
| | - Slim Fourati
- Department of Virology, Hôpitaux Universitaires Henri Mondor, AP-HP, Créteil, France.,Team "Viruses, Hepatology, Cancer", Institut Mondor de Recherche Biomédicale, INSERM U955, Université Paris-Est, Créteil, France
| | - Jean-Michel Pawlotsky
- Department of Virology, Hôpitaux Universitaires Henri Mondor, AP-HP, Créteil, France.,Team "Viruses, Hepatology, Cancer", Institut Mondor de Recherche Biomédicale, INSERM U955, Université Paris-Est, Créteil, France
| | - David Boutolleau
- Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), Assistance Publique-Hôpitaux de Paris (AP-HP), Pitié Salpêtrière Hospital, Department of Virology, Paris, France
| | - Sonia Burrel
- Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), Assistance Publique-Hôpitaux de Paris (AP-HP), Pitié Salpêtrière Hospital, Department of Virology, Paris, France
| | - Vincent Calvez
- Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), Assistance Publique-Hôpitaux de Paris (AP-HP), Pitié Salpêtrière Hospital, Department of Virology, Paris, France
| | - Anne-Geneviève Marcelin
- Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), Assistance Publique-Hôpitaux de Paris (AP-HP), Pitié Salpêtrière Hospital, Department of Virology, Paris, France
| | - Aude Jary
- Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), Assistance Publique-Hôpitaux de Paris (AP-HP), Pitié Salpêtrière Hospital, Department of Virology, Paris, France
| |
Collapse
|
24
|
Marot S, Malet I, Leducq V, Zafilaza K, Sterlin D, Planas D, Gothland A, Jary A, Dorgham K, Bruel T, Burrel S, Boutolleau D, Schwartz O, Gorochov G, Calvez V, Marcelin AG. Author Correction: Rapid decline of neutralizing antibodies against SARS-CoV-2 among infected healthcare workers. Nat Commun 2021; 12:2824. [PMID: 33972561 PMCID: PMC8108407 DOI: 10.1038/s41467-021-23128-6] [Citation(s) in RCA: 12] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022] Open
Affiliation(s)
- Stéphane Marot
- Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), Assistance Publique-Hôpitaux de Paris (AP-HP), Pitié Salpêtrière Hospital, Department of Virology, Paris, France.
| | - Isabelle Malet
- Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), Assistance Publique-Hôpitaux de Paris (AP-HP), Pitié Salpêtrière Hospital, Department of Virology, Paris, France
| | - Valentin Leducq
- Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), Assistance Publique-Hôpitaux de Paris (AP-HP), Pitié Salpêtrière Hospital, Department of Virology, Paris, France
| | - Karen Zafilaza
- Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), Assistance Publique-Hôpitaux de Paris (AP-HP), Pitié Salpêtrière Hospital, Department of Virology, Paris, France
| | - Delphine Sterlin
- Sorbonne Université, INSERM, Centre d'Immunologie et des Maladies Infectieuses (CIMI-Paris), AP-HP, Pitié Salpêtrière Hospital, Department of Immunology, Paris, France
| | - Delphine Planas
- Virus and Immunity Unit, Department of Virology, Institut Pasteur, CNRS UMR 3569, Paris, France.,Vaccine Research Institute, Creteil, France
| | - Adélie Gothland
- Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), Assistance Publique-Hôpitaux de Paris (AP-HP), Pitié Salpêtrière Hospital, Department of Virology, Paris, France
| | - Aude Jary
- Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), Assistance Publique-Hôpitaux de Paris (AP-HP), Pitié Salpêtrière Hospital, Department of Virology, Paris, France
| | - Karim Dorgham
- Sorbonne Université, INSERM, Centre d'Immunologie et des Maladies Infectieuses (CIMI-Paris), AP-HP, Pitié Salpêtrière Hospital, Department of Immunology, Paris, France
| | - Timothée Bruel
- Virus and Immunity Unit, Department of Virology, Institut Pasteur, CNRS UMR 3569, Paris, France.,Vaccine Research Institute, Creteil, France
| | | | - Sonia Burrel
- Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), Assistance Publique-Hôpitaux de Paris (AP-HP), Pitié Salpêtrière Hospital, Department of Virology, Paris, France
| | - David Boutolleau
- Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), Assistance Publique-Hôpitaux de Paris (AP-HP), Pitié Salpêtrière Hospital, Department of Virology, Paris, France
| | - Olivier Schwartz
- Virus and Immunity Unit, Department of Virology, Institut Pasteur, CNRS UMR 3569, Paris, France.,Vaccine Research Institute, Creteil, France
| | - Guy Gorochov
- Sorbonne Université, INSERM, Centre d'Immunologie et des Maladies Infectieuses (CIMI-Paris), AP-HP, Pitié Salpêtrière Hospital, Department of Immunology, Paris, France
| | - Vincent Calvez
- Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), Assistance Publique-Hôpitaux de Paris (AP-HP), Pitié Salpêtrière Hospital, Department of Virology, Paris, France
| | - Anne-Geneviève Marcelin
- Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), Assistance Publique-Hôpitaux de Paris (AP-HP), Pitié Salpêtrière Hospital, Department of Virology, Paris, France
| |
Collapse
|
25
|
Marot S, Malet I, Leducq V, Zafilaza K, Sterlin D, Planas D, Gothland A, Jary A, Dorgham K, Bruel T, Burrel S, Boutolleau D, Schwartz O, Gorochov G, Calvez V, Marcelin AG. Rapid decline of neutralizing antibodies against SARS-CoV-2 among infected healthcare workers. Nat Commun 2021; 12:844. [PMID: 33558507 PMCID: PMC7870823 DOI: 10.1038/s41467-021-21111-9] [Citation(s) in RCA: 112] [Impact Index Per Article: 37.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/20/2020] [Accepted: 01/13/2021] [Indexed: 12/16/2022] Open
Abstract
There are only few data concerning persistence of neutralizing antibodies (NAbs) among SARS-CoV-2-infected healthcare workers (HCW). These individuals are particularly exposed to SARS-CoV-2 infection and at potential risk of reinfection. We followed 26 HCW with mild COVID-19 three weeks (D21), two months (M2) and three months (M3) after the onset of symptoms. All the HCW had anti-receptor binding domain (RBD) IgA at D21, decreasing to 38.5% at M3 (p < 0.0001). Concomitantly a significant decrease in NAb titers was observed between D21 and M2 (p = 0.03) and between D21 and M3 (p < 0.0001). Here, we report that SARS-CoV-2 can elicit a NAb response correlated with anti-RBD antibody levels. However, this neutralizing activity declines, and may even be lost, in association with a decrease in systemic IgA antibody levels, from two months after disease onset. This short-lasting humoral protection supports strong recommendations to maintain infection prevention and control measures in HCW, and suggests that periodic boosts of SARS-CoV-2 vaccination may be required. The humoral immune response to SARS-CoV-2 infection is not yet fully understood. Here, Marot et al. monitor the longitudinal profile and neutralizing activity of IgG, IgA, and IgM among 26 healthcare workers and provide evidence for a short-lasting humoral immune protection due to a decrease of neutralizing antibody titers within 3 months.
Collapse
Affiliation(s)
- Stéphane Marot
- Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), Assistance Publique-Hôpitaux de Paris (AP-HP), Pitié Salpêtrière Hospital, Department of Virology, Paris, France.
| | - Isabelle Malet
- Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), Assistance Publique-Hôpitaux de Paris (AP-HP), Pitié Salpêtrière Hospital, Department of Virology, Paris, France
| | - Valentin Leducq
- Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), Assistance Publique-Hôpitaux de Paris (AP-HP), Pitié Salpêtrière Hospital, Department of Virology, Paris, France
| | - Karen Zafilaza
- Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), Assistance Publique-Hôpitaux de Paris (AP-HP), Pitié Salpêtrière Hospital, Department of Virology, Paris, France
| | - Delphine Sterlin
- Sorbonne Université, INSERM, Centre d'Immunologie et des Maladies Infectieuses (CIMI-Paris), AP-HP, Pitié Salpêtrière Hospital, Department of Immunology, Paris, France
| | - Delphine Planas
- Virus and Immunity Unit, Department of Virology, Institut Pasteur, CNRS UMR 3569, Paris, France.,Vaccine Research Institute, Creteil, France
| | - Adélie Gothland
- Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), Assistance Publique-Hôpitaux de Paris (AP-HP), Pitié Salpêtrière Hospital, Department of Virology, Paris, France
| | - Aude Jary
- Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), Assistance Publique-Hôpitaux de Paris (AP-HP), Pitié Salpêtrière Hospital, Department of Virology, Paris, France
| | - Karim Dorgham
- Sorbonne Université, INSERM, Centre d'Immunologie et des Maladies Infectieuses (CIMI-Paris), AP-HP, Pitié Salpêtrière Hospital, Department of Immunology, Paris, France
| | - Timothée Bruel
- Virus and Immunity Unit, Department of Virology, Institut Pasteur, CNRS UMR 3569, Paris, France.,Vaccine Research Institute, Creteil, France
| | | | - Sonia Burrel
- Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), Assistance Publique-Hôpitaux de Paris (AP-HP), Pitié Salpêtrière Hospital, Department of Virology, Paris, France
| | - David Boutolleau
- Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), Assistance Publique-Hôpitaux de Paris (AP-HP), Pitié Salpêtrière Hospital, Department of Virology, Paris, France
| | - Olivier Schwartz
- Virus and Immunity Unit, Department of Virology, Institut Pasteur, CNRS UMR 3569, Paris, France.,Vaccine Research Institute, Creteil, France
| | - Guy Gorochov
- Sorbonne Université, INSERM, Centre d'Immunologie et des Maladies Infectieuses (CIMI-Paris), AP-HP, Pitié Salpêtrière Hospital, Department of Immunology, Paris, France
| | - Vincent Calvez
- Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), Assistance Publique-Hôpitaux de Paris (AP-HP), Pitié Salpêtrière Hospital, Department of Virology, Paris, France
| | - Anne-Geneviève Marcelin
- Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), Assistance Publique-Hôpitaux de Paris (AP-HP), Pitié Salpêtrière Hospital, Department of Virology, Paris, France
| |
Collapse
|
26
|
Boutolleau D, Coutance G, Désiré E, Bouglé A, Bréchot N, Leprince P, Varnous S. Association between cytomegalovirus infection and allograft rejection in a large contemporary cohort of heart transplant recipients. Transpl Infect Dis 2021; 23:e13569. [PMID: 33452851 DOI: 10.1111/tid.13569] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/04/2020] [Revised: 12/29/2020] [Accepted: 01/04/2021] [Indexed: 01/01/2023]
Abstract
BACKGROUND Cytomegalovirus (CMV) infection remains a common complication after heart transplantation (HTx). The association between CMV infection and allograft rejection is debated in the era of efficient prophylactic antiviral therapies. METHODS This single-center cohort study utilized a highly phenotyped database of HTx recipients (2012-2016). The primary endpoint was the analysis of the association between CMV infection (CMV load ≥ 500 IU/mL whole blood) and the risk of allograft rejection (cellular rejection ≥ 1R1B, antibody-mediated rejection ≥ pAMR1). Secondary endpoints included the analysis of a higher CMV load threshold (≥10 000 IU/mL) and different risk periods after PCR positivity. A mixed-effect logistic regression model with a random intercept was applied. Results were adjusted for important risk factors of rejection. RESULTS Overall, 384 patients were included and 6388 CMV loads and 3,494 endomyocardial biopsies were analyzed. CMV infections ≥ 500 IU/mL were diagnosed on 1223 (19.2%) blood samples from 284 (72.1%) patients and allograft rejections on 246 biopsies (7%) from 149 patients (38.8%). We did not find any association between CMV infection ≥ 500 IU/mL and rejection (univariable: OR 0.94, 95% CI [0.61, 1.45], P = .78, multivariable: OR 0.86, 95% CI [0.55, 1.33], P = .85). These results were consistent when analyzing a higher CMV load threshold and different periods of risk, reinforced by internal validation procedures and a posteriori calculation of the power (primary endpoint: power = 0.82, 95% CI [0.79-0.84]) and reproducible across different clinical scenarios. CONCLUSIONS CMV infection was not associated with an increased risk of rejection in a contemporary cohort of HTx recipients.
Collapse
Affiliation(s)
- David Boutolleau
- Virology Department, Sorbonne Université, INSERM UMR U1136, Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), Team 3 THERAVIR, and Assistance Publique-Hôpitaux de Paris (AP-HP), Pitié-Salpêtrière Hospital, National Reference Centre for Herpesviruses, Paris, France
| | - Guillaume Coutance
- Department of Cardiac and Thoracic Surgery, Cardiology Institute, Pitié Salpêtrière Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), Sorbonne University Medical School, Paris, France
| | - Eva Désiré
- Department of Cardiac and Thoracic Surgery, Cardiology Institute, Pitié Salpêtrière Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), Sorbonne University Medical School, Paris, France
| | - Adrien Bouglé
- Department of Anesthesiology and Critical Care Medicine, Sorbonne Université, UMR INSERM 1166, IHU ICAN, Assistance Publique-Hôpitaux de Paris (AP-HP), Cardiology Institute, Pitié-Salpêtrière Hospital, Paris, France
| | - Nicolas Bréchot
- Department of Medical Intensive Care Unit, Cardiology Institute, Pitié Salpêtrière Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), Sorbonne University Medical School, Paris, France.,INSERM, UMRS 1166-ICAN, Institute of Cardiometabolism and Nutrition, Paris, France
| | - Pascal Leprince
- Department of Cardiac and Thoracic Surgery, Cardiology Institute, Pitié Salpêtrière Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), Sorbonne University Medical School, Paris, France
| | - Shaida Varnous
- Department of Cardiac and Thoracic Surgery, Cardiology Institute, Pitié Salpêtrière Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), Sorbonne University Medical School, Paris, France
| |
Collapse
|
27
|
Luyt CE, Vidal P, Burrel S, Hekimian G, Brechot N, Schmidt M, Combes A, Boutolleau D, Robert J, Chastre J. 359. Ventilator-associated pneumonia in patients with SARS-CoV-2–associated acute respiratory failure requiring mechanical ventilation: a retrospective cohort study. Open Forum Infect Dis 2020. [PMCID: PMC7778222 DOI: 10.1093/ofid/ofaa439.554] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Background Data on incidence, clinical presentation and outcomes of ventilator-associated pneumonia (VAP) in patients with severe coronavirus disease 2019 (COVID-19) pneumonia requiring mechanical ventilation (MV) are limited. Methods Case series of patients with COVID-19 pneumonia admitted to a single ICU in France. All consecutive patients requiring MV with RT-PCR–confirmed SARS-CoV-2 infection between March 12th and April 24th, 2020 were included. Frequency, clinical characteristics, responsible pathogens and outcomes of VAP were assessed, and compared to an historical cohort of patients with severe influenza-associated pneumonia requiring MV admitted to the same ICU during the preceding three winter seasons. Results Fifty-four consecutive patients with COVID-19–associated respiratory failure requiring MV were included (median (IQR) age 48 (42–58) years; 74% male; 93% requiring veno-venous ECMO). VAP occurred in 46 (85%) of them (median (IQR) prior MV duration before the first episode, 11 (8–16) days) (Table 1). Pathogens responsible for VAP were predominantly Enterobacteriaceae (72%), and particularly inducible AmpC-cephalosporinase producers (41%), followed by Pseudomonas aeruginosa (35%) (Table 2). Pulmonary infection recurrence and death were observed in 46 (85%) and 17 (31%) patients, respectively. Details on recurrent episodes and pathogens responsible for recurrences are given in Table 3. Most recurrences were relapse (i.e. infection with the same pathogen), with a high proportion occurring during antimicrobial treatment despite its adequacy. Despite a high rate of P. aeruginosa VAP in patients with influenza-associated ARDS, pulmonary infection recurrence rate was significantly lower than in patients with COVID-19. Overall mortality was similar in the two groups. Baseline characteristics of patients ![]()
Characteristics of first ventilator-associated pneumonia episode ![]()
Characteristics of recurrent VAP episodes in Covid-19 and influenza patients. ![]()
Conclusion Patients with severe COVID-19–associated respiratory failure requiring MV had a very high late-onset VAP rate. Inducible AmpC cephalosporinase–producing Enterobacteriaceae and Pseudomonas aeruginosa appeared to be frequently responsible for VAP, with multiple subsequent episodes and difficulties to eradicate the pathogen from the lung. Disclosures All Authors: No reported disclosures
Collapse
Affiliation(s)
- Charles-Edouard Luyt
- Hôpital Pitié-Salpêtrière, Assistance Publique-Hôpitaux de Paris, APHP Sorbonne Université, Paris, Ile-de-France, France
| | | | - Sonia Burrel
- Sorbonne Université, Paris, Ile-de-France, France
| | | | | | | | - Alain Combes
- Sorbonne Université, Paris, Ile-de-France, France
| | | | | | - Jean Chastre
- Sorbonne Université, Paris, Ile-de-France, France
| |
Collapse
|
28
|
Klement E, Godefroy N, Burrel S, Kornblum D, Monsel G, Bleibtreu A, Marcelin AG, Calvez V, Caumes E, Boutolleau D, Pourcher V. The First Locally Acquired Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection in a Healthcare Worker in the Paris Area. Clin Infect Dis 2020; 71:e530-e531. [PMID: 32211789 PMCID: PMC7184333 DOI: 10.1093/cid/ciaa171] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Affiliation(s)
- Elise Klement
- Assistance Publique-Hôpitaux de Paris, Hôpitaux Universitaires Pitié-Salpêtrière Charles Foix, Service de Maladies infectieuses et Tropicales, Paris, France
| | - Nagisa Godefroy
- Assistance Publique-Hôpitaux de Paris, Hôpitaux Universitaires Pitié-Salpêtrière Charles Foix, Service de Maladies infectieuses et Tropicales, Paris, France
| | - Sonia Burrel
- Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, Paris, France.,Assistance Publique-Hôpitaux de Paris, Hôpitaux Universitaires Pitié-Salpêtrière Charles Foix, AP-HP, Laboratoire de Virologie, Paris, France
| | - Dimitri Kornblum
- Assistance Publique-Hôpitaux de Paris, Hôpitaux Universitaires Pitié-Salpêtrière Charles Foix, Service de Maladies infectieuses et Tropicales, Paris, France
| | - Gentiane Monsel
- Assistance Publique-Hôpitaux de Paris, Hôpitaux Universitaires Pitié-Salpêtrière Charles Foix, Service de Maladies infectieuses et Tropicales, Paris, France
| | - Alexandre Bleibtreu
- Assistance Publique-Hôpitaux de Paris, Hôpitaux Universitaires Pitié-Salpêtrière Charles Foix, Service de Maladies infectieuses et Tropicales, Paris, France
| | - Anne-Geneviève Marcelin
- Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, Paris, France.,Assistance Publique-Hôpitaux de Paris, Hôpitaux Universitaires Pitié-Salpêtrière Charles Foix, AP-HP, Laboratoire de Virologie, Paris, France
| | - Vincent Calvez
- Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, Paris, France.,Assistance Publique-Hôpitaux de Paris, Hôpitaux Universitaires Pitié-Salpêtrière Charles Foix, AP-HP, Laboratoire de Virologie, Paris, France
| | - Eric Caumes
- Assistance Publique-Hôpitaux de Paris, Hôpitaux Universitaires Pitié-Salpêtrière Charles Foix, Service de Maladies infectieuses et Tropicales, Paris, France.,Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, Paris, France
| | - David Boutolleau
- Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, Paris, France.,Assistance Publique-Hôpitaux de Paris, Hôpitaux Universitaires Pitié-Salpêtrière Charles Foix, AP-HP, Laboratoire de Virologie, Paris, France
| | - Valérie Pourcher
- Assistance Publique-Hôpitaux de Paris, Hôpitaux Universitaires Pitié-Salpêtrière Charles Foix, Service de Maladies infectieuses et Tropicales, Paris, France.,Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, Paris, France
| |
Collapse
|
29
|
Chougar L, Shor N, Weiss N, Galanaud D, Leclercq D, Mathon B, Belkacem S, Stroër S, Burrel S, Boutolleau D, Demoule A, Rosso C, Delorme C, Seilhean D, Dormont D, Morawiec E, Raux M, Demeret S, Gerber S, Trunet S, Similowski T, Degos V, Rufat P, Corvol JC, Lehéricy S, Pyatigorskaya N. Retrospective Observational Study of Brain MRI Findings in Patients with Acute SARS-CoV-2 Infection and Neurologic Manifestations. Radiology 2020; 297:E313-E323. [PMID: 32677875 PMCID: PMC7370354 DOI: 10.1148/radiol.2020202422] [Citation(s) in RCA: 110] [Impact Index Per Article: 27.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/08/2023]
Abstract
Background This study provides a detailed imaging assessment in a large series of patients infected with coronavirus disease 2019 (COVID-19) and presenting with neurologic manifestations. Purpose To review the MRI findings associated with acute neurologic manifestations in patients with COVID-19. Materials and Methods This was a cross-sectional study conducted between March 23 and May 7, 2020, at the Pitié-Salpêtrière Hospital, a reference center for COVID-19 in the Paris area. Adult patients were included if they had a diagnosis of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection with acute neurologic manifestations and referral for brain MRI. Patients with a prior history of neurologic disease were excluded. The characteristics and frequency of different MRI features were investigated. The findings were analyzed separately in patients in intensive care units (ICUs) and other departments (non-ICU). Results During the inclusion period, 1176 patients suspected of having COVID-19 were hospitalized. Of 308 patients with acute neurologic symptoms, 73 met the inclusion criteria and were included (23.7%): thirty-five patients were in the ICU (47.9%) and 38 were not (52.1%). The mean age was 58.5 years ± 15.6 [standard deviation], with a male predominance (65.8% vs 34.2%). Forty-three patients had abnormal MRI findings 2-4 weeks after symptom onset (58.9%), including 17 with acute ischemic infarct (23.3%), one with a deep venous thrombosis (1.4%), eight with multiple microhemorrhages (11.3%), 22 with perfusion abnormalities (47.7%), and three with restricted diffusion foci within the corpus callosum consistent with cytotoxic lesions of the corpus callosum (4.1%). Multifocal white matter-enhancing lesions were seen in four patients in the ICU (5%). Basal ganglia abnormalities were seen in four other patients (5%). Cerebrospinal fluid analyses were negative for SARS-CoV-2 in all patients tested (n = 39). Conclusion In addition to cerebrovascular lesions, perfusion abnormalities, cytotoxic lesions of the corpus callosum, and intensive care unit-related complications, we identified two patterns including white matter-enhancing lesions and basal ganglia abnormalities that could be related to severe acute respiratory syndrome coronavirus 2 infection. © RSNA, 2020 Online supplemental material is available for this article.
Collapse
Affiliation(s)
- Lydia Chougar
- Sorbonne Université, Inserm, CNRS, Institut du Cerveau - Paris Brain Institute - ICM, F-75013, Paris, France (L.C., D.G., B.M., C.R., D.D., J.C., S.L., N.P.); Sorbonne Université, 75013, Paris, France (L.C., N.S., N.W., D.G., B.M., S.B., D.B., A.D., C.R., D.S., D.D., E.M., M.R., T.S., V.D., J.C., S.L., N.P.); ICM, “Movement Investigations and Therapeutics” Team (MOV’IT), Paris, France (L.C., S.L., N.P.); ICM, Centre de NeuroImagerie de Recherche – CENIR, Paris, France (L.C., D.G., S.L., N.P.); Assistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Service de neuroradiologie, Paris, France (L.C., N.S., D.G., D.L., S.B., S.S., D.D., S.G., S.T., S.L., N.P.); Brain Liver Pitié-Salpêtrière (BLIPS) Study Group, INSERM UMR_S 938, Centre de recherche Saint-Antoine, Maladies métaboliques, biliaires et fibro-inflammatoire du foie, Institute of Cardiometabolism and Nutrition (ICAN) (N.W., S.D.); Assistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Médecine Intensive Réanimation Neurologique, Paris, France (N.W.); Assistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Service de neurochirurgie, Paris, France (B.M.); Assistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Service de virologie, Centre d’Investigation Clinique Neurosciences, Paris, France (S.B., D.B.); CNR Herpèsvirus (laboratoire associé HSV), SU-INSERM UMR_S 1136 Team 3 THERAVIR IPLESP (S.B., D.B.); Assistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Service de Pneumologie, Médecine Intensive et Réanimation, Paris, France (A.D., E.M., T.S.); Assistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Urgences Cérébro-Vasculaires, Paris, France (C.R.); ICM, stroke network, STAR team, Paris, France (C.R.); Assistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Département de Neurologie, Centre d’Investigation Clinique Neurosciences, Paris, France (C.D., J.C.); Assistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Département de Neuropathologie, Paris, France (D.S.); ICM, INRIA, ARAMIS project-team, Paris, France (D.D., M.R., M.R.); Assistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Department of Anesthesia, Critical Care and Peri-Operative Medicine, Paris, France (M.R., V.D.); Clinical Research Group ARPE, Sorbonne University, Paris, France (V.D.); INSERM UMR 1141, Paris France (V.D.); Assistance Publique Hôpitaux de Paris, DMU ESPRIT, Paris, France(P.R.)
| | - Natalia Shor
- Sorbonne Université, Inserm, CNRS, Institut du Cerveau - Paris Brain Institute - ICM, F-75013, Paris, France (L.C., D.G., B.M., C.R., D.D., J.C., S.L., N.P.); Sorbonne Université, 75013, Paris, France (L.C., N.S., N.W., D.G., B.M., S.B., D.B., A.D., C.R., D.S., D.D., E.M., M.R., T.S., V.D., J.C., S.L., N.P.); ICM, “Movement Investigations and Therapeutics” Team (MOV’IT), Paris, France (L.C., S.L., N.P.); ICM, Centre de NeuroImagerie de Recherche – CENIR, Paris, France (L.C., D.G., S.L., N.P.); Assistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Service de neuroradiologie, Paris, France (L.C., N.S., D.G., D.L., S.B., S.S., D.D., S.G., S.T., S.L., N.P.); Brain Liver Pitié-Salpêtrière (BLIPS) Study Group, INSERM UMR_S 938, Centre de recherche Saint-Antoine, Maladies métaboliques, biliaires et fibro-inflammatoire du foie, Institute of Cardiometabolism and Nutrition (ICAN) (N.W., S.D.); Assistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Médecine Intensive Réanimation Neurologique, Paris, France (N.W.); Assistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Service de neurochirurgie, Paris, France (B.M.); Assistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Service de virologie, Centre d’Investigation Clinique Neurosciences, Paris, France (S.B., D.B.); CNR Herpèsvirus (laboratoire associé HSV), SU-INSERM UMR_S 1136 Team 3 THERAVIR IPLESP (S.B., D.B.); Assistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Service de Pneumologie, Médecine Intensive et Réanimation, Paris, France (A.D., E.M., T.S.); Assistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Urgences Cérébro-Vasculaires, Paris, France (C.R.); ICM, stroke network, STAR team, Paris, France (C.R.); Assistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Département de Neurologie, Centre d’Investigation Clinique Neurosciences, Paris, France (C.D., J.C.); Assistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Département de Neuropathologie, Paris, France (D.S.); ICM, INRIA, ARAMIS project-team, Paris, France (D.D., M.R., M.R.); Assistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Department of Anesthesia, Critical Care and Peri-Operative Medicine, Paris, France (M.R., V.D.); Clinical Research Group ARPE, Sorbonne University, Paris, France (V.D.); INSERM UMR 1141, Paris France (V.D.); Assistance Publique Hôpitaux de Paris, DMU ESPRIT, Paris, France(P.R.)
| | - Nicolas Weiss
- Sorbonne Université, Inserm, CNRS, Institut du Cerveau - Paris Brain Institute - ICM, F-75013, Paris, France (L.C., D.G., B.M., C.R., D.D., J.C., S.L., N.P.); Sorbonne Université, 75013, Paris, France (L.C., N.S., N.W., D.G., B.M., S.B., D.B., A.D., C.R., D.S., D.D., E.M., M.R., T.S., V.D., J.C., S.L., N.P.); ICM, “Movement Investigations and Therapeutics” Team (MOV’IT), Paris, France (L.C., S.L., N.P.); ICM, Centre de NeuroImagerie de Recherche – CENIR, Paris, France (L.C., D.G., S.L., N.P.); Assistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Service de neuroradiologie, Paris, France (L.C., N.S., D.G., D.L., S.B., S.S., D.D., S.G., S.T., S.L., N.P.); Brain Liver Pitié-Salpêtrière (BLIPS) Study Group, INSERM UMR_S 938, Centre de recherche Saint-Antoine, Maladies métaboliques, biliaires et fibro-inflammatoire du foie, Institute of Cardiometabolism and Nutrition (ICAN) (N.W., S.D.); Assistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Médecine Intensive Réanimation Neurologique, Paris, France (N.W.); Assistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Service de neurochirurgie, Paris, France (B.M.); Assistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Service de virologie, Centre d’Investigation Clinique Neurosciences, Paris, France (S.B., D.B.); CNR Herpèsvirus (laboratoire associé HSV), SU-INSERM UMR_S 1136 Team 3 THERAVIR IPLESP (S.B., D.B.); Assistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Service de Pneumologie, Médecine Intensive et Réanimation, Paris, France (A.D., E.M., T.S.); Assistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Urgences Cérébro-Vasculaires, Paris, France (C.R.); ICM, stroke network, STAR team, Paris, France (C.R.); Assistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Département de Neurologie, Centre d’Investigation Clinique Neurosciences, Paris, France (C.D., J.C.); Assistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Département de Neuropathologie, Paris, France (D.S.); ICM, INRIA, ARAMIS project-team, Paris, France (D.D., M.R., M.R.); Assistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Department of Anesthesia, Critical Care and Peri-Operative Medicine, Paris, France (M.R., V.D.); Clinical Research Group ARPE, Sorbonne University, Paris, France (V.D.); INSERM UMR 1141, Paris France (V.D.); Assistance Publique Hôpitaux de Paris, DMU ESPRIT, Paris, France(P.R.)
| | - Damien Galanaud
- Sorbonne Université, Inserm, CNRS, Institut du Cerveau - Paris Brain Institute - ICM, F-75013, Paris, France (L.C., D.G., B.M., C.R., D.D., J.C., S.L., N.P.); Sorbonne Université, 75013, Paris, France (L.C., N.S., N.W., D.G., B.M., S.B., D.B., A.D., C.R., D.S., D.D., E.M., M.R., T.S., V.D., J.C., S.L., N.P.); ICM, “Movement Investigations and Therapeutics” Team (MOV’IT), Paris, France (L.C., S.L., N.P.); ICM, Centre de NeuroImagerie de Recherche – CENIR, Paris, France (L.C., D.G., S.L., N.P.); Assistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Service de neuroradiologie, Paris, France (L.C., N.S., D.G., D.L., S.B., S.S., D.D., S.G., S.T., S.L., N.P.); Brain Liver Pitié-Salpêtrière (BLIPS) Study Group, INSERM UMR_S 938, Centre de recherche Saint-Antoine, Maladies métaboliques, biliaires et fibro-inflammatoire du foie, Institute of Cardiometabolism and Nutrition (ICAN) (N.W., S.D.); Assistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Médecine Intensive Réanimation Neurologique, Paris, France (N.W.); Assistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Service de neurochirurgie, Paris, France (B.M.); Assistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Service de virologie, Centre d’Investigation Clinique Neurosciences, Paris, France (S.B., D.B.); CNR Herpèsvirus (laboratoire associé HSV), SU-INSERM UMR_S 1136 Team 3 THERAVIR IPLESP (S.B., D.B.); Assistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Service de Pneumologie, Médecine Intensive et Réanimation, Paris, France (A.D., E.M., T.S.); Assistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Urgences Cérébro-Vasculaires, Paris, France (C.R.); ICM, stroke network, STAR team, Paris, France (C.R.); Assistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Département de Neurologie, Centre d’Investigation Clinique Neurosciences, Paris, France (C.D., J.C.); Assistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Département de Neuropathologie, Paris, France (D.S.); ICM, INRIA, ARAMIS project-team, Paris, France (D.D., M.R., M.R.); Assistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Department of Anesthesia, Critical Care and Peri-Operative Medicine, Paris, France (M.R., V.D.); Clinical Research Group ARPE, Sorbonne University, Paris, France (V.D.); INSERM UMR 1141, Paris France (V.D.); Assistance Publique Hôpitaux de Paris, DMU ESPRIT, Paris, France(P.R.)
| | - Delphine Leclercq
- Sorbonne Université, Inserm, CNRS, Institut du Cerveau - Paris Brain Institute - ICM, F-75013, Paris, France (L.C., D.G., B.M., C.R., D.D., J.C., S.L., N.P.); Sorbonne Université, 75013, Paris, France (L.C., N.S., N.W., D.G., B.M., S.B., D.B., A.D., C.R., D.S., D.D., E.M., M.R., T.S., V.D., J.C., S.L., N.P.); ICM, “Movement Investigations and Therapeutics” Team (MOV’IT), Paris, France (L.C., S.L., N.P.); ICM, Centre de NeuroImagerie de Recherche – CENIR, Paris, France (L.C., D.G., S.L., N.P.); Assistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Service de neuroradiologie, Paris, France (L.C., N.S., D.G., D.L., S.B., S.S., D.D., S.G., S.T., S.L., N.P.); Brain Liver Pitié-Salpêtrière (BLIPS) Study Group, INSERM UMR_S 938, Centre de recherche Saint-Antoine, Maladies métaboliques, biliaires et fibro-inflammatoire du foie, Institute of Cardiometabolism and Nutrition (ICAN) (N.W., S.D.); Assistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Médecine Intensive Réanimation Neurologique, Paris, France (N.W.); Assistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Service de neurochirurgie, Paris, France (B.M.); Assistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Service de virologie, Centre d’Investigation Clinique Neurosciences, Paris, France (S.B., D.B.); CNR Herpèsvirus (laboratoire associé HSV), SU-INSERM UMR_S 1136 Team 3 THERAVIR IPLESP (S.B., D.B.); Assistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Service de Pneumologie, Médecine Intensive et Réanimation, Paris, France (A.D., E.M., T.S.); Assistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Urgences Cérébro-Vasculaires, Paris, France (C.R.); ICM, stroke network, STAR team, Paris, France (C.R.); Assistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Département de Neurologie, Centre d’Investigation Clinique Neurosciences, Paris, France (C.D., J.C.); Assistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Département de Neuropathologie, Paris, France (D.S.); ICM, INRIA, ARAMIS project-team, Paris, France (D.D., M.R., M.R.); Assistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Department of Anesthesia, Critical Care and Peri-Operative Medicine, Paris, France (M.R., V.D.); Clinical Research Group ARPE, Sorbonne University, Paris, France (V.D.); INSERM UMR 1141, Paris France (V.D.); Assistance Publique Hôpitaux de Paris, DMU ESPRIT, Paris, France(P.R.)
| | - Bertrand Mathon
- Sorbonne Université, Inserm, CNRS, Institut du Cerveau - Paris Brain Institute - ICM, F-75013, Paris, France (L.C., D.G., B.M., C.R., D.D., J.C., S.L., N.P.); Sorbonne Université, 75013, Paris, France (L.C., N.S., N.W., D.G., B.M., S.B., D.B., A.D., C.R., D.S., D.D., E.M., M.R., T.S., V.D., J.C., S.L., N.P.); ICM, “Movement Investigations and Therapeutics” Team (MOV’IT), Paris, France (L.C., S.L., N.P.); ICM, Centre de NeuroImagerie de Recherche – CENIR, Paris, France (L.C., D.G., S.L., N.P.); Assistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Service de neuroradiologie, Paris, France (L.C., N.S., D.G., D.L., S.B., S.S., D.D., S.G., S.T., S.L., N.P.); Brain Liver Pitié-Salpêtrière (BLIPS) Study Group, INSERM UMR_S 938, Centre de recherche Saint-Antoine, Maladies métaboliques, biliaires et fibro-inflammatoire du foie, Institute of Cardiometabolism and Nutrition (ICAN) (N.W., S.D.); Assistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Médecine Intensive Réanimation Neurologique, Paris, France (N.W.); Assistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Service de neurochirurgie, Paris, France (B.M.); Assistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Service de virologie, Centre d’Investigation Clinique Neurosciences, Paris, France (S.B., D.B.); CNR Herpèsvirus (laboratoire associé HSV), SU-INSERM UMR_S 1136 Team 3 THERAVIR IPLESP (S.B., D.B.); Assistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Service de Pneumologie, Médecine Intensive et Réanimation, Paris, France (A.D., E.M., T.S.); Assistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Urgences Cérébro-Vasculaires, Paris, France (C.R.); ICM, stroke network, STAR team, Paris, France (C.R.); Assistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Département de Neurologie, Centre d’Investigation Clinique Neurosciences, Paris, France (C.D., J.C.); Assistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Département de Neuropathologie, Paris, France (D.S.); ICM, INRIA, ARAMIS project-team, Paris, France (D.D., M.R., M.R.); Assistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Department of Anesthesia, Critical Care and Peri-Operative Medicine, Paris, France (M.R., V.D.); Clinical Research Group ARPE, Sorbonne University, Paris, France (V.D.); INSERM UMR 1141, Paris France (V.D.); Assistance Publique Hôpitaux de Paris, DMU ESPRIT, Paris, France(P.R.)
| | - Samia Belkacem
- Sorbonne Université, Inserm, CNRS, Institut du Cerveau - Paris Brain Institute - ICM, F-75013, Paris, France (L.C., D.G., B.M., C.R., D.D., J.C., S.L., N.P.); Sorbonne Université, 75013, Paris, France (L.C., N.S., N.W., D.G., B.M., S.B., D.B., A.D., C.R., D.S., D.D., E.M., M.R., T.S., V.D., J.C., S.L., N.P.); ICM, “Movement Investigations and Therapeutics” Team (MOV’IT), Paris, France (L.C., S.L., N.P.); ICM, Centre de NeuroImagerie de Recherche – CENIR, Paris, France (L.C., D.G., S.L., N.P.); Assistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Service de neuroradiologie, Paris, France (L.C., N.S., D.G., D.L., S.B., S.S., D.D., S.G., S.T., S.L., N.P.); Brain Liver Pitié-Salpêtrière (BLIPS) Study Group, INSERM UMR_S 938, Centre de recherche Saint-Antoine, Maladies métaboliques, biliaires et fibro-inflammatoire du foie, Institute of Cardiometabolism and Nutrition (ICAN) (N.W., S.D.); Assistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Médecine Intensive Réanimation Neurologique, Paris, France (N.W.); Assistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Service de neurochirurgie, Paris, France (B.M.); Assistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Service de virologie, Centre d’Investigation Clinique Neurosciences, Paris, France (S.B., D.B.); CNR Herpèsvirus (laboratoire associé HSV), SU-INSERM UMR_S 1136 Team 3 THERAVIR IPLESP (S.B., D.B.); Assistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Service de Pneumologie, Médecine Intensive et Réanimation, Paris, France (A.D., E.M., T.S.); Assistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Urgences Cérébro-Vasculaires, Paris, France (C.R.); ICM, stroke network, STAR team, Paris, France (C.R.); Assistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Département de Neurologie, Centre d’Investigation Clinique Neurosciences, Paris, France (C.D., J.C.); Assistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Département de Neuropathologie, Paris, France (D.S.); ICM, INRIA, ARAMIS project-team, Paris, France (D.D., M.R., M.R.); Assistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Department of Anesthesia, Critical Care and Peri-Operative Medicine, Paris, France (M.R., V.D.); Clinical Research Group ARPE, Sorbonne University, Paris, France (V.D.); INSERM UMR 1141, Paris France (V.D.); Assistance Publique Hôpitaux de Paris, DMU ESPRIT, Paris, France(P.R.)
| | - Sebastian Stroër
- Sorbonne Université, Inserm, CNRS, Institut du Cerveau - Paris Brain Institute - ICM, F-75013, Paris, France (L.C., D.G., B.M., C.R., D.D., J.C., S.L., N.P.); Sorbonne Université, 75013, Paris, France (L.C., N.S., N.W., D.G., B.M., S.B., D.B., A.D., C.R., D.S., D.D., E.M., M.R., T.S., V.D., J.C., S.L., N.P.); ICM, “Movement Investigations and Therapeutics” Team (MOV’IT), Paris, France (L.C., S.L., N.P.); ICM, Centre de NeuroImagerie de Recherche – CENIR, Paris, France (L.C., D.G., S.L., N.P.); Assistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Service de neuroradiologie, Paris, France (L.C., N.S., D.G., D.L., S.B., S.S., D.D., S.G., S.T., S.L., N.P.); Brain Liver Pitié-Salpêtrière (BLIPS) Study Group, INSERM UMR_S 938, Centre de recherche Saint-Antoine, Maladies métaboliques, biliaires et fibro-inflammatoire du foie, Institute of Cardiometabolism and Nutrition (ICAN) (N.W., S.D.); Assistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Médecine Intensive Réanimation Neurologique, Paris, France (N.W.); Assistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Service de neurochirurgie, Paris, France (B.M.); Assistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Service de virologie, Centre d’Investigation Clinique Neurosciences, Paris, France (S.B., D.B.); CNR Herpèsvirus (laboratoire associé HSV), SU-INSERM UMR_S 1136 Team 3 THERAVIR IPLESP (S.B., D.B.); Assistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Service de Pneumologie, Médecine Intensive et Réanimation, Paris, France (A.D., E.M., T.S.); Assistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Urgences Cérébro-Vasculaires, Paris, France (C.R.); ICM, stroke network, STAR team, Paris, France (C.R.); Assistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Département de Neurologie, Centre d’Investigation Clinique Neurosciences, Paris, France (C.D., J.C.); Assistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Département de Neuropathologie, Paris, France (D.S.); ICM, INRIA, ARAMIS project-team, Paris, France (D.D., M.R., M.R.); Assistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Department of Anesthesia, Critical Care and Peri-Operative Medicine, Paris, France (M.R., V.D.); Clinical Research Group ARPE, Sorbonne University, Paris, France (V.D.); INSERM UMR 1141, Paris France (V.D.); Assistance Publique Hôpitaux de Paris, DMU ESPRIT, Paris, France(P.R.)
| | - Sonia Burrel
- Sorbonne Université, Inserm, CNRS, Institut du Cerveau - Paris Brain Institute - ICM, F-75013, Paris, France (L.C., D.G., B.M., C.R., D.D., J.C., S.L., N.P.); Sorbonne Université, 75013, Paris, France (L.C., N.S., N.W., D.G., B.M., S.B., D.B., A.D., C.R., D.S., D.D., E.M., M.R., T.S., V.D., J.C., S.L., N.P.); ICM, “Movement Investigations and Therapeutics” Team (MOV’IT), Paris, France (L.C., S.L., N.P.); ICM, Centre de NeuroImagerie de Recherche – CENIR, Paris, France (L.C., D.G., S.L., N.P.); Assistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Service de neuroradiologie, Paris, France (L.C., N.S., D.G., D.L., S.B., S.S., D.D., S.G., S.T., S.L., N.P.); Brain Liver Pitié-Salpêtrière (BLIPS) Study Group, INSERM UMR_S 938, Centre de recherche Saint-Antoine, Maladies métaboliques, biliaires et fibro-inflammatoire du foie, Institute of Cardiometabolism and Nutrition (ICAN) (N.W., S.D.); Assistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Médecine Intensive Réanimation Neurologique, Paris, France (N.W.); Assistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Service de neurochirurgie, Paris, France (B.M.); Assistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Service de virologie, Centre d’Investigation Clinique Neurosciences, Paris, France (S.B., D.B.); CNR Herpèsvirus (laboratoire associé HSV), SU-INSERM UMR_S 1136 Team 3 THERAVIR IPLESP (S.B., D.B.); Assistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Service de Pneumologie, Médecine Intensive et Réanimation, Paris, France (A.D., E.M., T.S.); Assistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Urgences Cérébro-Vasculaires, Paris, France (C.R.); ICM, stroke network, STAR team, Paris, France (C.R.); Assistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Département de Neurologie, Centre d’Investigation Clinique Neurosciences, Paris, France (C.D., J.C.); Assistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Département de Neuropathologie, Paris, France (D.S.); ICM, INRIA, ARAMIS project-team, Paris, France (D.D., M.R., M.R.); Assistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Department of Anesthesia, Critical Care and Peri-Operative Medicine, Paris, France (M.R., V.D.); Clinical Research Group ARPE, Sorbonne University, Paris, France (V.D.); INSERM UMR 1141, Paris France (V.D.); Assistance Publique Hôpitaux de Paris, DMU ESPRIT, Paris, France(P.R.)
| | - David Boutolleau
- Sorbonne Université, Inserm, CNRS, Institut du Cerveau - Paris Brain Institute - ICM, F-75013, Paris, France (L.C., D.G., B.M., C.R., D.D., J.C., S.L., N.P.); Sorbonne Université, 75013, Paris, France (L.C., N.S., N.W., D.G., B.M., S.B., D.B., A.D., C.R., D.S., D.D., E.M., M.R., T.S., V.D., J.C., S.L., N.P.); ICM, “Movement Investigations and Therapeutics” Team (MOV’IT), Paris, France (L.C., S.L., N.P.); ICM, Centre de NeuroImagerie de Recherche – CENIR, Paris, France (L.C., D.G., S.L., N.P.); Assistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Service de neuroradiologie, Paris, France (L.C., N.S., D.G., D.L., S.B., S.S., D.D., S.G., S.T., S.L., N.P.); Brain Liver Pitié-Salpêtrière (BLIPS) Study Group, INSERM UMR_S 938, Centre de recherche Saint-Antoine, Maladies métaboliques, biliaires et fibro-inflammatoire du foie, Institute of Cardiometabolism and Nutrition (ICAN) (N.W., S.D.); Assistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Médecine Intensive Réanimation Neurologique, Paris, France (N.W.); Assistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Service de neurochirurgie, Paris, France (B.M.); Assistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Service de virologie, Centre d’Investigation Clinique Neurosciences, Paris, France (S.B., D.B.); CNR Herpèsvirus (laboratoire associé HSV), SU-INSERM UMR_S 1136 Team 3 THERAVIR IPLESP (S.B., D.B.); Assistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Service de Pneumologie, Médecine Intensive et Réanimation, Paris, France (A.D., E.M., T.S.); Assistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Urgences Cérébro-Vasculaires, Paris, France (C.R.); ICM, stroke network, STAR team, Paris, France (C.R.); Assistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Département de Neurologie, Centre d’Investigation Clinique Neurosciences, Paris, France (C.D., J.C.); Assistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Département de Neuropathologie, Paris, France (D.S.); ICM, INRIA, ARAMIS project-team, Paris, France (D.D., M.R., M.R.); Assistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Department of Anesthesia, Critical Care and Peri-Operative Medicine, Paris, France (M.R., V.D.); Clinical Research Group ARPE, Sorbonne University, Paris, France (V.D.); INSERM UMR 1141, Paris France (V.D.); Assistance Publique Hôpitaux de Paris, DMU ESPRIT, Paris, France(P.R.)
| | - Alexandre Demoule
- Sorbonne Université, Inserm, CNRS, Institut du Cerveau - Paris Brain Institute - ICM, F-75013, Paris, France (L.C., D.G., B.M., C.R., D.D., J.C., S.L., N.P.); Sorbonne Université, 75013, Paris, France (L.C., N.S., N.W., D.G., B.M., S.B., D.B., A.D., C.R., D.S., D.D., E.M., M.R., T.S., V.D., J.C., S.L., N.P.); ICM, “Movement Investigations and Therapeutics” Team (MOV’IT), Paris, France (L.C., S.L., N.P.); ICM, Centre de NeuroImagerie de Recherche – CENIR, Paris, France (L.C., D.G., S.L., N.P.); Assistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Service de neuroradiologie, Paris, France (L.C., N.S., D.G., D.L., S.B., S.S., D.D., S.G., S.T., S.L., N.P.); Brain Liver Pitié-Salpêtrière (BLIPS) Study Group, INSERM UMR_S 938, Centre de recherche Saint-Antoine, Maladies métaboliques, biliaires et fibro-inflammatoire du foie, Institute of Cardiometabolism and Nutrition (ICAN) (N.W., S.D.); Assistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Médecine Intensive Réanimation Neurologique, Paris, France (N.W.); Assistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Service de neurochirurgie, Paris, France (B.M.); Assistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Service de virologie, Centre d’Investigation Clinique Neurosciences, Paris, France (S.B., D.B.); CNR Herpèsvirus (laboratoire associé HSV), SU-INSERM UMR_S 1136 Team 3 THERAVIR IPLESP (S.B., D.B.); Assistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Service de Pneumologie, Médecine Intensive et Réanimation, Paris, France (A.D., E.M., T.S.); Assistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Urgences Cérébro-Vasculaires, Paris, France (C.R.); ICM, stroke network, STAR team, Paris, France (C.R.); Assistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Département de Neurologie, Centre d’Investigation Clinique Neurosciences, Paris, France (C.D., J.C.); Assistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Département de Neuropathologie, Paris, France (D.S.); ICM, INRIA, ARAMIS project-team, Paris, France (D.D., M.R., M.R.); Assistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Department of Anesthesia, Critical Care and Peri-Operative Medicine, Paris, France (M.R., V.D.); Clinical Research Group ARPE, Sorbonne University, Paris, France (V.D.); INSERM UMR 1141, Paris France (V.D.); Assistance Publique Hôpitaux de Paris, DMU ESPRIT, Paris, France(P.R.)
| | - Charlotte Rosso
- Sorbonne Université, Inserm, CNRS, Institut du Cerveau - Paris Brain Institute - ICM, F-75013, Paris, France (L.C., D.G., B.M., C.R., D.D., J.C., S.L., N.P.); Sorbonne Université, 75013, Paris, France (L.C., N.S., N.W., D.G., B.M., S.B., D.B., A.D., C.R., D.S., D.D., E.M., M.R., T.S., V.D., J.C., S.L., N.P.); ICM, “Movement Investigations and Therapeutics” Team (MOV’IT), Paris, France (L.C., S.L., N.P.); ICM, Centre de NeuroImagerie de Recherche – CENIR, Paris, France (L.C., D.G., S.L., N.P.); Assistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Service de neuroradiologie, Paris, France (L.C., N.S., D.G., D.L., S.B., S.S., D.D., S.G., S.T., S.L., N.P.); Brain Liver Pitié-Salpêtrière (BLIPS) Study Group, INSERM UMR_S 938, Centre de recherche Saint-Antoine, Maladies métaboliques, biliaires et fibro-inflammatoire du foie, Institute of Cardiometabolism and Nutrition (ICAN) (N.W., S.D.); Assistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Médecine Intensive Réanimation Neurologique, Paris, France (N.W.); Assistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Service de neurochirurgie, Paris, France (B.M.); Assistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Service de virologie, Centre d’Investigation Clinique Neurosciences, Paris, France (S.B., D.B.); CNR Herpèsvirus (laboratoire associé HSV), SU-INSERM UMR_S 1136 Team 3 THERAVIR IPLESP (S.B., D.B.); Assistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Service de Pneumologie, Médecine Intensive et Réanimation, Paris, France (A.D., E.M., T.S.); Assistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Urgences Cérébro-Vasculaires, Paris, France (C.R.); ICM, stroke network, STAR team, Paris, France (C.R.); Assistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Département de Neurologie, Centre d’Investigation Clinique Neurosciences, Paris, France (C.D., J.C.); Assistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Département de Neuropathologie, Paris, France (D.S.); ICM, INRIA, ARAMIS project-team, Paris, France (D.D., M.R., M.R.); Assistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Department of Anesthesia, Critical Care and Peri-Operative Medicine, Paris, France (M.R., V.D.); Clinical Research Group ARPE, Sorbonne University, Paris, France (V.D.); INSERM UMR 1141, Paris France (V.D.); Assistance Publique Hôpitaux de Paris, DMU ESPRIT, Paris, France(P.R.)
| | - Cécile Delorme
- Sorbonne Université, Inserm, CNRS, Institut du Cerveau - Paris Brain Institute - ICM, F-75013, Paris, France (L.C., D.G., B.M., C.R., D.D., J.C., S.L., N.P.); Sorbonne Université, 75013, Paris, France (L.C., N.S., N.W., D.G., B.M., S.B., D.B., A.D., C.R., D.S., D.D., E.M., M.R., T.S., V.D., J.C., S.L., N.P.); ICM, “Movement Investigations and Therapeutics” Team (MOV’IT), Paris, France (L.C., S.L., N.P.); ICM, Centre de NeuroImagerie de Recherche – CENIR, Paris, France (L.C., D.G., S.L., N.P.); Assistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Service de neuroradiologie, Paris, France (L.C., N.S., D.G., D.L., S.B., S.S., D.D., S.G., S.T., S.L., N.P.); Brain Liver Pitié-Salpêtrière (BLIPS) Study Group, INSERM UMR_S 938, Centre de recherche Saint-Antoine, Maladies métaboliques, biliaires et fibro-inflammatoire du foie, Institute of Cardiometabolism and Nutrition (ICAN) (N.W., S.D.); Assistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Médecine Intensive Réanimation Neurologique, Paris, France (N.W.); Assistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Service de neurochirurgie, Paris, France (B.M.); Assistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Service de virologie, Centre d’Investigation Clinique Neurosciences, Paris, France (S.B., D.B.); CNR Herpèsvirus (laboratoire associé HSV), SU-INSERM UMR_S 1136 Team 3 THERAVIR IPLESP (S.B., D.B.); Assistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Service de Pneumologie, Médecine Intensive et Réanimation, Paris, France (A.D., E.M., T.S.); Assistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Urgences Cérébro-Vasculaires, Paris, France (C.R.); ICM, stroke network, STAR team, Paris, France (C.R.); Assistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Département de Neurologie, Centre d’Investigation Clinique Neurosciences, Paris, France (C.D., J.C.); Assistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Département de Neuropathologie, Paris, France (D.S.); ICM, INRIA, ARAMIS project-team, Paris, France (D.D., M.R., M.R.); Assistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Department of Anesthesia, Critical Care and Peri-Operative Medicine, Paris, France (M.R., V.D.); Clinical Research Group ARPE, Sorbonne University, Paris, France (V.D.); INSERM UMR 1141, Paris France (V.D.); Assistance Publique Hôpitaux de Paris, DMU ESPRIT, Paris, France(P.R.)
| | - Danielle Seilhean
- Sorbonne Université, Inserm, CNRS, Institut du Cerveau - Paris Brain Institute - ICM, F-75013, Paris, France (L.C., D.G., B.M., C.R., D.D., J.C., S.L., N.P.); Sorbonne Université, 75013, Paris, France (L.C., N.S., N.W., D.G., B.M., S.B., D.B., A.D., C.R., D.S., D.D., E.M., M.R., T.S., V.D., J.C., S.L., N.P.); ICM, “Movement Investigations and Therapeutics” Team (MOV’IT), Paris, France (L.C., S.L., N.P.); ICM, Centre de NeuroImagerie de Recherche – CENIR, Paris, France (L.C., D.G., S.L., N.P.); Assistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Service de neuroradiologie, Paris, France (L.C., N.S., D.G., D.L., S.B., S.S., D.D., S.G., S.T., S.L., N.P.); Brain Liver Pitié-Salpêtrière (BLIPS) Study Group, INSERM UMR_S 938, Centre de recherche Saint-Antoine, Maladies métaboliques, biliaires et fibro-inflammatoire du foie, Institute of Cardiometabolism and Nutrition (ICAN) (N.W., S.D.); Assistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Médecine Intensive Réanimation Neurologique, Paris, France (N.W.); Assistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Service de neurochirurgie, Paris, France (B.M.); Assistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Service de virologie, Centre d’Investigation Clinique Neurosciences, Paris, France (S.B., D.B.); CNR Herpèsvirus (laboratoire associé HSV), SU-INSERM UMR_S 1136 Team 3 THERAVIR IPLESP (S.B., D.B.); Assistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Service de Pneumologie, Médecine Intensive et Réanimation, Paris, France (A.D., E.M., T.S.); Assistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Urgences Cérébro-Vasculaires, Paris, France (C.R.); ICM, stroke network, STAR team, Paris, France (C.R.); Assistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Département de Neurologie, Centre d’Investigation Clinique Neurosciences, Paris, France (C.D., J.C.); Assistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Département de Neuropathologie, Paris, France (D.S.); ICM, INRIA, ARAMIS project-team, Paris, France (D.D., M.R., M.R.); Assistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Department of Anesthesia, Critical Care and Peri-Operative Medicine, Paris, France (M.R., V.D.); Clinical Research Group ARPE, Sorbonne University, Paris, France (V.D.); INSERM UMR 1141, Paris France (V.D.); Assistance Publique Hôpitaux de Paris, DMU ESPRIT, Paris, France(P.R.)
| | - Didier Dormont
- Sorbonne Université, Inserm, CNRS, Institut du Cerveau - Paris Brain Institute - ICM, F-75013, Paris, France (L.C., D.G., B.M., C.R., D.D., J.C., S.L., N.P.); Sorbonne Université, 75013, Paris, France (L.C., N.S., N.W., D.G., B.M., S.B., D.B., A.D., C.R., D.S., D.D., E.M., M.R., T.S., V.D., J.C., S.L., N.P.); ICM, “Movement Investigations and Therapeutics” Team (MOV’IT), Paris, France (L.C., S.L., N.P.); ICM, Centre de NeuroImagerie de Recherche – CENIR, Paris, France (L.C., D.G., S.L., N.P.); Assistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Service de neuroradiologie, Paris, France (L.C., N.S., D.G., D.L., S.B., S.S., D.D., S.G., S.T., S.L., N.P.); Brain Liver Pitié-Salpêtrière (BLIPS) Study Group, INSERM UMR_S 938, Centre de recherche Saint-Antoine, Maladies métaboliques, biliaires et fibro-inflammatoire du foie, Institute of Cardiometabolism and Nutrition (ICAN) (N.W., S.D.); Assistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Médecine Intensive Réanimation Neurologique, Paris, France (N.W.); Assistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Service de neurochirurgie, Paris, France (B.M.); Assistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Service de virologie, Centre d’Investigation Clinique Neurosciences, Paris, France (S.B., D.B.); CNR Herpèsvirus (laboratoire associé HSV), SU-INSERM UMR_S 1136 Team 3 THERAVIR IPLESP (S.B., D.B.); Assistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Service de Pneumologie, Médecine Intensive et Réanimation, Paris, France (A.D., E.M., T.S.); Assistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Urgences Cérébro-Vasculaires, Paris, France (C.R.); ICM, stroke network, STAR team, Paris, France (C.R.); Assistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Département de Neurologie, Centre d’Investigation Clinique Neurosciences, Paris, France (C.D., J.C.); Assistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Département de Neuropathologie, Paris, France (D.S.); ICM, INRIA, ARAMIS project-team, Paris, France (D.D., M.R., M.R.); Assistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Department of Anesthesia, Critical Care and Peri-Operative Medicine, Paris, France (M.R., V.D.); Clinical Research Group ARPE, Sorbonne University, Paris, France (V.D.); INSERM UMR 1141, Paris France (V.D.); Assistance Publique Hôpitaux de Paris, DMU ESPRIT, Paris, France(P.R.)
| | - Elise Morawiec
- Sorbonne Université, Inserm, CNRS, Institut du Cerveau - Paris Brain Institute - ICM, F-75013, Paris, France (L.C., D.G., B.M., C.R., D.D., J.C., S.L., N.P.); Sorbonne Université, 75013, Paris, France (L.C., N.S., N.W., D.G., B.M., S.B., D.B., A.D., C.R., D.S., D.D., E.M., M.R., T.S., V.D., J.C., S.L., N.P.); ICM, “Movement Investigations and Therapeutics” Team (MOV’IT), Paris, France (L.C., S.L., N.P.); ICM, Centre de NeuroImagerie de Recherche – CENIR, Paris, France (L.C., D.G., S.L., N.P.); Assistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Service de neuroradiologie, Paris, France (L.C., N.S., D.G., D.L., S.B., S.S., D.D., S.G., S.T., S.L., N.P.); Brain Liver Pitié-Salpêtrière (BLIPS) Study Group, INSERM UMR_S 938, Centre de recherche Saint-Antoine, Maladies métaboliques, biliaires et fibro-inflammatoire du foie, Institute of Cardiometabolism and Nutrition (ICAN) (N.W., S.D.); Assistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Médecine Intensive Réanimation Neurologique, Paris, France (N.W.); Assistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Service de neurochirurgie, Paris, France (B.M.); Assistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Service de virologie, Centre d’Investigation Clinique Neurosciences, Paris, France (S.B., D.B.); CNR Herpèsvirus (laboratoire associé HSV), SU-INSERM UMR_S 1136 Team 3 THERAVIR IPLESP (S.B., D.B.); Assistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Service de Pneumologie, Médecine Intensive et Réanimation, Paris, France (A.D., E.M., T.S.); Assistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Urgences Cérébro-Vasculaires, Paris, France (C.R.); ICM, stroke network, STAR team, Paris, France (C.R.); Assistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Département de Neurologie, Centre d’Investigation Clinique Neurosciences, Paris, France (C.D., J.C.); Assistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Département de Neuropathologie, Paris, France (D.S.); ICM, INRIA, ARAMIS project-team, Paris, France (D.D., M.R., M.R.); Assistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Department of Anesthesia, Critical Care and Peri-Operative Medicine, Paris, France (M.R., V.D.); Clinical Research Group ARPE, Sorbonne University, Paris, France (V.D.); INSERM UMR 1141, Paris France (V.D.); Assistance Publique Hôpitaux de Paris, DMU ESPRIT, Paris, France(P.R.)
| | - Mathieu Raux
- Sorbonne Université, Inserm, CNRS, Institut du Cerveau - Paris Brain Institute - ICM, F-75013, Paris, France (L.C., D.G., B.M., C.R., D.D., J.C., S.L., N.P.); Sorbonne Université, 75013, Paris, France (L.C., N.S., N.W., D.G., B.M., S.B., D.B., A.D., C.R., D.S., D.D., E.M., M.R., T.S., V.D., J.C., S.L., N.P.); ICM, “Movement Investigations and Therapeutics” Team (MOV’IT), Paris, France (L.C., S.L., N.P.); ICM, Centre de NeuroImagerie de Recherche – CENIR, Paris, France (L.C., D.G., S.L., N.P.); Assistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Service de neuroradiologie, Paris, France (L.C., N.S., D.G., D.L., S.B., S.S., D.D., S.G., S.T., S.L., N.P.); Brain Liver Pitié-Salpêtrière (BLIPS) Study Group, INSERM UMR_S 938, Centre de recherche Saint-Antoine, Maladies métaboliques, biliaires et fibro-inflammatoire du foie, Institute of Cardiometabolism and Nutrition (ICAN) (N.W., S.D.); Assistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Médecine Intensive Réanimation Neurologique, Paris, France (N.W.); Assistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Service de neurochirurgie, Paris, France (B.M.); Assistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Service de virologie, Centre d’Investigation Clinique Neurosciences, Paris, France (S.B., D.B.); CNR Herpèsvirus (laboratoire associé HSV), SU-INSERM UMR_S 1136 Team 3 THERAVIR IPLESP (S.B., D.B.); Assistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Service de Pneumologie, Médecine Intensive et Réanimation, Paris, France (A.D., E.M., T.S.); Assistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Urgences Cérébro-Vasculaires, Paris, France (C.R.); ICM, stroke network, STAR team, Paris, France (C.R.); Assistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Département de Neurologie, Centre d’Investigation Clinique Neurosciences, Paris, France (C.D., J.C.); Assistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Département de Neuropathologie, Paris, France (D.S.); ICM, INRIA, ARAMIS project-team, Paris, France (D.D., M.R., M.R.); Assistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Department of Anesthesia, Critical Care and Peri-Operative Medicine, Paris, France (M.R., V.D.); Clinical Research Group ARPE, Sorbonne University, Paris, France (V.D.); INSERM UMR 1141, Paris France (V.D.); Assistance Publique Hôpitaux de Paris, DMU ESPRIT, Paris, France(P.R.)
| | - Sophie Demeret
- Sorbonne Université, Inserm, CNRS, Institut du Cerveau - Paris Brain Institute - ICM, F-75013, Paris, France (L.C., D.G., B.M., C.R., D.D., J.C., S.L., N.P.); Sorbonne Université, 75013, Paris, France (L.C., N.S., N.W., D.G., B.M., S.B., D.B., A.D., C.R., D.S., D.D., E.M., M.R., T.S., V.D., J.C., S.L., N.P.); ICM, “Movement Investigations and Therapeutics” Team (MOV’IT), Paris, France (L.C., S.L., N.P.); ICM, Centre de NeuroImagerie de Recherche – CENIR, Paris, France (L.C., D.G., S.L., N.P.); Assistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Service de neuroradiologie, Paris, France (L.C., N.S., D.G., D.L., S.B., S.S., D.D., S.G., S.T., S.L., N.P.); Brain Liver Pitié-Salpêtrière (BLIPS) Study Group, INSERM UMR_S 938, Centre de recherche Saint-Antoine, Maladies métaboliques, biliaires et fibro-inflammatoire du foie, Institute of Cardiometabolism and Nutrition (ICAN) (N.W., S.D.); Assistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Médecine Intensive Réanimation Neurologique, Paris, France (N.W.); Assistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Service de neurochirurgie, Paris, France (B.M.); Assistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Service de virologie, Centre d’Investigation Clinique Neurosciences, Paris, France (S.B., D.B.); CNR Herpèsvirus (laboratoire associé HSV), SU-INSERM UMR_S 1136 Team 3 THERAVIR IPLESP (S.B., D.B.); Assistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Service de Pneumologie, Médecine Intensive et Réanimation, Paris, France (A.D., E.M., T.S.); Assistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Urgences Cérébro-Vasculaires, Paris, France (C.R.); ICM, stroke network, STAR team, Paris, France (C.R.); Assistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Département de Neurologie, Centre d’Investigation Clinique Neurosciences, Paris, France (C.D., J.C.); Assistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Département de Neuropathologie, Paris, France (D.S.); ICM, INRIA, ARAMIS project-team, Paris, France (D.D., M.R., M.R.); Assistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Department of Anesthesia, Critical Care and Peri-Operative Medicine, Paris, France (M.R., V.D.); Clinical Research Group ARPE, Sorbonne University, Paris, France (V.D.); INSERM UMR 1141, Paris France (V.D.); Assistance Publique Hôpitaux de Paris, DMU ESPRIT, Paris, France(P.R.)
| | - Sophie Gerber
- Sorbonne Université, Inserm, CNRS, Institut du Cerveau - Paris Brain Institute - ICM, F-75013, Paris, France (L.C., D.G., B.M., C.R., D.D., J.C., S.L., N.P.); Sorbonne Université, 75013, Paris, France (L.C., N.S., N.W., D.G., B.M., S.B., D.B., A.D., C.R., D.S., D.D., E.M., M.R., T.S., V.D., J.C., S.L., N.P.); ICM, “Movement Investigations and Therapeutics” Team (MOV’IT), Paris, France (L.C., S.L., N.P.); ICM, Centre de NeuroImagerie de Recherche – CENIR, Paris, France (L.C., D.G., S.L., N.P.); Assistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Service de neuroradiologie, Paris, France (L.C., N.S., D.G., D.L., S.B., S.S., D.D., S.G., S.T., S.L., N.P.); Brain Liver Pitié-Salpêtrière (BLIPS) Study Group, INSERM UMR_S 938, Centre de recherche Saint-Antoine, Maladies métaboliques, biliaires et fibro-inflammatoire du foie, Institute of Cardiometabolism and Nutrition (ICAN) (N.W., S.D.); Assistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Médecine Intensive Réanimation Neurologique, Paris, France (N.W.); Assistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Service de neurochirurgie, Paris, France (B.M.); Assistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Service de virologie, Centre d’Investigation Clinique Neurosciences, Paris, France (S.B., D.B.); CNR Herpèsvirus (laboratoire associé HSV), SU-INSERM UMR_S 1136 Team 3 THERAVIR IPLESP (S.B., D.B.); Assistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Service de Pneumologie, Médecine Intensive et Réanimation, Paris, France (A.D., E.M., T.S.); Assistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Urgences Cérébro-Vasculaires, Paris, France (C.R.); ICM, stroke network, STAR team, Paris, France (C.R.); Assistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Département de Neurologie, Centre d’Investigation Clinique Neurosciences, Paris, France (C.D., J.C.); Assistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Département de Neuropathologie, Paris, France (D.S.); ICM, INRIA, ARAMIS project-team, Paris, France (D.D., M.R., M.R.); Assistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Department of Anesthesia, Critical Care and Peri-Operative Medicine, Paris, France (M.R., V.D.); Clinical Research Group ARPE, Sorbonne University, Paris, France (V.D.); INSERM UMR 1141, Paris France (V.D.); Assistance Publique Hôpitaux de Paris, DMU ESPRIT, Paris, France(P.R.)
| | - Stéphanie Trunet
- Sorbonne Université, Inserm, CNRS, Institut du Cerveau - Paris Brain Institute - ICM, F-75013, Paris, France (L.C., D.G., B.M., C.R., D.D., J.C., S.L., N.P.); Sorbonne Université, 75013, Paris, France (L.C., N.S., N.W., D.G., B.M., S.B., D.B., A.D., C.R., D.S., D.D., E.M., M.R., T.S., V.D., J.C., S.L., N.P.); ICM, “Movement Investigations and Therapeutics” Team (MOV’IT), Paris, France (L.C., S.L., N.P.); ICM, Centre de NeuroImagerie de Recherche – CENIR, Paris, France (L.C., D.G., S.L., N.P.); Assistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Service de neuroradiologie, Paris, France (L.C., N.S., D.G., D.L., S.B., S.S., D.D., S.G., S.T., S.L., N.P.); Brain Liver Pitié-Salpêtrière (BLIPS) Study Group, INSERM UMR_S 938, Centre de recherche Saint-Antoine, Maladies métaboliques, biliaires et fibro-inflammatoire du foie, Institute of Cardiometabolism and Nutrition (ICAN) (N.W., S.D.); Assistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Médecine Intensive Réanimation Neurologique, Paris, France (N.W.); Assistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Service de neurochirurgie, Paris, France (B.M.); Assistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Service de virologie, Centre d’Investigation Clinique Neurosciences, Paris, France (S.B., D.B.); CNR Herpèsvirus (laboratoire associé HSV), SU-INSERM UMR_S 1136 Team 3 THERAVIR IPLESP (S.B., D.B.); Assistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Service de Pneumologie, Médecine Intensive et Réanimation, Paris, France (A.D., E.M., T.S.); Assistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Urgences Cérébro-Vasculaires, Paris, France (C.R.); ICM, stroke network, STAR team, Paris, France (C.R.); Assistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Département de Neurologie, Centre d’Investigation Clinique Neurosciences, Paris, France (C.D., J.C.); Assistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Département de Neuropathologie, Paris, France (D.S.); ICM, INRIA, ARAMIS project-team, Paris, France (D.D., M.R., M.R.); Assistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Department of Anesthesia, Critical Care and Peri-Operative Medicine, Paris, France (M.R., V.D.); Clinical Research Group ARPE, Sorbonne University, Paris, France (V.D.); INSERM UMR 1141, Paris France (V.D.); Assistance Publique Hôpitaux de Paris, DMU ESPRIT, Paris, France(P.R.)
| | - Thomas Similowski
- Sorbonne Université, Inserm, CNRS, Institut du Cerveau - Paris Brain Institute - ICM, F-75013, Paris, France (L.C., D.G., B.M., C.R., D.D., J.C., S.L., N.P.); Sorbonne Université, 75013, Paris, France (L.C., N.S., N.W., D.G., B.M., S.B., D.B., A.D., C.R., D.S., D.D., E.M., M.R., T.S., V.D., J.C., S.L., N.P.); ICM, “Movement Investigations and Therapeutics” Team (MOV’IT), Paris, France (L.C., S.L., N.P.); ICM, Centre de NeuroImagerie de Recherche – CENIR, Paris, France (L.C., D.G., S.L., N.P.); Assistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Service de neuroradiologie, Paris, France (L.C., N.S., D.G., D.L., S.B., S.S., D.D., S.G., S.T., S.L., N.P.); Brain Liver Pitié-Salpêtrière (BLIPS) Study Group, INSERM UMR_S 938, Centre de recherche Saint-Antoine, Maladies métaboliques, biliaires et fibro-inflammatoire du foie, Institute of Cardiometabolism and Nutrition (ICAN) (N.W., S.D.); Assistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Médecine Intensive Réanimation Neurologique, Paris, France (N.W.); Assistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Service de neurochirurgie, Paris, France (B.M.); Assistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Service de virologie, Centre d’Investigation Clinique Neurosciences, Paris, France (S.B., D.B.); CNR Herpèsvirus (laboratoire associé HSV), SU-INSERM UMR_S 1136 Team 3 THERAVIR IPLESP (S.B., D.B.); Assistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Service de Pneumologie, Médecine Intensive et Réanimation, Paris, France (A.D., E.M., T.S.); Assistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Urgences Cérébro-Vasculaires, Paris, France (C.R.); ICM, stroke network, STAR team, Paris, France (C.R.); Assistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Département de Neurologie, Centre d’Investigation Clinique Neurosciences, Paris, France (C.D., J.C.); Assistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Département de Neuropathologie, Paris, France (D.S.); ICM, INRIA, ARAMIS project-team, Paris, France (D.D., M.R., M.R.); Assistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Department of Anesthesia, Critical Care and Peri-Operative Medicine, Paris, France (M.R., V.D.); Clinical Research Group ARPE, Sorbonne University, Paris, France (V.D.); INSERM UMR 1141, Paris France (V.D.); Assistance Publique Hôpitaux de Paris, DMU ESPRIT, Paris, France(P.R.)
| | - Vincent Degos
- Sorbonne Université, Inserm, CNRS, Institut du Cerveau - Paris Brain Institute - ICM, F-75013, Paris, France (L.C., D.G., B.M., C.R., D.D., J.C., S.L., N.P.); Sorbonne Université, 75013, Paris, France (L.C., N.S., N.W., D.G., B.M., S.B., D.B., A.D., C.R., D.S., D.D., E.M., M.R., T.S., V.D., J.C., S.L., N.P.); ICM, “Movement Investigations and Therapeutics” Team (MOV’IT), Paris, France (L.C., S.L., N.P.); ICM, Centre de NeuroImagerie de Recherche – CENIR, Paris, France (L.C., D.G., S.L., N.P.); Assistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Service de neuroradiologie, Paris, France (L.C., N.S., D.G., D.L., S.B., S.S., D.D., S.G., S.T., S.L., N.P.); Brain Liver Pitié-Salpêtrière (BLIPS) Study Group, INSERM UMR_S 938, Centre de recherche Saint-Antoine, Maladies métaboliques, biliaires et fibro-inflammatoire du foie, Institute of Cardiometabolism and Nutrition (ICAN) (N.W., S.D.); Assistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Médecine Intensive Réanimation Neurologique, Paris, France (N.W.); Assistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Service de neurochirurgie, Paris, France (B.M.); Assistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Service de virologie, Centre d’Investigation Clinique Neurosciences, Paris, France (S.B., D.B.); CNR Herpèsvirus (laboratoire associé HSV), SU-INSERM UMR_S 1136 Team 3 THERAVIR IPLESP (S.B., D.B.); Assistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Service de Pneumologie, Médecine Intensive et Réanimation, Paris, France (A.D., E.M., T.S.); Assistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Urgences Cérébro-Vasculaires, Paris, France (C.R.); ICM, stroke network, STAR team, Paris, France (C.R.); Assistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Département de Neurologie, Centre d’Investigation Clinique Neurosciences, Paris, France (C.D., J.C.); Assistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Département de Neuropathologie, Paris, France (D.S.); ICM, INRIA, ARAMIS project-team, Paris, France (D.D., M.R., M.R.); Assistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Department of Anesthesia, Critical Care and Peri-Operative Medicine, Paris, France (M.R., V.D.); Clinical Research Group ARPE, Sorbonne University, Paris, France (V.D.); INSERM UMR 1141, Paris France (V.D.); Assistance Publique Hôpitaux de Paris, DMU ESPRIT, Paris, France(P.R.)
| | - Pierre Rufat
- Sorbonne Université, Inserm, CNRS, Institut du Cerveau - Paris Brain Institute - ICM, F-75013, Paris, France (L.C., D.G., B.M., C.R., D.D., J.C., S.L., N.P.); Sorbonne Université, 75013, Paris, France (L.C., N.S., N.W., D.G., B.M., S.B., D.B., A.D., C.R., D.S., D.D., E.M., M.R., T.S., V.D., J.C., S.L., N.P.); ICM, “Movement Investigations and Therapeutics” Team (MOV’IT), Paris, France (L.C., S.L., N.P.); ICM, Centre de NeuroImagerie de Recherche – CENIR, Paris, France (L.C., D.G., S.L., N.P.); Assistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Service de neuroradiologie, Paris, France (L.C., N.S., D.G., D.L., S.B., S.S., D.D., S.G., S.T., S.L., N.P.); Brain Liver Pitié-Salpêtrière (BLIPS) Study Group, INSERM UMR_S 938, Centre de recherche Saint-Antoine, Maladies métaboliques, biliaires et fibro-inflammatoire du foie, Institute of Cardiometabolism and Nutrition (ICAN) (N.W., S.D.); Assistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Médecine Intensive Réanimation Neurologique, Paris, France (N.W.); Assistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Service de neurochirurgie, Paris, France (B.M.); Assistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Service de virologie, Centre d’Investigation Clinique Neurosciences, Paris, France (S.B., D.B.); CNR Herpèsvirus (laboratoire associé HSV), SU-INSERM UMR_S 1136 Team 3 THERAVIR IPLESP (S.B., D.B.); Assistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Service de Pneumologie, Médecine Intensive et Réanimation, Paris, France (A.D., E.M., T.S.); Assistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Urgences Cérébro-Vasculaires, Paris, France (C.R.); ICM, stroke network, STAR team, Paris, France (C.R.); Assistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Département de Neurologie, Centre d’Investigation Clinique Neurosciences, Paris, France (C.D., J.C.); Assistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Département de Neuropathologie, Paris, France (D.S.); ICM, INRIA, ARAMIS project-team, Paris, France (D.D., M.R., M.R.); Assistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Department of Anesthesia, Critical Care and Peri-Operative Medicine, Paris, France (M.R., V.D.); Clinical Research Group ARPE, Sorbonne University, Paris, France (V.D.); INSERM UMR 1141, Paris France (V.D.); Assistance Publique Hôpitaux de Paris, DMU ESPRIT, Paris, France(P.R.)
| | - Jean-Christophe Corvol
- Sorbonne Université, Inserm, CNRS, Institut du Cerveau - Paris Brain Institute - ICM, F-75013, Paris, France (L.C., D.G., B.M., C.R., D.D., J.C., S.L., N.P.); Sorbonne Université, 75013, Paris, France (L.C., N.S., N.W., D.G., B.M., S.B., D.B., A.D., C.R., D.S., D.D., E.M., M.R., T.S., V.D., J.C., S.L., N.P.); ICM, “Movement Investigations and Therapeutics” Team (MOV’IT), Paris, France (L.C., S.L., N.P.); ICM, Centre de NeuroImagerie de Recherche – CENIR, Paris, France (L.C., D.G., S.L., N.P.); Assistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Service de neuroradiologie, Paris, France (L.C., N.S., D.G., D.L., S.B., S.S., D.D., S.G., S.T., S.L., N.P.); Brain Liver Pitié-Salpêtrière (BLIPS) Study Group, INSERM UMR_S 938, Centre de recherche Saint-Antoine, Maladies métaboliques, biliaires et fibro-inflammatoire du foie, Institute of Cardiometabolism and Nutrition (ICAN) (N.W., S.D.); Assistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Médecine Intensive Réanimation Neurologique, Paris, France (N.W.); Assistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Service de neurochirurgie, Paris, France (B.M.); Assistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Service de virologie, Centre d’Investigation Clinique Neurosciences, Paris, France (S.B., D.B.); CNR Herpèsvirus (laboratoire associé HSV), SU-INSERM UMR_S 1136 Team 3 THERAVIR IPLESP (S.B., D.B.); Assistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Service de Pneumologie, Médecine Intensive et Réanimation, Paris, France (A.D., E.M., T.S.); Assistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Urgences Cérébro-Vasculaires, Paris, France (C.R.); ICM, stroke network, STAR team, Paris, France (C.R.); Assistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Département de Neurologie, Centre d’Investigation Clinique Neurosciences, Paris, France (C.D., J.C.); Assistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Département de Neuropathologie, Paris, France (D.S.); ICM, INRIA, ARAMIS project-team, Paris, France (D.D., M.R., M.R.); Assistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Department of Anesthesia, Critical Care and Peri-Operative Medicine, Paris, France (M.R., V.D.); Clinical Research Group ARPE, Sorbonne University, Paris, France (V.D.); INSERM UMR 1141, Paris France (V.D.); Assistance Publique Hôpitaux de Paris, DMU ESPRIT, Paris, France(P.R.)
| | - Stéphane Lehéricy
- Sorbonne Université, Inserm, CNRS, Institut du Cerveau - Paris Brain Institute - ICM, F-75013, Paris, France (L.C., D.G., B.M., C.R., D.D., J.C., S.L., N.P.); Sorbonne Université, 75013, Paris, France (L.C., N.S., N.W., D.G., B.M., S.B., D.B., A.D., C.R., D.S., D.D., E.M., M.R., T.S., V.D., J.C., S.L., N.P.); ICM, “Movement Investigations and Therapeutics” Team (MOV’IT), Paris, France (L.C., S.L., N.P.); ICM, Centre de NeuroImagerie de Recherche – CENIR, Paris, France (L.C., D.G., S.L., N.P.); Assistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Service de neuroradiologie, Paris, France (L.C., N.S., D.G., D.L., S.B., S.S., D.D., S.G., S.T., S.L., N.P.); Brain Liver Pitié-Salpêtrière (BLIPS) Study Group, INSERM UMR_S 938, Centre de recherche Saint-Antoine, Maladies métaboliques, biliaires et fibro-inflammatoire du foie, Institute of Cardiometabolism and Nutrition (ICAN) (N.W., S.D.); Assistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Médecine Intensive Réanimation Neurologique, Paris, France (N.W.); Assistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Service de neurochirurgie, Paris, France (B.M.); Assistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Service de virologie, Centre d’Investigation Clinique Neurosciences, Paris, France (S.B., D.B.); CNR Herpèsvirus (laboratoire associé HSV), SU-INSERM UMR_S 1136 Team 3 THERAVIR IPLESP (S.B., D.B.); Assistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Service de Pneumologie, Médecine Intensive et Réanimation, Paris, France (A.D., E.M., T.S.); Assistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Urgences Cérébro-Vasculaires, Paris, France (C.R.); ICM, stroke network, STAR team, Paris, France (C.R.); Assistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Département de Neurologie, Centre d’Investigation Clinique Neurosciences, Paris, France (C.D., J.C.); Assistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Département de Neuropathologie, Paris, France (D.S.); ICM, INRIA, ARAMIS project-team, Paris, France (D.D., M.R., M.R.); Assistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Department of Anesthesia, Critical Care and Peri-Operative Medicine, Paris, France (M.R., V.D.); Clinical Research Group ARPE, Sorbonne University, Paris, France (V.D.); INSERM UMR 1141, Paris France (V.D.); Assistance Publique Hôpitaux de Paris, DMU ESPRIT, Paris, France(P.R.)
| | - Nadya Pyatigorskaya
- Sorbonne Université, Inserm, CNRS, Institut du Cerveau - Paris Brain Institute - ICM, F-75013, Paris, France (L.C., D.G., B.M., C.R., D.D., J.C., S.L., N.P.); Sorbonne Université, 75013, Paris, France (L.C., N.S., N.W., D.G., B.M., S.B., D.B., A.D., C.R., D.S., D.D., E.M., M.R., T.S., V.D., J.C., S.L., N.P.); ICM, “Movement Investigations and Therapeutics” Team (MOV’IT), Paris, France (L.C., S.L., N.P.); ICM, Centre de NeuroImagerie de Recherche – CENIR, Paris, France (L.C., D.G., S.L., N.P.); Assistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Service de neuroradiologie, Paris, France (L.C., N.S., D.G., D.L., S.B., S.S., D.D., S.G., S.T., S.L., N.P.); Brain Liver Pitié-Salpêtrière (BLIPS) Study Group, INSERM UMR_S 938, Centre de recherche Saint-Antoine, Maladies métaboliques, biliaires et fibro-inflammatoire du foie, Institute of Cardiometabolism and Nutrition (ICAN) (N.W., S.D.); Assistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Médecine Intensive Réanimation Neurologique, Paris, France (N.W.); Assistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Service de neurochirurgie, Paris, France (B.M.); Assistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Service de virologie, Centre d’Investigation Clinique Neurosciences, Paris, France (S.B., D.B.); CNR Herpèsvirus (laboratoire associé HSV), SU-INSERM UMR_S 1136 Team 3 THERAVIR IPLESP (S.B., D.B.); Assistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Service de Pneumologie, Médecine Intensive et Réanimation, Paris, France (A.D., E.M., T.S.); Assistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Urgences Cérébro-Vasculaires, Paris, France (C.R.); ICM, stroke network, STAR team, Paris, France (C.R.); Assistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Département de Neurologie, Centre d’Investigation Clinique Neurosciences, Paris, France (C.D., J.C.); Assistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Département de Neuropathologie, Paris, France (D.S.); ICM, INRIA, ARAMIS project-team, Paris, France (D.D., M.R., M.R.); Assistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Department of Anesthesia, Critical Care and Peri-Operative Medicine, Paris, France (M.R., V.D.); Clinical Research Group ARPE, Sorbonne University, Paris, France (V.D.); INSERM UMR 1141, Paris France (V.D.); Assistance Publique Hôpitaux de Paris, DMU ESPRIT, Paris, France(P.R.)
| | - On behalf of the CoCo Neurosciences study group
- Sorbonne Université, Inserm, CNRS, Institut du Cerveau - Paris Brain Institute - ICM, F-75013, Paris, France (L.C., D.G., B.M., C.R., D.D., J.C., S.L., N.P.); Sorbonne Université, 75013, Paris, France (L.C., N.S., N.W., D.G., B.M., S.B., D.B., A.D., C.R., D.S., D.D., E.M., M.R., T.S., V.D., J.C., S.L., N.P.); ICM, “Movement Investigations and Therapeutics” Team (MOV’IT), Paris, France (L.C., S.L., N.P.); ICM, Centre de NeuroImagerie de Recherche – CENIR, Paris, France (L.C., D.G., S.L., N.P.); Assistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Service de neuroradiologie, Paris, France (L.C., N.S., D.G., D.L., S.B., S.S., D.D., S.G., S.T., S.L., N.P.); Brain Liver Pitié-Salpêtrière (BLIPS) Study Group, INSERM UMR_S 938, Centre de recherche Saint-Antoine, Maladies métaboliques, biliaires et fibro-inflammatoire du foie, Institute of Cardiometabolism and Nutrition (ICAN) (N.W., S.D.); Assistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Médecine Intensive Réanimation Neurologique, Paris, France (N.W.); Assistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Service de neurochirurgie, Paris, France (B.M.); Assistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Service de virologie, Centre d’Investigation Clinique Neurosciences, Paris, France (S.B., D.B.); CNR Herpèsvirus (laboratoire associé HSV), SU-INSERM UMR_S 1136 Team 3 THERAVIR IPLESP (S.B., D.B.); Assistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Service de Pneumologie, Médecine Intensive et Réanimation, Paris, France (A.D., E.M., T.S.); Assistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Urgences Cérébro-Vasculaires, Paris, France (C.R.); ICM, stroke network, STAR team, Paris, France (C.R.); Assistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Département de Neurologie, Centre d’Investigation Clinique Neurosciences, Paris, France (C.D., J.C.); Assistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Département de Neuropathologie, Paris, France (D.S.); ICM, INRIA, ARAMIS project-team, Paris, France (D.D., M.R., M.R.); Assistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Department of Anesthesia, Critical Care and Peri-Operative Medicine, Paris, France (M.R., V.D.); Clinical Research Group ARPE, Sorbonne University, Paris, France (V.D.); INSERM UMR 1141, Paris France (V.D.); Assistance Publique Hôpitaux de Paris, DMU ESPRIT, Paris, France(P.R.)
| |
Collapse
|
30
|
Luyt CE, Sahnoun T, Gautier M, Vidal P, Burrel S, Pineton de Chambrun M, Chommeloux J, Desnos C, Arzoine J, Nieszkowska A, Bréchot N, Schmidt M, Hekimian G, Boutolleau D, Robert J, Combes A, Chastre J. Ventilator-associated pneumonia in patients with SARS-CoV-2-associated acute respiratory distress syndrome requiring ECMO: a retrospective cohort study. Ann Intensive Care 2020; 10:158. [PMID: 33230710 PMCID: PMC7682692 DOI: 10.1186/s13613-020-00775-4] [Citation(s) in RCA: 91] [Impact Index Per Article: 22.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/03/2020] [Accepted: 11/13/2020] [Indexed: 02/08/2023] Open
Abstract
Background The data on incidence, clinical presentation, and outcomes of ventilator-associated pneumonia (VAP) in patients with severe coronavirus disease 2019 (COVID-19) pneumonia requiring mechanical ventilation (MV) are limited. We performed this retrospective cohort study to assess frequency, clinical characteristics, responsible pathogens, and outcomes of VAP in patients COVID-19 pneumonia requiring MV between March 12th and April 24th, 2020 (all had RT-PCR-confirmed SARS-CoV-2 infection). Patients with COVID-19-associated acute respiratory distress syndrome (ARDS) requiring ECMO were compared with an historical cohort of 45 patients with severe influenza-associated ARDS requiring ECMO admitted to the same ICU during the preceding three winter seasons. Results Among 50 consecutive patients with Covid-19-associated ARDS requiring ECMO included [median (IQR) age 48 (42–56) years; 72% male], 43 (86%) developed VAP [median (IQR) MV duration before the first episode, 10 (8–16) days]. VAP-causative pathogens were predominantly Enterobacteriaceae (70%), particularly inducible AmpC-cephalosporinase producers (40%), followed by Pseudomonas aeruginosa (37%). VAP recurred in 34 (79%) patients and 17 (34%) died. Most recurrences were relapses (i.e., infection with the same pathogen), with a high percentage occurring on adequate antimicrobial treatment. Estimated cumulative incidence of VAP, taking into account death and extubation as competing events, was significantly higher in Covid-19 patients than in influenza patients (p = 0.002). Despite a high P. aeruginosa-VAP rate in patients with influenza-associated ARDS (54%), the pulmonary infection recurrence rate was significantly lower than in Covid-19 patients. Overall mortality was similar for the two groups. Conclusions Patients with severe Covid-19-associated ARDS requiring ECMO had a very high late-onset VAP rate. Inducible AmpC-cephalosporinase-producing Enterobacteriaceae and Pseudomonas aeruginosa frequently caused VAP, with multiple recurrences and difficulties eradicating the pathogen from the lung.
Collapse
Affiliation(s)
- Charles-Edouard Luyt
- Service de Médecine Intensive Réanimation, Institut de Cardiologie, ICAN, Assistance Publique-Hôpitaux de Paris (APHP), Sorbonne-Université, Groupe Hospitalier Pitié-Salpêtrière, 47-83, Boulevard de L'Hôpital, 75651, Paris Cedex 13, France. .,INSERM, UMRS_1166-ICAN Institute of Cardiometabolism and Nutrition, Sorbonne Université, Paris, France.
| | - Tarek Sahnoun
- Service de Médecine Intensive Réanimation, Institut de Cardiologie, ICAN, Assistance Publique-Hôpitaux de Paris (APHP), Sorbonne-Université, Groupe Hospitalier Pitié-Salpêtrière, 47-83, Boulevard de L'Hôpital, 75651, Paris Cedex 13, France
| | - Melchior Gautier
- Service de Médecine Intensive Réanimation, Institut de Cardiologie, ICAN, Assistance Publique-Hôpitaux de Paris (APHP), Sorbonne-Université, Groupe Hospitalier Pitié-Salpêtrière, 47-83, Boulevard de L'Hôpital, 75651, Paris Cedex 13, France
| | - Pauline Vidal
- Service de Bactériologie-Hygiène, APHP, Sorbonne-Université, Hôpital Pitié-Salpêtrière, Paris, France
| | - Sonia Burrel
- Centre National de Référence Herpesvirus (Laboratoire Associé), Service de Virologie, Groupe Hospitalo-Universitaire (GHU) AP-HP, Sorbonne Université, Hôpital Pitié-Salpêtrière, Paris, France.,INSERM U1136, Institut Pierre Louis D'Epidémiologie Et de Santé Publique (iPLESP), Sorbonne Université, Paris, France
| | - Marc Pineton de Chambrun
- Service de Médecine Intensive Réanimation, Institut de Cardiologie, ICAN, Assistance Publique-Hôpitaux de Paris (APHP), Sorbonne-Université, Groupe Hospitalier Pitié-Salpêtrière, 47-83, Boulevard de L'Hôpital, 75651, Paris Cedex 13, France
| | - Juliette Chommeloux
- Service de Médecine Intensive Réanimation, Institut de Cardiologie, ICAN, Assistance Publique-Hôpitaux de Paris (APHP), Sorbonne-Université, Groupe Hospitalier Pitié-Salpêtrière, 47-83, Boulevard de L'Hôpital, 75651, Paris Cedex 13, France
| | - Cyrielle Desnos
- Service de Médecine Intensive Réanimation, Institut de Cardiologie, ICAN, Assistance Publique-Hôpitaux de Paris (APHP), Sorbonne-Université, Groupe Hospitalier Pitié-Salpêtrière, 47-83, Boulevard de L'Hôpital, 75651, Paris Cedex 13, France
| | - Jeremy Arzoine
- Département D'Anesthésie-Réanimation, Assistance Publique-Hôpitaux de Paris (APHP), Sorbonne-Université, Hôpital Pitié-Salpêtrière, Paris, France
| | - Ania Nieszkowska
- Service de Médecine Intensive Réanimation, Institut de Cardiologie, ICAN, Assistance Publique-Hôpitaux de Paris (APHP), Sorbonne-Université, Groupe Hospitalier Pitié-Salpêtrière, 47-83, Boulevard de L'Hôpital, 75651, Paris Cedex 13, France
| | - Nicolas Bréchot
- Service de Médecine Intensive Réanimation, Institut de Cardiologie, ICAN, Assistance Publique-Hôpitaux de Paris (APHP), Sorbonne-Université, Groupe Hospitalier Pitié-Salpêtrière, 47-83, Boulevard de L'Hôpital, 75651, Paris Cedex 13, France.,INSERM, UMRS_1166-ICAN Institute of Cardiometabolism and Nutrition, Sorbonne Université, Paris, France
| | - Matthieu Schmidt
- Service de Médecine Intensive Réanimation, Institut de Cardiologie, ICAN, Assistance Publique-Hôpitaux de Paris (APHP), Sorbonne-Université, Groupe Hospitalier Pitié-Salpêtrière, 47-83, Boulevard de L'Hôpital, 75651, Paris Cedex 13, France.,INSERM, UMRS_1166-ICAN Institute of Cardiometabolism and Nutrition, Sorbonne Université, Paris, France
| | - Guillaume Hekimian
- Service de Médecine Intensive Réanimation, Institut de Cardiologie, ICAN, Assistance Publique-Hôpitaux de Paris (APHP), Sorbonne-Université, Groupe Hospitalier Pitié-Salpêtrière, 47-83, Boulevard de L'Hôpital, 75651, Paris Cedex 13, France
| | - David Boutolleau
- Centre National de Référence Herpesvirus (Laboratoire Associé), Service de Virologie, Groupe Hospitalo-Universitaire (GHU) AP-HP, Sorbonne Université, Hôpital Pitié-Salpêtrière, Paris, France.,INSERM U1136, Institut Pierre Louis D'Epidémiologie Et de Santé Publique (iPLESP), Sorbonne Université, Paris, France
| | - Jérôme Robert
- Service de Bactériologie-Hygiène, APHP, Sorbonne-Université, Hôpital Pitié-Salpêtrière, Paris, France
| | - Alain Combes
- Service de Médecine Intensive Réanimation, Institut de Cardiologie, ICAN, Assistance Publique-Hôpitaux de Paris (APHP), Sorbonne-Université, Groupe Hospitalier Pitié-Salpêtrière, 47-83, Boulevard de L'Hôpital, 75651, Paris Cedex 13, France.,INSERM, UMRS_1166-ICAN Institute of Cardiometabolism and Nutrition, Sorbonne Université, Paris, France
| | - Jean Chastre
- Service de Médecine Intensive Réanimation, Institut de Cardiologie, ICAN, Assistance Publique-Hôpitaux de Paris (APHP), Sorbonne-Université, Groupe Hospitalier Pitié-Salpêtrière, 47-83, Boulevard de L'Hôpital, 75651, Paris Cedex 13, France.,INSERM, UMRS_1166-ICAN Institute of Cardiometabolism and Nutrition, Sorbonne Université, Paris, France
| |
Collapse
|
31
|
Burrel S, Hausfater P, Dres M, Pourcher V, Luyt CE, Teyssou E, Soulié C, Calvez V, Marcelin AG, Boutolleau D. Co-infection of SARS-CoV-2 with other respiratory viruses and performance of lower respiratory tract samples for the diagnosis of COVID-19. Int J Infect Dis 2020; 102:10-13. [PMID: 33115679 PMCID: PMC7585729 DOI: 10.1016/j.ijid.2020.10.040] [Citation(s) in RCA: 25] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/10/2020] [Revised: 10/19/2020] [Accepted: 10/22/2020] [Indexed: 02/04/2023] Open
Abstract
Objectives This study was performed during the early outbreak period of coronavirus disease 2019 (COVID-19) and the seasonal epidemics of other respiratory viral infections, in order to describe the extent of co-infections of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) with other respiratory viruses. It also compared the diagnostic performances of upper respiratory tract (URT) and lower respiratory tract (LRT) samples for SARS-CoV-2 infection. Methods From 25 January to 29 March 2020, all URT and LRT samples collected from patients with suspected COVID-19 received in the virology laboratory of Pitié-Salpêtrière University Hospital (Paris, France) were simultaneously tested for SARS-CoV-2 and other respiratory viruses. Results A total of 1423 consecutive patients were tested: 677 (47.6%) males, 746 (52.4%) females, median age 50 (range, 1–103) years. Twenty-one (1.5%) patients were positive for both SARS-CoV-2 and other respiratory viruses. The detection rate of SARS-CoV-2 was significantly higher in LRT than in URT (53.6% vs. 13.4%; p < 0.0001). The analysis of paired samples from 117 (8.2%) patients showed that SARS-CoV-2 load was lower in URT than in LRT samples in 65% of cases. Conclusion The detection of other respiratory viruses in patients during this epidemic period could not rule out SARS-CoV-2 co-infection. Furthermore, LRT samples increased the accuracy of diagnosis of COVID-19.
Collapse
Affiliation(s)
- Sonia Burrel
- AP-HP, Sorbonne Université, Hôpital Pitié-Salpêtrière, Service de Virologie, Paris, France; Sorbonne Université, INSERM U1136, Institut Pierre Louis d'Epidémiologie et de Santé Publique (IPLESP), Paris, France
| | - Pierre Hausfater
- AP-HP, Sorbonne Université, Hôpital Pitié-Salpêtrière, Service d'Accueil des Urgences, Paris, France; Sorbonne Universités GRC-14 BIOSFAST et INSERM UMR-S 1166, Paris, France
| | - Martin Dres
- Sorbonne Université, INSERM, UMRS1158 Neurophysiologie respiratoire expérimentale et clinique, Paris, France; AP-HP, Sorbonne Université, Hôpital Pitié-Salpêtrière, Service de Pneumologie, Médecine intensive-Réanimation (Département 'R3S'), Paris, France
| | - Valérie Pourcher
- Sorbonne Université, INSERM U1136, Institut Pierre Louis d'Epidémiologie et de Santé Publique (IPLESP), Paris, France; AP-HP, Sorbonne Université, Hôpital Pitié-Salpêtrière, Service de Maladies Infectieuses et Tropicales, Paris, France
| | - Charles-Edouard Luyt
- AP-HP, Sorbonne Université, Hôpital Pitié-Salpêtrière, Service de Médecine Intensive Réanimation, Institut de Cardiologie, Paris, France; Sorbonne Université, INSERM, UMRS_1166-ICAN Institut de Cardiométabolisme et Nutrition, Paris, France
| | - Elisa Teyssou
- AP-HP, Sorbonne Université, Hôpital Pitié-Salpêtrière, Service de Virologie, Paris, France; Sorbonne Université, INSERM U1136, Institut Pierre Louis d'Epidémiologie et de Santé Publique (IPLESP), Paris, France
| | - Cathia Soulié
- AP-HP, Sorbonne Université, Hôpital Pitié-Salpêtrière, Service de Virologie, Paris, France; Sorbonne Université, INSERM U1136, Institut Pierre Louis d'Epidémiologie et de Santé Publique (IPLESP), Paris, France
| | - Vincent Calvez
- AP-HP, Sorbonne Université, Hôpital Pitié-Salpêtrière, Service de Virologie, Paris, France; Sorbonne Université, INSERM U1136, Institut Pierre Louis d'Epidémiologie et de Santé Publique (IPLESP), Paris, France
| | - Anne-Geneviève Marcelin
- AP-HP, Sorbonne Université, Hôpital Pitié-Salpêtrière, Service de Virologie, Paris, France; Sorbonne Université, INSERM U1136, Institut Pierre Louis d'Epidémiologie et de Santé Publique (IPLESP), Paris, France
| | - David Boutolleau
- AP-HP, Sorbonne Université, Hôpital Pitié-Salpêtrière, Service de Virologie, Paris, France; Sorbonne Université, INSERM U1136, Institut Pierre Louis d'Epidémiologie et de Santé Publique (IPLESP), Paris, France.
| |
Collapse
|
32
|
Pernet J, de Bonnières H, Breton C, Hirsch V, Molitor J, Boutolleau D, Piarroux R, Hausfater P. Retour d’expérience sur Covisan : un dispositif médicosocial pour casser les chaînes de transmission de la Covid-19. Ann Fr Med Urgence 2020. [DOI: 10.3166/afmu-2020-0266] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/19/2023]
Abstract
Covisan a été mis en place à partir du 14 avril 2020 au niveau de quatre sites pilotes de l’Assistance publique-Hôpitaux de Paris (APHP) pour casser les chaînes de transmission au SARS-CoV-2 selon un modèle original déjà éprouvé en Haïti pour éliminer le choléra dans les années 2010. Le dispositif consiste en un dépistage systématique des cas possibles de Covid-19, un accompagnement dans leur confinement et une prise en charge de leurs proches. Des équipes mobiles se sont déplacées au domicile des cas contacts afin d’évaluer les possibilités d’un isolement au domicile, de proposer des aides matérielles (courses, blanchisserie, hébergement externalisé) et de dépister leurs proches. Au 17 juin 2020, 6 376 patients ont été orientés vers Covisan, parmi lesquels 153 avaient une RT-PCR (reverse transciptase polymerase chain reaction) positive au SARSCoV-2. Covisan a permis un partenariat ville–hôpital innovant, en impliquant de multiples acteurs (personnels soignants, administratifs, logisticiens, métiers de service). Les autorités sanitaires se sont d’ailleurs inspirées de ce modèle pour lutter contre l’épidémie en mettant en place le contact tracing. Covisan, qui a appris en marchant, a également rencontré quelques difficultés, en particulier au niveau de la gestion des différents statuts des personnels ainsi qu’au niveau de la communication interne et externe.
Collapse
|
33
|
Castandet L, Danton E, Bernard F, Oger K, Breger I, Tamames C, Boutolleau D, Caumes E, Godefroy N, Klement-frutos E. AMBUCOV : description d’un système de dépistage hospitalier en ambulatoire en réponse à l’épidémie de CoViD-19. Med Mal Infect 2020. [PMCID: PMC7441949 DOI: 10.1016/j.medmal.2020.06.465] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Abstract
Introduction Suite à la déclaration d’épidémie de pneumopathies au nouveau coronavirus CoViD-19 en Chine en décembre 2019, 11 patients ont été confirmés infectés en France du 20/01 au 10/02/2020 dont 5 en Île-de-France. Devant l’afflux de personnes nécessitant un dépistage et le manque de place en unité d’isolement dans les établissements de soins référent (ESR), un système dégradé d’accueil pour le dépistage des cas suspects de CoViD-19 a été élaboré. En concertation avec les autorités sanitaires françaises et la direction de l’hôpital, le département des maladies infectieuses a développé le projet AmbuCoV pour pouvoir accueillir au mieux et sans délais toutes les personnes qui lui étaient adressées. Matériels et méthodes Mise en place d’une unité dédiée pour la prise en charge des personnes nécessitant un dépistage pour le CoViD-19 et ne justifiant pas d’une hospitalisation. L’unité AmbuCoV, ouverte 24 h/24 et 7j/7, a fonctionné avec le personnel minimum et respecté un parcours patient développé par l’équipe pluridisciplinaire du service pour le dépistage et l’isolement au sein de l’établissement. Le laboratoire de virologie procédait à deux séries de PCR par jour, avec un rendu des résultats vers 13 h pour les prélèvements envoyés avant 8 h, et 19 h pour ceux envoyés avant 14 h. Une évaluation interne a été menée afin d’évaluer quantitativement et qualitativement ce dispositif. Résultats AmbuCoV a été ouvert le 31 janvier 2020 et comprenait 22 lits répartis en 16 chambres. Une infirmière effectuait le prélèvement nasopharyngé et la prise des constantes dans le box dédié en pression négative de l’unite d’isolement. Les personnes sans ATCD et paucisymptomatiques (constantes normales, t < 38 °C, absence de dyspnée et de toux) étaient accompagnées pour être isolées dans l’unité AmbuCoV jusqu’à réception des résultats. Ces patients ne nécessitant pas de soins infirmiers, une aide-soignante présente dans l’unité en permanence répondait à leurs besoins et assurait le lien avec les infirmières et médecins du service. En cas d’infection CoViD-19 confirmée les patients devaient être hospitalisés dans l’unité d’isolement. Les deux premières semaines, 15 personnes de 10 à 48 ans ont été admises dans AmbuCov soit 20 % des personnes admises pour dépistage du CoViD-19 dans notre ESR. Nous présentons en photos et à l’aide de figures la procédure et le parcours des personnes prises en charge. Aucune personne suspecte d’infection à CoViD-19 ne s’est vue refusée l’admission pour dépistage dans notre ESR. Les usagers et le personnel soignant se sont montrés satisfaits de ce programme. La principale limitation à l’utilisation de l’unité AmbuCoV était l’absence de pression négative dans les chambres qui contre-indiquait la prise en charge des personnes présentant une toux ou des signes broncho-pulmonaires. Un système de recyclage de l’air par appareil mobile (Plasmair) est à l’essai. Conclusion Nous avons mis en place une stratégie de dépistage ambulatoire d’une infection virale émergente pour faire face à l’augmentation de patients et de cas suspects en contexte épidémique. Cette unité baptisée AmbuCoV nous a permis de faire face rapidement et efficacement à l’afflux de personnes et pourra être réutilisée à l’avenir en cas de nouvelle épidémie. Nous souhaitons partager notre expérience, ainsi que son évaluation en termes de points forts et difficultés rencontrées, afin qu’elle puisse servir à d’autres personnels de santé.
Collapse
|
34
|
Boutolleau D, Burrel S. Caution is required for the interpretation of mutations in herpes simplex virus DNA polymerase for resistance to acyclovir. J Glob Antimicrob Resist 2020; 22:695-696. [DOI: 10.1016/j.jgar.2020.07.007] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/07/2020] [Revised: 07/01/2020] [Accepted: 07/09/2020] [Indexed: 11/29/2022] Open
|
35
|
Faury H, Courboulès C, Payen M, Jary A, Hausfater P, Luyt C, Dres M, Pourcher V, Abdi B, Wirden M, Calvez V, Marcelin AG, Boutolleau D, Burrel S. Medical features of COVID-19 and influenza infection: A comparative study in Paris, France. J Infect 2020; 82:e36-e39. [PMID: 32798533 PMCID: PMC7426213 DOI: 10.1016/j.jinf.2020.08.017] [Citation(s) in RCA: 13] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/10/2020] [Accepted: 08/11/2020] [Indexed: 12/27/2022]
Affiliation(s)
- Hélène Faury
- AP-HP.Sorbonne Université, Hôpital Pitié-Salpêtrière, Service de Virologie, Paris, France
| | - Camille Courboulès
- AP-HP.Sorbonne Université, Hôpital Pitié-Salpêtrière, Service de Virologie, Paris, France
| | - Mathilde Payen
- AP-HP.Sorbonne Université, Hôpital Pitié-Salpêtrière, Service de Virologie, Paris, France
| | - Aude Jary
- Sorbonne Université, INSERM U1136, Institut Pierre Louis d'Epidémiologie et de Santé Publique (IPLESP), AP-HP, Hôpital Pitié-Salpêtrière, Service de Virologie, 83 boulevard de l'hôpital, F 75013 Paris, France
| | - Pierre Hausfater
- AP-HP.Sorbonne Université, Hôpital Pitié-Salpêtrière, Service d'Accueil des Urgences and Sorbonne Universités GRC-14 BIOSFAST et INSERM UMR-S 1166, Paris, France
| | - CharlesEdouard Luyt
- AP-HP.Sorbonne Université, Hôpital Pitié-Salpêtrière, Service de Médecine Intensive Réanimation, Institut de Cardiologie and Sorbonne Université, INSERM, UMRS_1166-ICAN Institut de Cardiométabolisme et Nutrition, Paris, France
| | - Martin Dres
- AP-HP. Sorbonne Université, Hôpital Pitié-Salpêtrière, Service de Pneumologie, Médecine intensive et Réanimation, Paris, France; Sorbonne Université, INSERM, UMRS1158 Neurophysiologie respiratoire expérimentale et clinique - Réanimation, Paris, France
| | - Valérie Pourcher
- Sorbonne Université, INSERM U1136, Institut Pierre Louis d'Epidémiologie et de Santé Publique (IPLESP), AP-HP, Hôpital Pitié-Salpêtrière, Service de Maladies Infectieuses, Paris, France
| | - Basma Abdi
- Sorbonne Université, INSERM U1136, Institut Pierre Louis d'Epidémiologie et de Santé Publique (IPLESP), AP-HP, Hôpital Pitié-Salpêtrière, Service de Virologie, 83 boulevard de l'hôpital, F 75013 Paris, France
| | - Marc Wirden
- Sorbonne Université, INSERM U1136, Institut Pierre Louis d'Epidémiologie et de Santé Publique (IPLESP), AP-HP, Hôpital Pitié-Salpêtrière, Service de Virologie, 83 boulevard de l'hôpital, F 75013 Paris, France
| | - Vincent Calvez
- Sorbonne Université, INSERM U1136, Institut Pierre Louis d'Epidémiologie et de Santé Publique (IPLESP), AP-HP, Hôpital Pitié-Salpêtrière, Service de Virologie, 83 boulevard de l'hôpital, F 75013 Paris, France
| | - Anne-Geneviève Marcelin
- Sorbonne Université, INSERM U1136, Institut Pierre Louis d'Epidémiologie et de Santé Publique (IPLESP), AP-HP, Hôpital Pitié-Salpêtrière, Service de Virologie, 83 boulevard de l'hôpital, F 75013 Paris, France
| | - David Boutolleau
- Sorbonne Université, INSERM U1136, Institut Pierre Louis d'Epidémiologie et de Santé Publique (IPLESP), AP-HP, Hôpital Pitié-Salpêtrière, Service de Virologie, 83 boulevard de l'hôpital, F 75013 Paris, France
| | - Sonia Burrel
- Sorbonne Université, INSERM U1136, Institut Pierre Louis d'Epidémiologie et de Santé Publique (IPLESP), AP-HP, Hôpital Pitié-Salpêtrière, Service de Virologie, 83 boulevard de l'hôpital, F 75013 Paris, France.
| |
Collapse
|
36
|
Dres M, Burrel S, Boutolleau D, Voiriot G, Demoule A, Combes A, Lebreton G, Schmidt M. SARS-CoV-2 Does Not Spread Through Extracorporeal Membrane Oxygenation or Dialysis Membranes. Am J Respir Crit Care Med 2020; 202:458-460. [PMID: 32525400 PMCID: PMC7397802 DOI: 10.1164/rccm.202004-1339le] [Citation(s) in RCA: 9] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/19/2023] Open
Affiliation(s)
- Martin Dres
- UMR_S 1158 Neurophysiologie respiratoire expérimentale et cliniqueParis, France.,AP-HP Sorbonne UniversitéParis, France
| | - Sonia Burrel
- AP-HP Sorbonne UniversitéParis, France.,INSERM UMR_S 1136Paris, Franceand
| | - David Boutolleau
- AP-HP Sorbonne UniversitéParis, France.,INSERM UMR_S 1136Paris, Franceand
| | | | - Alexandre Demoule
- UMR_S 1158 Neurophysiologie respiratoire expérimentale et cliniqueParis, France.,AP-HP Sorbonne UniversitéParis, France
| | - Alain Combes
- AP-HP Sorbonne UniversitéParis, France.,UMRS_1166-ICAN Institute of Cardiometabolism and NutritionParis, France
| | - Guillaume Lebreton
- AP-HP Sorbonne UniversitéParis, France.,UMRS_1166-ICAN Institute of Cardiometabolism and NutritionParis, France
| | - Matthieu Schmidt
- AP-HP Sorbonne UniversitéParis, France.,UMRS_1166-ICAN Institute of Cardiometabolism and NutritionParis, France
| |
Collapse
|
37
|
Cancella de Abreu M, Choquet C, Petit H, Bouzid D, Damond F, Marot S, Ferre VM, Burrel S, Boutolleau D, Houdou-Fidouh N, Marcelin AG, Descamps D, Hausfater P. SARS-CoV-2 IGM and IGG rapid serologic test for the diagnosis of COVID-19 in the emergency department. J Infect 2020; 81:816-846. [PMID: 32739490 PMCID: PMC7392071 DOI: 10.1016/j.jinf.2020.07.032] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/30/2020] [Revised: 07/27/2020] [Accepted: 07/28/2020] [Indexed: 01/22/2023]
Affiliation(s)
- Marta Cancella de Abreu
- Emergency Department, Hôpital Pitié-Salpêtrière, 7-83 Boulevard de l'Hôpital, 75013 Paris, France.
| | - Christophe Choquet
- Emergency Department, Hôpital Pitié-Salpêtrière, 7-83 Boulevard de l'Hôpital, 75013 Paris, France
| | - Héloise Petit
- Emergency Department, Hôpital Pitié-Salpêtrière, 7-83 Boulevard de l'Hôpital, 75013 Paris, France
| | - Donia Bouzid
- Emergency Department, Hôpital Pitié-Salpêtrière, 7-83 Boulevard de l'Hôpital, 75013 Paris, France
| | - Florence Damond
- Emergency Department, Hôpital Pitié-Salpêtrière, 7-83 Boulevard de l'Hôpital, 75013 Paris, France
| | - Stephane Marot
- Emergency Department, Hôpital Pitié-Salpêtrière, 7-83 Boulevard de l'Hôpital, 75013 Paris, France
| | - Valentine Marie Ferre
- Emergency Department, Hôpital Pitié-Salpêtrière, 7-83 Boulevard de l'Hôpital, 75013 Paris, France
| | - Sonia Burrel
- Emergency Department, Hôpital Pitié-Salpêtrière, 7-83 Boulevard de l'Hôpital, 75013 Paris, France
| | - David Boutolleau
- Emergency Department, Hôpital Pitié-Salpêtrière, 7-83 Boulevard de l'Hôpital, 75013 Paris, France
| | - Nadhira Houdou-Fidouh
- Emergency Department, Hôpital Pitié-Salpêtrière, 7-83 Boulevard de l'Hôpital, 75013 Paris, France
| | - Anne-Geneviève Marcelin
- Emergency Department, Hôpital Pitié-Salpêtrière, 7-83 Boulevard de l'Hôpital, 75013 Paris, France
| | - Diane Descamps
- Emergency Department, Hôpital Pitié-Salpêtrière, 7-83 Boulevard de l'Hôpital, 75013 Paris, France
| | - Pierre Hausfater
- Emergency Department, Hôpital Pitié-Salpêtrière, 7-83 Boulevard de l'Hôpital, 75013 Paris, France
| |
Collapse
|
38
|
Jary A, Leducq V, Malet I, Marot S, Klement-Frutos E, Teyssou E, Soulié C, Abdi B, Wirden M, Pourcher V, Caumes E, Calvez V, Burrel S, Marcelin AG, Boutolleau D. Evolution of viral quasispecies during SARS-CoV-2 infection. Clin Microbiol Infect 2020; 26:1560.e1-1560.e4. [PMID: 32717416 PMCID: PMC7378485 DOI: 10.1016/j.cmi.2020.07.032] [Citation(s) in RCA: 68] [Impact Index Per Article: 17.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/08/2020] [Revised: 07/09/2020] [Accepted: 07/21/2020] [Indexed: 11/25/2022]
Abstract
Objectives Studies are needed to better understand the genomic evolution of the recently emerged severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). This study aimed to describe genomic diversity of SARS-CoV-2 by next-generation sequencing (NGS) in a patient with longitudinal follow-up for SARS-CoV-2 infection. Methods Sequential samples collected between January 29th and February 4th, 2020, from a patient infected by SARS-CoV-2 were used to perform amplification of two genome fragments—including genes encoding spike, envelope, membrane and nucleocapsid proteins—and NGS was carried out with Illumina® technology. Phylogenetic analysis was performed with PhyML and viral variant identification with VarScan. Results Majority consensus sequences were identical in most of the samples (5/7) and differed in one synonymous mutation from the Wuhan reference sequence. We identified 233 variants; each sample harboured in median 38 different minority variants, and only four were shared by different samples. The frequency of mutation was similar between genes and correlated with the length of the gene (r = 0.93, p = 0.0002). Most of mutations were substitution variations (n = 217, 93.1%) and about 50% had moderate or high impact on gene expression. Viral variants also differed between lower and upper respiratory tract samples collected on the same day, suggesting independent sites of replication of SARS-CoV-2. Conclusions We report for the first time minority viral populations representing up to 1% during the course of SARS-CoV-2 infection. Quasispecies were different from one day to the next, as well as between anatomical sites, suggesting that in vivo this new coronavirus appears as a complex and dynamic distributions of variants.
Collapse
Affiliation(s)
- Aude Jary
- Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), AP-HP, Hôpital Pitié Salpêtrière, Service de Virologie, Paris, France.
| | - Valentin Leducq
- Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), AP-HP, Hôpital Pitié Salpêtrière, Service de Virologie, Paris, France
| | - Isabelle Malet
- Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), AP-HP, Hôpital Pitié Salpêtrière, Service de Virologie, Paris, France
| | - Stéphane Marot
- Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), AP-HP, Hôpital Pitié Salpêtrière, Service de Virologie, Paris, France
| | - Elise Klement-Frutos
- Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), AP-HP, Hôpital Pitié Salpêtrière, Service de Maladie Infectieuses et Tropicales, Paris, France
| | - Elisa Teyssou
- Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), AP-HP, Hôpital Pitié Salpêtrière, Service de Virologie, Paris, France
| | - Cathia Soulié
- Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), AP-HP, Hôpital Pitié Salpêtrière, Service de Virologie, Paris, France
| | - Basma Abdi
- Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), AP-HP, Hôpital Pitié Salpêtrière, Service de Virologie, Paris, France
| | - Marc Wirden
- Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), AP-HP, Hôpital Pitié Salpêtrière, Service de Virologie, Paris, France
| | - Valérie Pourcher
- Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), AP-HP, Hôpital Pitié Salpêtrière, Service de Maladie Infectieuses et Tropicales, Paris, France
| | - Eric Caumes
- Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), AP-HP, Hôpital Pitié Salpêtrière, Service de Maladie Infectieuses et Tropicales, Paris, France
| | - Vincent Calvez
- Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), AP-HP, Hôpital Pitié Salpêtrière, Service de Virologie, Paris, France
| | - Sonia Burrel
- Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), AP-HP, Hôpital Pitié Salpêtrière, Service de Virologie, Paris, France
| | - Anne-Geneviève Marcelin
- Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), AP-HP, Hôpital Pitié Salpêtrière, Service de Virologie, Paris, France
| | - David Boutolleau
- Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), AP-HP, Hôpital Pitié Salpêtrière, Service de Virologie, Paris, France
| |
Collapse
|
39
|
Le Guennec L, Devianne J, Jalin L, Cao A, Galanaud D, Navarro V, Boutolleau D, Rohaut B, Weiss N, Demeret S. Orbitofrontal involvement in a neuroCOVID-19 patient. Epilepsia 2020; 61:e90-e94. [PMID: 32589794 PMCID: PMC7361605 DOI: 10.1111/epi.16612] [Citation(s) in RCA: 55] [Impact Index Per Article: 13.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/20/2020] [Revised: 06/15/2020] [Accepted: 06/23/2020] [Indexed: 01/01/2023]
Abstract
Neurological manifestations of coronavirus disease 19 (COVID‐19) such as encephalitis and seizures have been reported increasingly, but our understanding of COVID‐19‐related brain injury is still limited. Herein we describe prefrontal involvement in a patient with COVID‐19 who presented prior anosmia, raising the question of a potential trans‐olfactory bulb brain invasion.
Collapse
Affiliation(s)
- Loïc Le Guennec
- Neurology Department, Neurological Intensive Care Unit, Pitié-Salpêtrière Hospital, AP-HP.Sorbonne Université, Paris, France.,Sorbonne Université, Paris, France.,Brain Institute Paris, ICM (Inserm, CNRS, Sorbonne Université), Paris, France
| | - Julia Devianne
- Neurology Department, Neurological Intensive Care Unit, Pitié-Salpêtrière Hospital, AP-HP.Sorbonne Université, Paris, France.,Sorbonne Université, Paris, France
| | - Laurence Jalin
- Sorbonne Université, Paris, France.,Neurosurgical Intensive Care Unit, Pitié-Salpêtrière Hospital, AP-HP.Sorbonne Université, Paris, France
| | - Albert Cao
- Neurology Department, Neurological Intensive Care Unit, Pitié-Salpêtrière Hospital, AP-HP.Sorbonne Université, Paris, France.,Sorbonne Université, Paris, France
| | - Damien Galanaud
- Sorbonne Université, Paris, France.,Neuroradiology Department, Hôpital Pitié-Salpêtrière, Pitié-Salpêtrière Hospital, AP-HP.Sorbonne Université, Paris, France
| | - Vincent Navarro
- Sorbonne Université, Paris, France.,Brain Institute Paris, ICM (Inserm, CNRS, Sorbonne Université), Paris, France.,Neurology and Neurophysiology Department, Hôpital Pitié-Salpêtrière, Pitié-Salpêtrière Hospital, AP-HP.Sorbonne Université, Paris, France
| | - David Boutolleau
- Sorbonne Université, Paris, France.,Virology Department, Pitié-Salpêtrière Hospital, AP-HP.Sorbonne Université, Paris, France
| | - Benjamin Rohaut
- Neurology Department, Neurological Intensive Care Unit, Pitié-Salpêtrière Hospital, AP-HP.Sorbonne Université, Paris, France.,Sorbonne Université, Paris, France.,Brain Institute Paris, ICM (Inserm, CNRS, Sorbonne Université), Paris, France.,Department of Neurology, Columbia University, New York, New York
| | - Nicolas Weiss
- Neurology Department, Neurological Intensive Care Unit, Pitié-Salpêtrière Hospital, AP-HP.Sorbonne Université, Paris, France.,Sorbonne Université, Paris, France.,Brain Institute Paris, ICM (Inserm, CNRS, Sorbonne Université), Paris, France
| | - Sophie Demeret
- Neurology Department, Neurological Intensive Care Unit, Pitié-Salpêtrière Hospital, AP-HP.Sorbonne Université, Paris, France.,Sorbonne Université, Paris, France.,Brain Institute Paris, ICM (Inserm, CNRS, Sorbonne Université), Paris, France
| |
Collapse
|
40
|
Lecronier M, Beurton A, Burrel S, Haudebourg L, Deleris R, Le Marec J, Virolle S, Nemlaghi S, Bureau C, Mora P, De Sarcus M, Clovet O, Duceau B, Grisot PH, Pari MH, Arzoine J, Clarac U, Boutolleau D, Raux M, Delemazure J, Faure M, Decavele M, Morawiec E, Mayaux J, Demoule A, Dres M. Comparison of hydroxychloroquine, lopinavir/ritonavir, and standard of care in critically ill patients with SARS-CoV-2 pneumonia: an opportunistic retrospective analysis. Crit Care 2020; 24:418. [PMID: 32653015 PMCID: PMC7351645 DOI: 10.1186/s13054-020-03117-9] [Citation(s) in RCA: 35] [Impact Index Per Article: 8.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/14/2020] [Accepted: 06/29/2020] [Indexed: 01/08/2023] Open
Abstract
BACKGROUND The severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) outbreak is spreading worldwide. To date, no specific treatment has convincingly demonstrated its efficacy. Hydroxychloroquine and lopinavir/ritonavir have potential interest, but virological and clinical data are scarce, especially in critically ill patients. METHODS The present report took the opportunity of compassionate use and successive drug shortages to compare the effects of two therapeutic options, lopinavir/ritonavir and hydroxychloroquine, as compared to standard of care only. The primary outcomes were treatment escalation (intubation, extra-corporeal membrane oxygenation support, or renal replacement therapy) after day 1 until day 28. Secondary outcomes included ventilator-free days at day 28, mortality at day 14 and day 28, treatment safety issues and changes in respiratory tracts, and plasma viral load (as estimated by cycle threshold value) between admission and day 7. RESULTS Eighty patients were treated during a 4-week period and included in the analysis: 22 (28%) received standard of care only, 20 (25%) patients received lopinavir/ritonavir associated to standard of care, and 38 (47%) patients received hydroxychloroquine and standard of care. Baseline characteristics were well balanced between the 3 groups. Treatment escalation occurred in 9 (41%), 10 (50%), and 15 (39%) patients who received standard of care only, standard of care and lopinavir/ritonavir, and standard of care and hydroxychloroquine, respectively (p = 0.567). There was no significant difference between groups regarding the number of ventilator-free days at day 28 and mortality at day 14 and day 28. Finally, there was no significant change between groups in viral respiratory or plasma load between admission and day 7. CONCLUSION In critically ill patients admitted for SARS-CoV-2-related pneumonia, no difference was found between hydroxychloroquine or lopinavir/ritonavir as compared to standard of care only on the proportion of patients who needed treatment escalation at day 28. Further randomized controlled trials are required to demonstrate whether these drugs may be useful in this context.
Collapse
Affiliation(s)
- Marie Lecronier
- AP-HP. Sorbonne Université, Hôpital Pitié-Salpêtrière, Service de Pneumologie, Médecine intensive - Réanimation (Département "R3S"), Paris, France.
| | - Alexandra Beurton
- AP-HP. Sorbonne Université, Hôpital Pitié-Salpêtrière, Service de Pneumologie, Médecine intensive - Réanimation (Département "R3S"), Paris, France
- Sorbonne Université, INSERM, UMR_S 1158 Neurophysiologie respiratoire expérimentale et clinique, Paris, France
| | - Sonia Burrel
- Sorbonne Université, INSERM UMR S 1136, Institut Pierre Louis d'Epidémiologie et de Santé Publique, Team 3 THERAVIR, Paris, France
- AP-HP. Sorbonne Université, Hôpital Pitié-Salpêtrière, Service de Virologie, Centre National de Référence Herpès virus, Paris, France
| | - Luc Haudebourg
- AP-HP. Sorbonne Université, Hôpital Pitié-Salpêtrière, Service de Pneumologie, Médecine intensive - Réanimation (Département "R3S"), Paris, France
| | - Robin Deleris
- AP-HP. Sorbonne Université, Hôpital Pitié-Salpêtrière, Service de Pneumologie, Médecine intensive - Réanimation (Département "R3S"), Paris, France
| | - Julien Le Marec
- AP-HP. Sorbonne Université, Hôpital Pitié-Salpêtrière, Service de Pneumologie, Médecine intensive - Réanimation (Département "R3S"), Paris, France
| | - Sara Virolle
- AP-HP. Sorbonne Université, Hôpital Pitié-Salpêtrière, Service de Pneumologie, Médecine intensive - Réanimation (Département "R3S"), Paris, France
| | - Safaa Nemlaghi
- AP-HP. Sorbonne Université, Hôpital Pitié-Salpêtrière, Service de Pneumologie, Médecine intensive - Réanimation (Département "R3S"), Paris, France
| | - Côme Bureau
- AP-HP. Sorbonne Université, Hôpital Pitié-Salpêtrière, Service de Pneumologie, Médecine intensive - Réanimation (Département "R3S"), Paris, France
- Sorbonne Université, INSERM, UMR_S 1158 Neurophysiologie respiratoire expérimentale et clinique, Paris, France
| | - Pierre Mora
- AP-HP. Sorbonne Université, Hôpital Pitié-Salpêtrière, Service de Pneumologie, Médecine intensive - Réanimation (Département "R3S"), Paris, France
| | - Martin De Sarcus
- AP-HP. Sorbonne Université, Hôpital Pitié-Salpêtrière, Département d'anesthésie réanimation, Paris, France
| | - Olivier Clovet
- AP-HP. Sorbonne Université, Hôpital Pitié-Salpêtrière, Département d'anesthésie réanimation, Paris, France
| | - Baptiste Duceau
- AP-HP. Sorbonne Université, Hôpital Pitié-Salpêtrière, Département d'anesthésie réanimation, Paris, France
| | - Paul Henri Grisot
- AP-HP. Sorbonne Université, Hôpital Pitié-Salpêtrière, Département d'anesthésie réanimation, Paris, France
| | - Marie Hélène Pari
- AP-HP. Sorbonne Université, Hôpital Pitié-Salpêtrière, Département d'anesthésie réanimation, Paris, France
| | - Jérémy Arzoine
- AP-HP. Sorbonne Université, Hôpital Pitié-Salpêtrière, Département d'anesthésie réanimation, Paris, France
| | - Ulrich Clarac
- AP-HP. Sorbonne Université, Hôpital Pitié-Salpêtrière, Département d'anesthésie réanimation, Paris, France
| | - David Boutolleau
- Sorbonne Université, INSERM UMR S 1136, Institut Pierre Louis d'Epidémiologie et de Santé Publique, Team 3 THERAVIR, Paris, France
- AP-HP. Sorbonne Université, Hôpital Pitié-Salpêtrière, Service de Virologie, Centre National de Référence Herpès virus, Paris, France
| | - Mathieu Raux
- Sorbonne Université, INSERM, UMR_S 1158 Neurophysiologie respiratoire expérimentale et clinique, Paris, France
- AP-HP. Sorbonne Université, Hôpital Pitié-Salpêtrière, Département d'anesthésie réanimation, Paris, France
| | - Julie Delemazure
- AP-HP. Sorbonne Université, Hôpital Pitié-Salpêtrière, Service de Pneumologie, Médecine intensive - Réanimation (Département "R3S"), Paris, France
| | - Morgane Faure
- AP-HP. Sorbonne Université, Hôpital Pitié-Salpêtrière, Service de Pneumologie, Médecine intensive - Réanimation (Département "R3S"), Paris, France
| | - Maxens Decavele
- AP-HP. Sorbonne Université, Hôpital Pitié-Salpêtrière, Service de Pneumologie, Médecine intensive - Réanimation (Département "R3S"), Paris, France
- Sorbonne Université, INSERM, UMR_S 1158 Neurophysiologie respiratoire expérimentale et clinique, Paris, France
| | - Elise Morawiec
- AP-HP. Sorbonne Université, Hôpital Pitié-Salpêtrière, Service de Pneumologie, Médecine intensive - Réanimation (Département "R3S"), Paris, France
| | - Julien Mayaux
- AP-HP. Sorbonne Université, Hôpital Pitié-Salpêtrière, Service de Pneumologie, Médecine intensive - Réanimation (Département "R3S"), Paris, France
| | - Alexandre Demoule
- AP-HP. Sorbonne Université, Hôpital Pitié-Salpêtrière, Service de Pneumologie, Médecine intensive - Réanimation (Département "R3S"), Paris, France
- Sorbonne Université, INSERM, UMR_S 1158 Neurophysiologie respiratoire expérimentale et clinique, Paris, France
| | - Martin Dres
- AP-HP. Sorbonne Université, Hôpital Pitié-Salpêtrière, Service de Pneumologie, Médecine intensive - Réanimation (Département "R3S"), Paris, France.
- Sorbonne Université, INSERM, UMR_S 1158 Neurophysiologie respiratoire expérimentale et clinique, Paris, France.
| |
Collapse
|
41
|
Jary A, Flandre P, Chabouis A, Nguyen S, Marot S, Burrel S, Boutolleau D, Calvez V, Marcelin AG, Louet M. Clinical presentation of Covid-19 in health care workers from a French University Hospital. J Infect 2020; 81:e61-e63. [PMID: 32579992 PMCID: PMC7306211 DOI: 10.1016/j.jinf.2020.06.048] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/07/2020] [Revised: 06/15/2020] [Accepted: 06/18/2020] [Indexed: 01/11/2023]
Affiliation(s)
- Aude Jary
- Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), AP-HP, Hôpital Pitié-Salpêtrière, Service de Virologie, Paris, France.
| | - Philippe Flandre
- INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique (IPLESP), Paris, France
| | - Agnès Chabouis
- AP-HP, Hôpital Pitié-Salpêtrière, Service de Santé au Travail, Paris, France
| | - Séverine Nguyen
- AP-HP, Hôpital Pitié-Salpêtrière, Service de Santé au Travail, Paris, France
| | - Stéphane Marot
- Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), AP-HP, Hôpital Pitié-Salpêtrière, Service de Virologie, Paris, France
| | - Sonia Burrel
- Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), AP-HP, Hôpital Pitié-Salpêtrière, Service de Virologie, Paris, France
| | - David Boutolleau
- Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), AP-HP, Hôpital Pitié-Salpêtrière, Service de Virologie, Paris, France
| | - Vincent Calvez
- Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), AP-HP, Hôpital Pitié-Salpêtrière, Service de Virologie, Paris, France
| | - Anne-Geneviève Marcelin
- Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), AP-HP, Hôpital Pitié-Salpêtrière, Service de Virologie, Paris, France
| | - Martine Louet
- AP-HP, Hôpital Pitié-Salpêtrière, Service de Santé au Travail, Paris, France
| |
Collapse
|
42
|
Paccoud O, Tubach F, Baptiste A, Bleibtreu A, Hajage D, Monsel G, Tebano G, Boutolleau D, Klement E, Godefroy N, Palich R, Itani O, Fayssal A, Valantin MA, Tubiana R, Burrel S, Calvez V, Caumes E, Marcelin AG, Pourcher V. Compassionate use of hydroxychloroquine in clinical practice for patients with mild to severe Covid-19 in a French university hospital. Clin Infect Dis 2020; 73:e4064-e4072. [PMID: 32556143 PMCID: PMC7337663 DOI: 10.1093/cid/ciaa791] [Citation(s) in RCA: 34] [Impact Index Per Article: 8.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/15/2020] [Indexed: 12/27/2022] Open
Abstract
Background Data from non-randomized studies have suggested that hydroxychloroquine could be an effective therapeutic agent against Covid-19. Methods We conducted an observational, retrospective cohort study involving hospitalized adult patients with confirmed, mild to severe Covid-19 in a French university hospital. Patients who received hydroxychloroquine (200mg tid dosage for 10 days) on a compassionate basis in addition to SOCwere compared to patients without contraindications to hydroxychloroquine who received SOCalone. A propensity score-weighted analysis was performed to control for confounders: age, sex, time between symptom onset and admission ≤ 7 days, Charlson comorbidity index, medical history of arterial hypertension, and obesity, NEWS2 score at admission, and pneumonia severity. The primary endpoint was time to unfavorable outcome, defined as: death, admission to an intensive care unit, or decision to withdraw or withhold life-sustaining treatments, whichever came first. Results Data from 89 patients with laboratory-confirmed Covid-19 were analyzed, 84 of whom were considered in the primary analysis; 38 patients treated with hydroxychloroquine and 46 patients treated with SOCalone. At admission, the mean age of patients was 66 years, the median Charlson comorbidity index was 3, and the median NEWS2 severity score was 3. After propensity score weighting, treatment with hydroxycholoroquine was not associated with a significantly reduced risk of unfavorable outcome (HR 0.90 [0.38; 2.1], p = 0.81). Overall survival was not significantly different between the two groups (HR 0.89 [0.23; 3.47], p = 1) Conclusion In hospitalized adults with Covid-19, no significant reduction of the risk of unfavorable outcomes was observed with hydroxychloroquine in comparison to standard of care. Unmeasured confounders may however have persisted despite careful propensity-weighted analysis and the study might be underpowered. Ongoing controlled trials in patients with varying degrees of initial severity on a larger scale will help determine whether there is a place for hydroxychloroquine in the treatment of Covid-19.
Collapse
Affiliation(s)
- Olivier Paccoud
- Assistance Publique - Hôpitaux de Paris, Hôpitaux Universitaires Pitié-Salpêtrière Charles Foix, Service de Maladies infectieuses et Tropicales, 75013, Paris, France
| | - Florence Tubach
- Sorbonne Université, INSERM UMR 1136, Département de Santé Publique, Unité de Recherche Clinique Pitié Salpêtrière - Charles Foix, Centre de Pharmaco-épidémiologie de l'AP-HP, Hôpitaux Universitaires Pitié-Salpêtrière Charles Foix, Paris, France
| | - Amandine Baptiste
- Sorbonne Université, INSERM UMR 1136, Département de Santé Publique, Unité de Recherche Clinique Pitié Salpêtrière - Charles Foix, Centre de Pharmaco-épidémiologie de l'AP-HP, Hôpitaux Universitaires Pitié-Salpêtrière Charles Foix, Paris, France
| | - Alexandre Bleibtreu
- Assistance Publique - Hôpitaux de Paris, Hôpitaux Universitaires Pitié-Salpêtrière Charles Foix, Service de Maladies infectieuses et Tropicales, 75013, Paris, France
| | - David Hajage
- Sorbonne Université, INSERM UMR 1136, Département de Santé Publique, Unité de Recherche Clinique Pitié Salpêtrière - Charles Foix, Centre de Pharmaco-épidémiologie de l'AP-HP, Hôpitaux Universitaires Pitié-Salpêtrière Charles Foix, Paris, France
| | - Gentiane Monsel
- Assistance Publique - Hôpitaux de Paris, Hôpitaux Universitaires Pitié-Salpêtrière Charles Foix, Service de Maladies infectieuses et Tropicales, 75013, Paris, France
| | - Gianpiero Tebano
- Assistance Publique - Hôpitaux de Paris, Hôpitaux Universitaires Pitié-Salpêtrière Charles Foix, Service de Maladies infectieuses et Tropicales, 75013, Paris, France
| | - David Boutolleau
- Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, AP-HP, Hôpitaux Universitaires Pitié-Salpêtrière - Charles Foix, laboratoire de virologie, Paris, France.,Sorbonne Université, INSERM 1136, Institut Pierre Louis d'Epidémiologie et de Santé Publique, Paris, France
| | - Elise Klement
- Assistance Publique - Hôpitaux de Paris, Hôpitaux Universitaires Pitié-Salpêtrière Charles Foix, Service de Maladies infectieuses et Tropicales, 75013, Paris, France
| | - Nagisa Godefroy
- Assistance Publique - Hôpitaux de Paris, Hôpitaux Universitaires Pitié-Salpêtrière Charles Foix, Service de Maladies infectieuses et Tropicales, 75013, Paris, France
| | - Romain Palich
- Assistance Publique - Hôpitaux de Paris, Hôpitaux Universitaires Pitié-Salpêtrière Charles Foix, Service de Maladies infectieuses et Tropicales, 75013, Paris, France
| | - Oula Itani
- Assistance Publique - Hôpitaux de Paris, Hôpitaux Universitaires Pitié-Salpêtrière Charles Foix, Service de Maladies infectieuses et Tropicales, 75013, Paris, France
| | - Antoine Fayssal
- Assistance Publique - Hôpitaux de Paris, Hôpitaux Universitaires Pitié-Salpêtrière Charles Foix, Service de Maladies infectieuses et Tropicales, 75013, Paris, France
| | - Marc-Antoine Valantin
- Assistance Publique - Hôpitaux de Paris, Hôpitaux Universitaires Pitié-Salpêtrière Charles Foix, Service de Maladies infectieuses et Tropicales, 75013, Paris, France
| | - Roland Tubiana
- Assistance Publique - Hôpitaux de Paris, Hôpitaux Universitaires Pitié-Salpêtrière Charles Foix, Service de Maladies infectieuses et Tropicales, 75013, Paris, France
| | - Sonia Burrel
- Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, AP-HP, Hôpitaux Universitaires Pitié-Salpêtrière - Charles Foix, laboratoire de virologie, Paris, France.,Sorbonne Université, INSERM 1136, Institut Pierre Louis d'Epidémiologie et de Santé Publique, Paris, France
| | - Vincent Calvez
- Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, AP-HP, Hôpitaux Universitaires Pitié-Salpêtrière - Charles Foix, laboratoire de virologie, Paris, France.,Sorbonne Université, INSERM 1136, Institut Pierre Louis d'Epidémiologie et de Santé Publique, Paris, France
| | - Eric Caumes
- Assistance Publique - Hôpitaux de Paris, Hôpitaux Universitaires Pitié-Salpêtrière Charles Foix, Service de Maladies infectieuses et Tropicales, 75013, Paris, France.,Sorbonne Université, INSERM 1136, Institut Pierre Louis d'Epidémiologie et de Santé Publique, Paris, France
| | - Anne-Geneviève Marcelin
- Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, AP-HP, Hôpitaux Universitaires Pitié-Salpêtrière - Charles Foix, laboratoire de virologie, Paris, France.,Sorbonne Université, INSERM 1136, Institut Pierre Louis d'Epidémiologie et de Santé Publique, Paris, France
| | - Valérie Pourcher
- Assistance Publique - Hôpitaux de Paris, Hôpitaux Universitaires Pitié-Salpêtrière Charles Foix, Service de Maladies infectieuses et Tropicales, 75013, Paris, France.,Sorbonne Université, INSERM 1136, Institut Pierre Louis d'Epidémiologie et de Santé Publique, Paris, France
| |
Collapse
|
43
|
Breillat P, Mathian A, Burrel S, Hié M, Fadlallah J, Pineton de Chambrun M, Cohen F, Boutolleau D, Rozenberg F, Calvez V, Amoura Z. FRI0157 EPSTEIN BARR VIRUS BLOOD REPLICATION INCREASES DURING ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS. Ann Rheum Dis 2020. [DOI: 10.1136/annrheumdis-2020-eular.734] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
Background:A role for Epstein Barr Virus (EBV) infection in Systemic Lupus Erythematosus (SLE) pathogenesis is highly suspected. The frequency of EBV seroprevalence and DNA detection in peripheral blood mononuclear cells are increased in SLE patients compared to healthy controls.Objectives:To analyse the relationship between EBV blood replication and SLE disease activity.Methods:Monocentric, observational and retrospective study of SLE patients (ACR or SLICC criteria) who have had a blood EBV DNA assessment using Polymerase Chain Reaction (artus® EBV Virus QS-RGQ assay) between 2012 and 2018. Exclusion criteria were: organ or bone marrow transplant, absence of EBV seroconversion and insufficient data. SLE clinical features, the Safety of Estrogens in Lupus Erythematosus National Assessment–Systemic Lupus Erythematosus Disease Activity Index (SELENA-SLEDAI) flare index (SFI) and therapeutic regimen on the day of EBV DNA load assessment were recorded. A SELENA-SLEDAI score > 4 defined an active SLE. A blood EBV DNA load ≥125 IU/mL was defined as elevated.Results:A total of 105 patients (98 women and 7 men) were included in the study. At inclusion, median (quartiles) age and SLE duration were 34 (23.5-43) and 7 (2-14) years old, respectively. Treatment were hydroxychloroquine (HCQ) (n = 67; 64%), prednisone (n = 66; 63%) with an average (±Standard Deviation) dose of 11.3 (±16) mg/day and an immunosuppressant (n = 42; 40%). According to SFI, 57 SLE patients were experiencing a flare at the time of EBV assessment; flares were classified as severe and mild/moderate in 38 (36%) and 19 (18%) SLE patients, respectively. According to the SELENA-SLEDAI score, 60 patients (57%) were deemed active and 45 (43%) inactive. Main clinical manifestations were arthritis in 32 (30%) patients, constitutional symptoms (fever, weight loss, anorexia or lymphadenopathy) in 31 (30%), cutaneous involvement in 23 (22%), glomerulonephritis in 19 (18%), cytopenia in 14 (13%), neuropsychiatric involvement in 13 (12%) and serositis in 10 (16%). Blood EBV DNA was elevated in 54 (90%) of the 60 patients with active lupus versus 6 (13%) of the 45 patients with inactive SLE (p <10-4). It was increased in 34 (89%) of the 38 patients with severe flare, in 17 (89%) of the 19 patients with a mild/moderate flare (p = 1) and in 8 (17%) of the 48 patients without flare (p <10-4vs severe flare and p <10-4vs mild/moderate flare). EBV DNA load correlated with SELENA-SLEDAI score (r=0.58; p<0.0001). Elevated blood EBV DNA was not associated with HCQ, prednisone or immunosuppressant intakes. Eighteen patients with active SLE had a second assessment of blood EBV DNA load. For these patients, the median [range] of viral load was significantly higher during periods of active SLE (236 [0-2680] IU/mL) compared with periods with lower SELENA-SLEDAI score (0 [0-1537] IU/mL, p<10-4in paired analysis).Conclusion:Blood EBV viral load is dramatically increased in active phase of SLE, independently of the treatment. We were unable to demonstrate whether the replication of EBV was the cause or the consequence or just an epiphenomenon of the disease activity. Further studies are needed to study whether EBV viral load is linked with Interferons secretion or B lymphocyte activation.Disclosure of Interests:None declared
Collapse
|
44
|
Klement-Frutos E, Burrel S, Peytavin G, Marot S, Lê MP, Godefroy N, Calvez V, Marcelin AG, Caumes E, Pourcher V, Boutolleau D. Early administration of ritonavir-boosted lopinavir could prevent severe COVID-19. J Infect 2020; 82:159-198. [PMID: 32473230 PMCID: PMC7251410 DOI: 10.1016/j.jinf.2020.05.039] [Citation(s) in RCA: 12] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/19/2020] [Accepted: 05/20/2020] [Indexed: 12/18/2022]
Affiliation(s)
- Elise Klement-Frutos
- Sorbonne Université, INSERM 1136, Institut Pierre Louis d'Epidémiologie et de Santé Publique, and Assistance Publique - Hôpitaux de Paris, Hôpitaux Universitaires Pitié-Salpêtrière - Charles Foix, Service de Maladies Infectieuses et Tropicales, Paris, France.
| | - Sonia Burrel
- Sorbonne Université, INSERM 1136, Institut Pierre Louis d'Epidémiologie et de Santé Publique, and Assistance Publique - Hôpitaux de Paris, Hôpitaux Universitaires Pitié-Salpêtrière - Charles Foix, Service de Virologie, Paris, France.
| | - Gilles Peytavin
- Assistance Publique - Hôpitaux de Paris, Hôpital Bichat-Claude Bernard, Laboratoire de Pharmacologie-Toxicologie, DMU Biologie et Génomique Médicale (BioGeM), IAME INSERM UMR-S 1137, Paris, France.
| | - Stéphane Marot
- Assistance Publique - Hôpitaux de Paris, Hôpitaux Universitaires Pitié-Salpêtrière - Charles Foix, Service de Virologie, Paris, France.
| | - Minh P Lê
- Assistance Publique - Hôpitaux de Paris, Hôpital Bichat-Claude Bernard, Laboratoire de Pharmacologie-Toxicologie, DMU Biologie et Génomique Médicale (BioGeM), INSERM UMR-S 1144, Paris, France.
| | - Nagisa Godefroy
- Assistance Publique - Hôpitaux de Paris, Hôpitaux Universitaires Pitié-Salpêtrière - Charles Foix, Service de Maladies Infectieuses et Tropicales, Paris, France.
| | - Vincent Calvez
- Sorbonne Université, INSERM 1136, Institut Pierre Louis d'Epidémiologie et de Santé Publique, and Assistance Publique - Hôpitaux de Paris, Hôpitaux Universitaires Pitié-Salpêtrière - Charles Foix, Service de Virologie, Paris, France.
| | - Anne-Geneviève Marcelin
- Sorbonne Université, INSERM 1136, Institut Pierre Louis d'Epidémiologie et de Santé Publique, and Assistance Publique - Hôpitaux de Paris, Hôpitaux Universitaires Pitié-Salpêtrière - Charles Foix, Service de Virologie, Paris, France.
| | - Eric Caumes
- Sorbonne Université, INSERM 1136, Institut Pierre Louis d'Epidémiologie et de Santé Publique, and Assistance Publique - Hôpitaux de Paris, Hôpitaux Universitaires Pitié-Salpêtrière - Charles Foix, Service de Maladies Infectieuses et Tropicales, Paris, France.
| | - Valérie Pourcher
- Sorbonne Université, INSERM 1136, Institut Pierre Louis d'Epidémiologie et de Santé Publique, and Assistance Publique - Hôpitaux de Paris, Hôpitaux Universitaires Pitié-Salpêtrière - Charles Foix, Service de Maladies Infectieuses et Tropicales, Paris, France.
| | - David Boutolleau
- Sorbonne Université, INSERM 1136, Institut Pierre Louis d'Epidémiologie et de Santé Publique, and Assistance Publique - Hôpitaux de Paris, Hôpitaux Universitaires Pitié-Salpêtrière - Charles Foix, Service de Virologie, Paris, France.
| |
Collapse
|
45
|
Foy JP, Bertolus C, Boutolleau D, Agut H, Gessain A, Herceg Z, Saintigny P. Arguments to Support a Viral Origin of Oral Squamous Cell Carcinoma in Non-Smoker and Non-Drinker Patients. Front Oncol 2020; 10:822. [PMID: 32528893 PMCID: PMC7253757 DOI: 10.3389/fonc.2020.00822] [Citation(s) in RCA: 17] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/14/2019] [Accepted: 04/28/2020] [Indexed: 12/18/2022] Open
Abstract
In some western countries, an increasing incidence of oral squamous cell carcinoma (OSCC) has been observed in non-smoker non-drinker patients (NSND), mostly in women with HPV-negative OSCC. In the context of the unknown etiology and mechanisms of tumorigenesis of OSCC in NSND, we discuss data supporting the hypothesis of a viral origin not related to HPV. OSCC from NSND are characterized by an antiviral DNA methylation and gene expression signature. Based on the similar increasing incidence of oral tongue SCC (OTSCC) and oropharyngeal SCC (OPSCC) in young women and men respectively, we hypothesize that changes in sexual behaviors may lead to an increasing incidence of herpesvirus in the oral cavity, especially HSV-2, similarly to what has already been described in HPV-positive OPSCC. Because viral genome integration has not been detected in OSCC from NSND, a "hit and run" viral mechanism involving epigenome deregulation could therefore play a key role at early steps of oral carcinogenesis in this population of patients. In conclusion, epidemiological, clinical and molecular data supports a "hit and run" viral origin of OSCC from NSND.
Collapse
Affiliation(s)
- Jean-Philippe Foy
- Univ Lyon, Université Claude Bernard Lyon 1, INSERM 1052, CNRS 5286, Centre Léon Bérard, Centre de Recherche en Cancérologie de Lyon, Lyon, France
- Department of Translational Research and Innovation, Centre Léon Bérard, Lyon, France
- Sorbonne Université, AP-HP, Groupe Hospitalier Pitié-Salpêtrière Charles Foix, Department of Oral and Maxillo-Facial Surgery, Paris, France
| | - Chloé Bertolus
- Sorbonne Université, AP-HP, Groupe Hospitalier Pitié-Salpêtrière Charles Foix, Department of Oral and Maxillo-Facial Surgery, Paris, France
| | - David Boutolleau
- Sorbonne Université, AP-HP, Groupe Hospitalier Pitié-Salpêtrière-Charles Foix, Centre National de Référence Herpèsvirus, Department of Virology, Paris, France
- Sorbonne Université, CR7, Centre d'Immunologie et de Maladies Infectieuses (CIMI-Paris), INSERM U1135, Paris, France
| | - Henri Agut
- Sorbonne Université, AP-HP, Groupe Hospitalier Pitié-Salpêtrière-Charles Foix, Centre National de Référence Herpèsvirus, Department of Virology, Paris, France
- Sorbonne Université, CR7, Centre d'Immunologie et de Maladies Infectieuses (CIMI-Paris), INSERM U1135, Paris, France
| | - Antoine Gessain
- Department of Virology, Institut Pasteur, CNRS, UMR 3569, Paris, France
| | - Zdenko Herceg
- Epigenetics Group, International Agency for Research on Cancer (IARC), Lyon, France
| | - Pierre Saintigny
- Univ Lyon, Université Claude Bernard Lyon 1, INSERM 1052, CNRS 5286, Centre Léon Bérard, Centre de Recherche en Cancérologie de Lyon, Lyon, France
- Department of Translational Research and Innovation, Centre Léon Bérard, Lyon, France
- Department of Medical Oncology, Centre Léon Bérard, Lyon, France
| |
Collapse
|
46
|
Coutance G, Boutolleau D, Rouvier P, Leprince P, Varnous S. Cytomegalovirus Infections are Frequent after Heart Transplantation but Do Not Increase the Risk of Biopsy-Proven Allograft Rejection in the Modern Era. J Heart Lung Transplant 2020. [DOI: 10.1016/j.healun.2020.01.819] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
|
47
|
Vetter P, Schibler M, Herrmann JL, Boutolleau D. Diagnostic challenges of central nervous system infection: extensive multiplex panels versus stepwise guided approach. Clin Microbiol Infect 2019; 26:706-712. [PMID: 31899336 DOI: 10.1016/j.cmi.2019.12.013] [Citation(s) in RCA: 15] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/02/2019] [Revised: 12/20/2019] [Accepted: 12/22/2019] [Indexed: 02/07/2023]
Abstract
BACKGROUND Cerebrospinal fluid (CSF) testing is a key component for the diagnosis of central nervous system (CNS) infections. Current meningitis and encephalitis management guidelines agree on the need for CSF molecular testing in combination with other direct and indirect biological testing, both in CSF and blood. Multiplex molecular tests have been developed to reduce turnaround times and facilitate the diagnostic approach. OBJECTIVES We aim to discuss the role of multiplex molecular panels in the management of CNS infections. SOURCES The MEDLINE database and the grey literature have been searched for relevant articles. CONTENT New molecular multiplex panels are being developed to simultaneously detect a large array of neuropathogens in CSF. Although one of these assays has been US Food and Drug Administration-approved, extensive analytical and clinical validation is still missing, and suboptimal performance related issues have been raised. Its use has been associated with decreased costs, reduced length of hospital stay and reduced antiviral therapy administration in retrospective, industry-sponsored studies. The pros and cons of this multiplex syndromic approach are discussed in this narrative review. IMPLICATIONS Molecular multiplex CNS infection diagnosis panels have been developed and present several attractive features, including ease of use and low turnaround time. However, suboptimal analytical performances render these tests difficult to use without additional confirmatory tests. Such panels are not comprehensive nor adapted to all situations, depending on the epidemiological or clinical context. Overall, available data in the literature currently do not support the use of a multiplex PCR panel in clinical routine as a 'stand-alone' molecular assay. Except in restricted laboratory capacity settings where such easy-to-use multiplex panels offer the diagnostic means that would otherwise not be available, the stepwise testing approach remains a more rational option. Serological testing both in blood and CSF should not be neglected, but it represents essential complementary tools regarding some neuropathogens.
Collapse
Affiliation(s)
- P Vetter
- Laboratory of Virology, Geneva University Hospitals, Geneva, Switzerland; Infectious Diseases Division, Geneva University Hospitals, Geneva, Switzerland.
| | - M Schibler
- Laboratory of Virology, Geneva University Hospitals, Geneva, Switzerland; Infectious Diseases Division, Geneva University Hospitals, Geneva, Switzerland
| | - J L Herrmann
- 2I, UVSQ, INSERM, Université Paris Saclay, Versailles France; AP-HP, GHU Paris Saclay, Hôpital Raymond Poincaré, Garches, France
| | - D Boutolleau
- Sorbonne Université, INSERM, Institut Pierre Louis D'Epidémiologie et de Santé Publique (iPLESP), Paris, France; AP-HP, GHU AP-HP. Sorbonne Université, Hôpitaux Universitaires Pitié-Salpêtrière - Charles Foix, Virology Department, National Reference Center for Herpesviruses (associate Laboratory), Paris, France
| |
Collapse
|
48
|
Ngangas ST, Lukashev A, Jugie G, Ivanova O, Mansuy JM, Mengelle C, Izopet J, L'honneur AS, Rozenberg F, Leyssene D, Hecquet D, Marque-Juillet S, Boutolleau D, Burrel S, Peigue-Lafeuille H, Archimbaud C, Benschop K, Henquell C, Mirand A, Bailly JL. Multirecombinant Enterovirus A71 Subgenogroup C1 Isolates Associated with Neurologic Disease, France, 2016-2017. Emerg Infect Dis 2019; 25:1204-1208. [PMID: 31107209 PMCID: PMC6537711 DOI: 10.3201/eid2506.181460] [Citation(s) in RCA: 18] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/28/2022] Open
Abstract
In 2016, an upsurge of neurologic disease associated with infection with multirecombinant enterovirus A71 subgenogroup C1 lineage viruses was reported in France. These viruses emerged in the 2000s; 1 recombinant is widespread. This virus lineage has the potential to be associated with a long-term risk for severe disease among children.
Collapse
|
49
|
Breillat P, Mathian A, Hie M, Pineton De Chambrun M, Miyara M, Cohen Aubart F, Boutolleau D, Pha M, Calvez V, Haroche J, Rozenberg F, Burrel S, Amoura Z. La réplication du virus Epstein-Barr est fréquente lors des poussées de lupus systémique. Rev Med Interne 2019. [DOI: 10.1016/j.revmed.2019.10.097] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
50
|
Guermouche H, Burrel S, Mercier-Darty M, Kofman T, Rogier O, Pawlotsky JM, Boutolleau D, Rodriguez C. Characterization of the dynamics of human cytomegalovirus resistance to antiviral drugs by ultra-deep sequencing. Antiviral Res 2019; 173:104647. [PMID: 31706899 DOI: 10.1016/j.antiviral.2019.104647] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/12/2019] [Revised: 09/30/2019] [Accepted: 11/04/2019] [Indexed: 12/12/2022]
Abstract
Prophylactic or preemptive treatment strategies are required to prevent human cytomegalovirus (CMV) infections in transplant recipients. However, treatment failure occurs when CMV resistant-associated variants (RAVs) are selected. Although the diversity of CMV is lower than that of RNA viruses, CMV appears to show some genetic instability, with possible minor emerging resistance that may be undetectable by Sanger sequencing. We aimed to examine CMV-resistance mutations over time by ultra-deep sequencing (UDS) and Sanger sequencing in a kidney transplant recipient experiencing CMV infection. This patient showed a transient response to three different antiviral drugs (valganciclovir, foscarnet, and maribavir) and four episodes of CMV resistance over two years. The full-length UL97 (2.3kpb) and partial UL54 (2.4kpb) CMV genes were studied by UDS and Sanger sequencing and linkage mutations calculated to determine RAVs. We detected four major and five minor resistance mutations. Minor resistant variants (2-20%) were detected by UDS, whereas major resistance substitutions (>20%) were identified by both UDS and Sanger method. We detected cross-resistance to three drugs, despite high CMV loads, suggesting that the fitness of the viral mutants was not impaired. In conclusion, CMV showed complex dynamic of resistance under antiviral drug pressure, as described for highly variable viruses. The emergence of successive RAVs constitutes a clinically challenging complication and contributes to the difficulty of therapeutic management of patients.
Collapse
Affiliation(s)
- Hélène Guermouche
- Laboratoire de Virologie, CHU Henri Mondor (AP-HP), INSERM U955 Eq18, Plateforme « Génomiques », IMRB, UPEC, Créteil, France
| | - Sonia Burrel
- Centre National de Référence Herpèsvirus (laboratoire associé), Laboratoire de Virologie, Hôpital Universitaire La Pitié-Salpêtrière, GHU AP-PH. Sorbonne Université (AP-HP), INSERM U1136, iPLESP, Sorbonne Université, Paris, France
| | - Mélanie Mercier-Darty
- Laboratoire de Virologie, CHU Henri Mondor (AP-HP), INSERM U955 Eq18, Plateforme « Génomiques », IMRB, UPEC, Créteil, France
| | - Thomas Kofman
- Service de Néphrologie, Hôpital Universitaire Henri Mondor (AP-HP), Créteil, France
| | - Olivier Rogier
- Laboratoire de Virologie, CHU Henri Mondor (AP-HP), INSERM U955 Eq18, Plateforme « Génomiques », IMRB, UPEC, Créteil, France
| | - Jean-Michel Pawlotsky
- Laboratoire de Virologie, CHU Henri Mondor (AP-HP), INSERM U955 Eq18, Plateforme « Génomiques », IMRB, UPEC, Créteil, France
| | - David Boutolleau
- Centre National de Référence Herpèsvirus (laboratoire associé), Laboratoire de Virologie, Hôpital Universitaire La Pitié-Salpêtrière, GHU AP-PH. Sorbonne Université (AP-HP), INSERM U1136, iPLESP, Sorbonne Université, Paris, France
| | - Christophe Rodriguez
- Laboratoire de Virologie, CHU Henri Mondor (AP-HP), INSERM U955 Eq18, Plateforme « Génomiques », IMRB, UPEC, Créteil, France.
| |
Collapse
|